Document:

EX-4.2

 Exhibit 4.2 

SECOND AMENDED AND RESTATED 

INVESTORS’ RIGHTS AGREEMENT 

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of March 2, 2021, by
and among Caribou Biosciences, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto (each, an “Investor”) and any Additional Purchaser (as defined in the Purchase
Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof. 
 WHEREAS,
certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock, and/or shares of Common
Stock (all as defined below) issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to an Amended and Restated Investors’ Rights Agreement dated as of May 12,
2016, among between the Company and such Investors (the “Prior Agreement”); and 
 WHEREAS, the Existing Investors
are holders of at least a majority of the outstanding Registrable Securities of the Company (as defined in the Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to this
Agreement in lieu of the rights granted to them under the Prior Agreement; and 
 WHEREAS, certain of the Investors are parties with
the Company to that certain Series C Preferred Stock Purchase Agreement of even date herewith (the “Purchase Agreement”), pursuant to which certain of the Company’s and such Investors’ obligations are conditioned upon the
execution and delivery of this Agreement. 
 NOW, THEREFORE, the Company and the Existing Investors agree that the Prior Agreement
shall be amended and restated in its entirety by this Agreement, and the parties to this Agreement further agree as follows: 
 1. Definitions.
For purposes of this Agreement: 
 1.1 “Affiliate” means, with respect to any specified Person, any other Person who,
directly or indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, limited partner, member, manager, managing member, employee, officer or director of such Person or
any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or is under common investment management with or shares the same management company with, such Person. For purposes of this
definition, the term “control” when used with respect to any Person shall mean the power to direct the management or policies of such Person, directly or indirectly, whether through ownership of voting securities, by contract or otherwise,
and the terms “controlling” and “controlled” shall have meanings correlative to the foregoing. 
 1.2
“Board” means the board of directors of the Company. 
 1.3 “Certificate of Incorporation” means the
Fourth Amended and Restated Certificate of Incorporation of the Company (as the same may be further amended or restated). 
 1.4
“Common Stock” means shares of the Company’s common stock, $0.0001 par value per share. 
 1.5
“Competitor” means a Person engaged, directly or indirectly (including through any partnership, limited liability company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in the same
business as the Company, but shall not include (1) any financial investment firm or collective investment vehicle that, together with its Affiliates, holds less than twenty percent (20%) of the outstanding equity of any business competitive
with the Company and does not, nor do any of its Affiliates, have a right to designate any members of the board of directors of any such company, (2) Pig Improvement Company UK Limited (“PIC”), (3) Novartis Institutes for
BioMedical Research, Inc. (“NIBR”), (4) E.I. du Pont de Nemours & Co. (“DuPont”), (5) F-Prime Capital Partners Healthcare Fund IV LP or its Affiliate funds (“F-Prime”), (6) Anterra F&A Ventures I Coöperatief U.A. or its Affiliate funds (“Anterra”), (7) PFM Healthcare Master Fund, L.P., Partner Investments, L.P., PFM Healthcare Growth
Equity Holdings I, LLC (collectively, “PFM”) or their Affiliate funds, (8) Zone III Healthcare Holdings, LLC or its Affiliate funds, (9) RIDGEBACK CAPITAL INVESTMENTS LP or its Affiliate 

 
funds and (10) AbbVie Inc. or AbbVie Manufacturing Management Unlimited Company as long as it remains an Affiliate of AbbVie, Inc.(collectively, “AbbVie”); provided,
however, that in the event that the Board unanimously determines in good faith that PIC, NIBR, DuPont, F-Prime, Anterra, or AbbVie is or becomes competitive with the business of the Company, the Board
shall be permitted to designate PIC, NIBR, DuPont, F-Prime, Anterra or AbbVie, as the case may be, as a “Competitor” for purposes of Section 3.2 of this Agreement. 

1.6 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under
the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a
material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities
Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.7 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each
case, directly or indirectly), Common Stock, including options and warrants. 
 1.8 “Exchange Act” means the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
 1.9 “Excluded Registration”
means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a
registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common
Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered. 
 1.10 “Form
S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.11 “Form S-3” means such form under the Securities Act as in effect on the
date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.12 “Holder” means any holder of Registrable Securities who is a party to this Agreement. 

1.13 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, in each case including adoptive relationships, of a natural person referred to
herein. 
 1.14 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this
Agreement. 
 1.15 “IPO” means the Company’s first underwritten public offering of its Common Stock under the
Securities Act. 
 1.16 “Lead Investors” means, collectively, PFM , Zone III Healthcare Holdings, LLC, and RIDGEBACK
CAPITAL INVESTMENTS LP (but shall not include the Affiliate funds of such entities for purposes of the entities covered by this definition), as long as, in determining the status of such entity as a Lead Investor, such entity, together with its
Affiliate funds, continues to beneficially own at least twenty percent (20%) of the shares of Series C Preferred Stock acquired by such Lead Investor pursuant to the Purchase Agreement. 

  
 2 

 1.17 “New Securities” means, collectively, equity securities of the
Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity
securities. 
 1.18 “Person” means any individual, corporation, partnership, trust, limited liability company, association
or other entity. 
 1.19 “Preferred Stock” means, collectively, shares of the Company’s Series C Preferred Stock,
Series B Preferred Stock, Series A-1 Preferred Stock, and Series A Preferred Stock. 
 1.20
“Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon
conversion and/or exercise of any other securities of the Company, acquired by the Investors after the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or
other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable
Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares
for which registration rights have terminated pursuant to Section 2.13 of this Agreement. 
 1.21
“Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable
(directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 
 1.22
“Restricted Securities” means the securities of the Company required to bear the legend set forth in Section 2.12(b) hereof. 

1.23 “SEC” means the Securities and Exchange Commission. 

1.24 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.25 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.26 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 1.27 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to
the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6. 

1.28 “Series A Preferred Stock” means shares of the Company’s Series A Preferred Stock, $0.0001 par value per share.

 1.29 “Series A-1 Preferred Stock” means shares of the Company’s Series A-1 Preferred Stock, $0.0001 par value per share. 
 1.30 “Series B Preferred Stock”
means shares of the Company’s Series B Preferred Stock, $0.0001 par value per share. 
 1.31 “Series C Preferred
Stock” means shares of the Company’s Series C Preferred Stock, $0.0001 par value per share. 

  
 3 

 1.32 “SPAC Transaction” means any transaction or series of related
transactions in which the Company’s outstanding shares of capital stock are exchanged for or otherwise converted into securities that are publicly listed on a securities exchange (the “Public Shares”), including through a
merger, acquisition, business combination, or similar transaction, in each case with a vehicle commonly known as a special purpose acquisition company (a “SPAC”). 

2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the date
of this Agreement or (ii) the date which is one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least a majority of the Registrable Securities
then outstanding that the Company file a Form S-1 registration statement with respect to Registrable Securities then outstanding having an anticipated aggregate offering price, net of Selling Expenses,
of at least $20 million, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders, and
(y) as soon as practicable, and in any event within one hundred twenty (120) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the
Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice
given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3. 

(b) Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from a Holder or Holders of Registrable Securities, that the Company file a Form S-3 registration statement with
respect to outstanding Registrable Securities of such Holder(s) having an anticipated aggregate offering price, net of Selling Expenses, of at least $1,000,000, then the Company shall (i) within ten (10) days after the date such request is
given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the
Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Board it would be materially detrimental to the Company and its stockholders for such
registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition,
corporate reorganization, or other similar transaction involving the Company, (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential, or (iii) render the
Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall
be tolled correspondingly, for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any
twelve (12) month period. 
 (d) The Company shall not be obligated to effect, or to take any action to effect, any registration
pursuant to Section 2.1(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the
effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has
effected two registrations pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form
S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Section 2.1(b) (i) 

  
 4 

 
during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date
of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two
registrations pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this
Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration
expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this
Section 2.1(d). 
 2.2 Company Registration. If the Company proposes to register (including, for this
purpose, a registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the
provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any
registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than
Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice. The
underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be
conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through
such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other
provision of this Section 2.3, if the managing underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders
shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable
Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders;
provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the
allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to
Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and
its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in
proportion (as nearly as practicable to) the number of 

  
 5 

 
Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance
with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable
Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering or (ii) the number of Registrable Securities included in the offering be
reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and
no other stockholder’s securities are included in such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company,
or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts
for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities
owned by all Persons included in such “selling Holder,” as defined in this sentence. 
 2.4 Obligations of the Company.
Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred
twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period
of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of
Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be
extended for up to one hundred eighty (180) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold; 

(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with
such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for
all such Registrable Securities, in each case not later than the effective date of such registration; 

  
 6 

 (h) promptly make available for inspection by the selling Holders, any underwriter(s)
participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate
documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in
each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 

(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been
declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 
 (j) after such
registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus. 

In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the
Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act.

 2.5 Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 
 2.6
Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification
fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $50,000 per registration, of one counsel for the selling Holders (“Selling Holder
Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the
registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable
Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the
case may be; provided, further, that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of
their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to
Sections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of
Registrable Securities registered on their behalf.  
 2.7 Delay of Registration. No Holder shall have any right to obtain or
seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other

  
 7 

 
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses
are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected
without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity
with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration. 

(b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of
its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the
Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based
upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company
and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided,
however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder,
which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the
proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of
any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure
materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Section 2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in
any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment
or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as
is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to
reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, 

  
 8 

 
whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the
indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case (x) no Holder will be required
to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided, further, that in no event shall a Holder’s liability
pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any
Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 
 (e) Notwithstanding the
foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions
in the underwriting agreement shall control. 
 (f) Unless otherwise superseded by an underwriting agreement entered into in connection with
the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this
Section 2, and otherwise shall survive the termination of this Agreement. 
 2.9 Reports Under Exchange
Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to
a registration on Form S-3, the Company shall: 
 (a) make and keep available adequate current
public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO; 

(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 
 (c)
furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any
time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or
that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and
such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without
registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

2.10 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that (i) would provide to such holder the right to
include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of
Registrable Securities that they wish to so include; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall
not apply to any additional Investor who becomes a party to this Agreement in accordance with Section 6.9. 

  
 9 

 2.11 “Market
Stand-off” Agreement. 
 (a) Each Holder hereby agrees that it will
not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its Common Stock or any other equity securities under the
Securities Act on a registration statement on Form S-1, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, which period may be extended upon the request
of the managing underwriter for an additional period of up to fifteen (15) days to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions,
including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase;
purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable
(directly or indirectly) for Common Stock, held immediately before the effective date of the registration statement for the IPO (excluding any shares purchased in connection with or conditioned on the IPO and any securities acquired following the
effective date of the registration statement for the IPO), or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any
such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall only apply to
the IPO and shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder,
provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided, further, that any such transfer shall not involve a disposition for value, and shall be applicable to the
Holders only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar agreement from all stockholders individually owning more than one percent (1%) of the
Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock). The underwriters in connection with such registration are intended third-party
beneficiaries of this Section 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be
reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto. Any discretionary waiver or termination of the
restrictions of any or all such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements. 

(b) In connection with a SPAC Transaction, each Holder agrees to enter into an agreement with the SPAC or the Company to not transfer the
Public Shares received by such Holder in connection with the SPAC Transaction (excluding (i) any Public Shares received in exchange for or upon conversion of securities issued in a private placement that is connected to or conditioned on the
SPAC Transaction and (ii) any securities acquired following the consummation of the SPAC Transaction) pursuant to terms substantially similar to the terms in Section 2.11(a) (modified as appropriate for a SPAC Transaction). 

2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144, in each case,
to be bound by the terms of this Agreement. 

  
 10 

 (b) Each certificate, instrument or book-entry representing (i) the Preferred Stock,
(ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event,
shall (unless otherwise permitted by the provisions of Section 2.12(c)) be notated, stamped or otherwise imprinted with a legend substantially in the following form: 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES
MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER,
A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to the Company making a notation in its records and
giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(c) The holder of such Restricted Securities, by acceptance thereof, agrees to comply in all respects with the provisions of this
Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall
give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the
effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or
transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the
terms of the notice given by the Holder to the Company. The Company will not require such a notice, legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which
such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that, with respect to transfers under the foregoing clause (y), each transferee agrees in writing to be subject to the terms of this
Section 2.12. Each certificate, instrument or book entry representing the Restricted Securities transferred as above provided shall bear, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive
legend set forth in Section 2.12(b), except that such certificate, instrument or book entry shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required
in order to establish compliance with any provisions of the Securities Act. 
 2.13 Termination of Registration Rights. The right of
any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1 or 2.2 shall terminate upon the earliest to occur of: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation; 

(b) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such Holder’s
shares without limitation during a three-month period without registration (and without the requirement for the Company to be in compliance with the current public information required under subsection (c)(1) of SEC Rule 144); and 

(c) the third (3rd) anniversary of the earliest to occur of (A) the IPO or
(B) a SPAC Transaction. 

  
 11 

 3. Information and Observer Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Investor, provided that the Board has not reasonably determined
that such Investor is a Competitor: 
 (a) as soon as practicable after the end of each fiscal year of the Company, and in any event within
one hundred fifty (150) days after the end of each fiscal year of the Company (provided that for the 2020 fiscal year end, such period shall be one hundred eighty (180) days after the 2020 fiscal year end), a consolidated balance sheet of
the Company and its subsidiaries, if any, as at the end of such fiscal year, and consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such year; all such financial statements audited and certified by
independent public accountants selected by the Company; 
 (b) as soon as practicable after the end of the first, second and third quarterly
accounting periods in each fiscal year of the Company, and in any event within forty-five (45) days after the end of the first, second, and third quarterly accounting periods in each fiscal year of the Company, an unaudited consolidated balance
sheet of the Company and its subsidiaries, if any, as of the end of each such quarterly period, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such period, prepared in accordance with
U.S. generally accepted accounting principles consistently applied, subject to changes resulting from normal year-end audit adjustments; 

(c) as soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the
Company, a summary statement showing the aggregate number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable
upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but
reserved for issuance, if any, all in sufficient detail as to permit the Investors to calculate their respective percentage equity ownership in the Company; and 

(d) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget for the next fiscal year,
prepared on a monthly basis, including revenue, expenses and cash position for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.

Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information
set forth in this Section 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must
do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is
no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 
 3.2
Inspection. The Company shall permit each Investor (provided that the Board has not reasonably determined that such Investor is a Competitor), at such Investor’s expense, to visit and inspect the Company’s properties; examine its
books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, in all cases during normal business hours of the Company as may be reasonably requested by the Investor; provided, however,
that the Company shall not provide, pursuant to this Section 3.2, access to any information that it in good faith considers to be (x) a trade secret or (y) scientific or technical confidential information that is
competitively sensitive; provided, further, that (i) the Company shall not be obligated to provide, pursuant to this Section 3.2, access to any information that it reasonably and in good faith determines
the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel and (ii) any confidential information disclosed pursuant to this Section 3.2 shall be subject to the
confidentiality and other restrictions under Section 3.5.  

  
 12 

 3.3 Observer Rights. As long as any shares of the Series A Preferred Stock, the
Series A-1 Preferred Stock, or the Series B Preferred are outstanding, the holders of a majority of the Series A Preferred, the Series A-1 Preferred, and the Series B
Preferred shall have the right, by a vote of a majority of the holders of such series of Preferred Stock, voting together as a single class on an as converted to Common Stock basis, to designate one (1) representative thereof who shall be
invited by the Company to attend all meetings of the Board in a nonvoting observer capacity and, in this respect, shall be given copies of all notices, minutes, consents, and other materials that the Company provides to the Board, such materials to
be made available to such representative at or about the time as such materials are provided to the Board; provided, however, that such representative shall agree to hold in confidence all information so provided (it being understood
that such representative shall be entitled to provide such information to the holders of the outstanding shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, and the Series B Preferred,
subject to the confidentiality and the other restrictions set forth in this Agreement); provided, further, that the Company reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof
if the Board has determined that such representative is a Competitor and/or if the representative’s access to such information or attendance at such meeting could adversely affect the attorney-client privilege between the Company and its
counsel or result in a conflict of interest or disclosure of trade secrets; and provided, further, that the Company may instruct such representative to withhold (and such representative shall withhold) such information from any holder
of shares of the Series A Preferred Stock, the Series A-1 Preferred Stock, and/or the Series B Preferred if the Board has determined that such holder is a Competitor. 

3.4 Termination of Rights. The covenants set forth in Section 3.1, Section 3.2 and
Section 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the earliest to occur of (A) the IPO or (B) a SPAC Transaction, (ii) when the Company first
becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act due to shares of the Company, or a parent of the Company, being listed on a national securities exchange or trading system, or (iii) upon
the closing of a Deemed Liquidation Event, whichever event occurs first. 
 3.5 Confidentiality. Each Investor agrees that such
Investor will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including
notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this
Section 3.5 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the
Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants,
consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such
prospective purchaser agrees to be bound by the provisions of this Section 3.5; (iii) to any Affiliate or any existing or prospective partner, member, stockholder, or wholly owned subsidiary of such Investor in the
ordinary course of business, provided, that, to the extent such Persons do not have professional confidentiality obligations under law or the applicable profession’s code of conduct, unless such Person is otherwise subject to an
obligation of confidentiality with respect to such information, the Investor obtains from such Person an agreement to comply with the confidentiality provisions that apply to the Investor pursuant to this Agreement; (iv) as requested by a
regulator or self-regulatory organization; (v) to the extent necessary in connection with Investor’s tax filings, financial, and other reporting (including with the SEC) and accounting matters; or (vi) as may otherwise be required by
law, provided that, such Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. Notwithstanding anything in this Agreement to the contrary and unless an
Investor is an Excepted Investor (as defined in the Purchase Agreement), the Company shall not provide any Investor that is a foreign person (as defined under Section 721 of the Defense Production Act of 1950, as amended, including all
implementing regulations thereof (the “DPA”)) with “material non-public technical information” within the meaning of Section 721 of the DPA. 

4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities
laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities 

  
 13 

 
to each Investor. An Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself, (ii) its
Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under
the Exchange Act, of such Investor (“Investor Beneficial Owners”); provided that each such Affiliate or Investor Beneficial Owner (x) is not a Competitor, unless such party’s purchase of New Securities is
otherwise consented to by the Board, (y) agrees to enter into this Agreement and each of the Voting Agreement and the Right of First Refusal and Co-Sale Agreement (as those terms are defined in the
Purchase Agreement) as an “Investor” under each such agreement (provided that any Competitor shall not be entitled to any rights as an Investor under Sections 3.1, 3.2, 3.3 and/or 4.1 hereof), and
(z) agrees to purchase at least such number of New Securities as are allocable hereunder to the Investor holding the fewest number of Preferred Stock and any other Derivative Securities. 

(a) The Company shall give notice (the “Offer Notice”) to each Investor, stating (i) its bona fide intention to offer
such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities. 

(b) By notification to the Company within ten (10) days after the Offer Notice is given, each Investor may elect to purchase or otherwise
acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Investor (including all shares of Common Stock then issuable
(directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Investor) bears to the total Common Stock of the Company then outstanding (assuming full conversion
and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such ten (10) day period, the Company shall promptly notify each Investor that elects to purchase or acquire all the shares available
to it (each, a “Fully Exercising Investor”) of any other Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving
notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Investors were entitled to subscribe but that were not subscribed for by the Investors which
is equal to the proportion that the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising
Investor bears to the Common Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors
who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial
sale of New Securities pursuant to Section 4.1(c). 
 (c) If all New Securities referred to in the Offer Notice
are not elected to be purchased or acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in
Section 4.1(b), offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer
Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within ninety (90) days of the execution thereof, the right provided hereunder shall be
deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with this Section 4.1. 

(d) The right of first offer in this Section 4.1 shall not be applicable to (i) Exempted Securities (as defined
in the Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of shares of Series C Preferred Stock to Additional Purchasers pursuant to the Purchase Agreement. 

(e) Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of this
Section 4.1, the Company may elect to give notice to the Investors within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities. Each
Investor shall have twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Investor, maintain such Investor’s percentage-ownership position, calculated as set
forth in Section 4.1(b) before giving effect to the issuance of such New Securities. The closing of such sale shall occur within sixty (60) days of the date notice is given to the Investors. 

  
 14 

 4.2 Termination. The covenants set forth in Section 4.1
shall terminate and be of no further force or effect (A) immediately before the consummation of the earliest to occur of (A) the IPO or (B) a SPAC Transaction, (B) when the Company first becomes subject to the periodic reporting
requirements of Section 12(g) or 15(d) of the Exchange Act due to shares of the Company, or a parent of the Company, being listed on a national securities exchange or trading system, or (C) upon the closing of a Deemed Liquidation Event,
whichever event occurs first. 
 5. Additional Covenants. 

5.1 Insurance. At all times the Company will maintain directors’ and officers’ liability, employment practices liability, and
product liability insurance in amounts and on terms to be determined by the Board. For so long as any Series C Director (as defined in the Certificate of Incorporation) is serving on the Board, the Company shall, no later than thirty
(30) calendar days after each expiration or renewal date of such directors’ and officers’ liability insurance policy, deliver to each Investor that designated a Series C Director then serving on the Board a copy of the new or renewed
directors’ and officers’ liability insurance policy (and evidence of such renewal thereof, if applicable) and written confirmation that such policy remains in effect. 

5.2 Key Person Insurance. The Company shall maintain key person insurance on the life of Rachel E. Haurwitz, in amounts satisfactory to
the Board, with the Company as a beneficiary and shall use commercially reasonable efforts to cause such insurance to be maintained until such time as the Board, including a majority of the Preferred Directors, determines that such insurance should
be discontinued. 
 5.3 Employee Agreements. The Company will cause each person now or hereafter employed by it or by any wholly
owned subsidiary with access to confidential information and/or trade secrets to enter into a confidential information and invention assignment agreement or similar agreement. 

5.4 Board Matters. The Company shall reimburse the non-employee directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board. As long as the holders of Series
C Preferred Stock have the right to designate a Series C Director, the Company shall permit at least one (1) Series C Director to serve on each committee of the Board. 

5.5 Right to Conduct Activities. The Company hereby agrees and acknowledges that each of the Lead Investors (together with its
Affiliate funds) is a professional investment organization and AbbVie makes similar investments consistent with a professional investment organization, and as such reviews the business plans and related proprietary information of many enterprises,
some of which may compete directly or indirectly with the Company’s business (as currently conducted or as currently propose to be conducted). Nothing in this Agreement shall preclude or in any way restrict the Lead Investors (or its Affiliate
funds) and AbbVie from evaluating or purchasing securities, including publicly traded securities, of a particular enterprise, or investing or participating in any particular enterprise whether or not such enterprise has products or services which
compete with those of the Company; and the Company hereby agrees that, to the extent permitted under applicable law, none of the Lead Investors (or their respective Affiliate funds) and AbbVie shall be liable to the Company for any claim arising out
of, or based upon, (i) the investment by such Lead Investor (or its Affiliate funds) and AbbVie in any entity competitive with the Company, or (ii) actions taken by any partner, officer, employee or other representative of such Lead
Investor (or its Affiliate funds) and AbbVie to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a
detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Lead Investors (or its Affiliate funds) and AbbVie from liability associated with the unauthorized disclosure of the
Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. 

5.6 Termination of Covenants. The covenants set forth in this Section 5 shall terminate and be of no further
force or effect (i) immediately before the consummation of the earliest to occur of (A) the IPO or (B) a SPAC Transaction, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g)
or 

  
 15 

 
15(d) of the Exchange Act due to shares of the Company, or a parent of the Company, being listed on a national securities exchange or trading system, or (iii) upon the closing of a Deemed
Liquidation Event, whichever event occurs first. 
 6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder
to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members;
or (iii) after such transfer, holds at least 250,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that
(x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such
transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining the
number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the
benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided, further, that all transferees who would not qualify individually for
assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The
terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the
parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed
in accordance with the laws of the State of Delaware without regard to conflict of law principles. 
 6.3 Counterparts. This
Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail
(including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, such as, www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be
valid and effective for all purposes. 
 6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for
convenience only and are not to be considered in construing or interpreting this Agreement. 
 6.5 Notices. All notices and other
communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by
electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day
delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to such email address, facsimile number, or address as subsequently modified by
written notice given in accordance with this Section 6.5. If notice is given to the Company, it shall be sent to Caribou Biosciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710, Attention: Chief Legal Officer,
email legalnotices@cariboubio.com; and a copy (which shall not constitute notice) shall also be sent to Reed Smith LLP, 1901 Avenue of the Stars, Suite 700, Los Angeles, California 90067, email amukhey@reedsmith.com, Attention: Ashok Mukhey,
Esq., and if notice is given to an Investor, a copy shall also be given to such counsel as may appear with such Investor’s address on Schedule A hereto. 

  
 16 

 6.6 Amendments and Waivers. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities
then outstanding; provided that the Company may in its sole discretion waive compliance with Section 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment
allegedly in violation of Section 2.12(c) shall be deemed to be a waiver); provided, further, that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent
of any other party. Notwithstanding the foregoing, (a) except as provided in clause (c) of this sentence, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor
without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a
particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such
transaction; (b) the definition of “Competitor” and this clause (b) may not be amended, terminated or waived without the written consent of PIC, NIBR, DuPont, F-Prime Capital Partners
Healthcare Fund IV LP, Anterra F&A Ventures I Coöperatief U.A., PFM, Zone III Healthcare Holdings, LLC, RIDGEBACK CAPITAL INVESTMENTS LP, or AbbVie Inc., as the case may be, to the extent such Person is affected by such amendment,
termination or waiver (it being understood that any such written consent by the Investor shall constitute consent on behalf of such Investor’s Affiliates and/or Affiliate funds, as applicable), (c) the waiver of the provisions of
Section 4 with respect to a particular transaction, and any amendment of this clause (c), shall require, in addition to any other approval requirements under this Agreement, the written consent of the holders of at least two-thirds (2/3rds) of the then outstanding shares of Series C Preferred Stock and if any holders of Series C Preferred Stock purchase securities in such
transaction, such two-thirds (2/3rds) of the then outstanding shares of Series C Preferred Stock must include each Lead Investor;
(d) Section 1.16, Section 5.5 and this clause (d) may not be amended or waived without the written consent of each Lead Investor and (e) Section 5.5 and this clause (e) may
not be amended or waived with respect to AbbVie without the written consent of AbbVie Inc. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such
amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No
waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 

6.7 Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal
or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid,
legal, and enforceable to the maximum extent permitted by law. 
 6.8 Aggregation of Stock. All shares of Registrable Securities held
or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.

 6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of
the Series C Preferred Stock after the date hereof pursuant to the Purchase Agreement, any purchaser of such shares of Series C Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page
to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional
Investor has agreed in writing to be bound by all of the obligations as an “Investor” hereunder. 
 6.10 Entire Agreement.
This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject
matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no
further force or effect. 

  
 17 

 6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally
submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement,
(b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and
agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from
attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such
court. 
 WAIVER OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY
COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY
DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY
KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. 
 6.12 Delays or Omissions. No
delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or
nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any
other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.13 Tekla Funds. A copy of the Declaration of Trust, as amended and restated, for each of Tekla Healthcare Investors and Tekla Life
Sciences Investors (together, the “Tekla Funds”) is on file with the Secretary of State of The Commonwealth of Massachusetts, and notice is hereby given that this Agreement is executed on behalf of the Tekla Funds by an officer or
trustee of the Tekla Funds in his or her capacity as an officer or trustee of the Tekla Funds, and not individually and that the obligations of or arising out of this Agreement are not binding upon any of the trustees, officers or shareholders
individually but are binding only upon the assets and property of each of the respective Tekla Funds. 
 [The remainder of this page is
left intentionally blank.] 

  
 18 

 IN WITNESS WHEREOF, the parties have executed this Seconded Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	CARIBOU BIOSCIENCES, INC.
		
	By:	 	 /s/ Rachel E. Haurwitz

	Name:	 	 Rachel E. Haurwitz

	Title:	 	 President and Chief Executive Officer

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	PFM Healthcare Master Fund, L.P.
	By: PFM Health Sciences, LP, its investment advisor
		
	By:	 	 /s/ Yuan DuBord

	Name:	 	 Yuan DuBord

	Title:	 	 CFO

	
	Partner Investments, L.P.
	By: PFM Health Sciences, LP, its investment advisor
		
	By:	 	 /s/ Yuan DuBord

	Name:	 	 Yuan DuBord

	Title:	 	 CFO

	
	PFM Healthcare Growth Equity Holdings I, LLC
	By: PFM Health Sciences GP, LLC, its member manager
		
	By:	 	 /s/ Yuan DuBord

	Name:	 	 Yuan DuBord

	Title:	 	 CFO

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	ZONE III HEALTHCARE HOLDINGS, LLC
	
	By: Farallon Capital Management, L.L.C., its Manager
		
	By:	 	 /s/ Philip Dreyfuss

	Name:	 	 Philip Dreyfuss

	Title:	 	 Authorized Signatory

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	RIDGEBACK CAPITAL INVESTMENTS LP
	by RIDGEBACK CAPITAL MANAGEMENT LLC its Fund Manager:
		
	By:	 	 /s/ Christian Sheldon

	Name:	 	 Christian Sheldon

	Title:	 	 COO

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	AbbVie Inc.
		
	By:	 	 /s/ Adam Houghton

	Name:	 	 Adam Houghton

	Title:	 	 VP & Head, AbbVie Ventures

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	MAVERICK VENTURES INVESTMENT FUND, L.P.
	
	By: Maverick Capital Ventures, LLC, its General Partner
	By: Maverick Capital Advisors, L.P., its Manager
		
	By:	 	 /s/ Ginessa Avila

	Name:	 	 Ginessa Avila

	Title:	 	 Authorized Signatory

	
	MAVERICK ADVISORS FUND, L.P.
	
	By: Maverick Capital Ventures, LLC, its General Partner
	By: Maverick Capital Advisors, L.P., its Manager
		
	By:	 	 /s/ Ginessa Avila

	Name:	 	 Ginessa Avila

	Title:	 	 Authorized Signatory

  
 SIGNATURE PAGE TO
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Adage Capital Partners, LP
	By: Adage Capital Partners. GP, LLC, it’s General Partner
	By: Adage Capital Advisors, LLC it’s Managing Member
		
	By:	 	 /s/ Dan Leham

	Name:	 	 Dan Leham

	Title:	 	 Chief Operating Officer

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Janus Henderson Capital Funds plc on behalf of its series Janus Henderson Global Life Sciences Fund
	
	By: Janus Capital Management LLC, its investment advisor
		
	By:	 	 /s/ Andrew Acker

	Name:	 	 Andrew Acker

	Title:	 	 Authorized Signatory

	
	Janus Henderson Biotech Innovation Master Fund Limited
	
	By: Janus Capital Management LLC, its investment advisor
	By:	 	 /s/ Andrew Acker

	Name:	 	 Andrew Acker

	Title:	 	 Authorized Signatory

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	CAROLEM CAPITAL LLC
		
	By	 	 /s/ Michael Karlin

	Name:	 	 Michael Karlin

	Title:	 	 Manager

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Central Valley Administrators, Inc.
		
	By:	 	 /s/Richard Merkin

	Name:	 	 Richard Merkin

	Title:	 	 President

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	AngelList-Cces-Fund, a series of AngelList-JR-Funds, LLC
		
	By:	 	 /s/ Brett Sagan

	Name:	 	 Brett Sagan

	Title:	 	 Authorized Person

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
 INVESTORS: 

AngelList-Cces-PR-Fund, a series of AngelList-JR-Funds, LLC 

			
		
	By:	 	 /s/ Brett Sagan

	Name:	 	 Brett Sagan

	Title:	 	 Authorized Person

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Jenny Rooke
		
	By:	 	 /s/ Jenny Rooke

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Point72 Biotech Private Investments, LLC
		
	By:	 	 /s/ Vincent Tortorella

	Name:	 	 Vincent Tortorella

	Title:	 	 Authorized Signatory

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	NRG CAPITAL HOLDINGS LLC
		
	By:	 	 /s/ Michael Karlin

	Name:	 	 Michael Karlin

	Title:	 	 Manager

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	LLS TAP, LLC
		
	By:	 	 /s/ Louis DeGennaro

	Name:	 	 Louis DeGennaro

	Title:	 	 President & CEO

		
	By:	 	 /s/ Gordon Miller

	Name:	 	 Gordon Miller

	Title:	 	 EVP & CFO

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Tekla Healthcare Investors*
		
	By:	 	 /s/ Daniel R. Omstead

	Name:	 	 Daniel R. Omstead

	Title:	 	 President

  

	*	 The name Tekla Healthcare Investors is the designation of the Trustees for the time being under an
Amended & Restated Declaration of Trust dated April 21, 1987, as amended, and all persons dealing with Tekla Healthcare Investors must look solely to the trust property for the enforcement of any claim against Tekla Healthcare
Investors, as neither the Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Healthcare Investors. 

 

			
	Tekla Life Sciences Investors*
		
	By:	 	 /s/ Daniel R. Omstead

	Name:	 	 Daniel R. Omstead

	Title:	 	 President

  

	*	 The name Tekla Life Sciences Investors is the designation of the Trustees for the time being under a
Declaration of Trust dated February 20, 1992, as amended, and all persons dealing with Tekla Life Sciences Investors must look solely to the trust property for the enforcement of any claim against Tekla Life Sciences Investors, as neither the
Trustees, officers nor shareholders assume any personal liability for the obligations entered into on behalf of Tekla Life Sciences Investors. 

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	PONTIFAX GLOBAL FOOD AND AGRICULTURE TECHNOLOGY FUND, L.P.
		
	By:	 	 /s/ Benjamin Belldegrun

	Name:	 	 Benjamin Belldegrun

	Title:	 	 Managing Partner

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Monashee Solitario Fund LP
		
	By:	 	 /s/ Jeff Muller

	Name:	 	 Jeff Muller

	Title:	 	 COO

	
	DS Liquid Div RVA MON LLC
		
	By:	 	 /s/ Jeff Muller

	Name:	 	 Jeff Muller

	Title:	 	 COO

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	James and Jennifer Doudna Cate Living Trust DTD 01/02/2014
		
	By:	 	 /s/ Jennifer Doudna

	Name:	 	 Jennifer Doudna

	Title:	 	 Trustee

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Rodolphe and Lisa Barrangon
		
	By:	 	 /s/ Rodolphe Barrangon

		
	By:	 	 /s/ Lisa Barrangon

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Mintz Levin Special Investments Fund LLC
		
	By:	 	 /s/ Megan N. Gates

	Name:	 	 Megan N. Gates

	Title:	 	 Member

	
	Mintz Levin Special Investments Fund LLC - Series FY21
		
	By:	 	 /s/ Megan N. Gates

	Name:	 	 Megan N. Gates

	Title:	 	 Member

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	F-PRIME CAPITAL PARTNERS HEALTHCARE FUND IV LP
	
	By: F-Prime Capital Partners Healthcare Advisors Fund IV LP, its General Partner
	By: Impresa Holdings LLC, its General Partner
	By: Impresa Management LLC, its Managing Member
		
	By:	 	 /s/ Mary Bevelock Pendergast

	Name:	 	 Mary Bevelock Pendergast

	Title:	 	 Vice President

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Zachary A. Robbins Trust dtd December 31, 1987
		
	By:	 	 /s/ Rich Robbins

	Name:	 	 Rich Robbins

	Title:	 	 Trustee

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Robbins Family Trust of 1986
		
	By:	 	 /s/ Rich Robbins

	Name:	 	 Rich Robbins

	Title:	 	 Trustee

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Lucas Hamilton Robbins Trust dtd November 17, 1991
		
	By:	 	 /s/ Rich Robbins

	Name:	 	 Rich Robbins

	Title:	 	 Trustee

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Avidity Master Fund LP
		
	By:	 	 /s/ Michael Gregory

	Name:	 	 Michael Gregory

	Title:	 	 Director

	
	Avidity Capital Fund II LP
		
	By:	 	 /s/ Michael Gregory

	Name:	 	 Michael Gregory

	Title:	 	 Director

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Anterra F&A Ventures I Coöperatief U.A.
		
	By:	 	 /s/ Adam Sanders

	Name:	 	 Adam Sanders

	Title:	 	 Director

		
	By:	 	 /s/ Martin Goossens

	Name:	 	 Martin Goossens

	Title:	 	 Director

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Novartis Institutes for BioMedical Research, Inc.
		
	By:	 	 /s/ Scott A Brown

	Name:	 	 Scott A Brown

	Title:	 	 VP CAO

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	INVUS PUBLIC EQUITIES, L.P.
		
	By:	 	 /s/ Raymond Debbane

	Name:	 	 Raymond Debbane

	Title:	 	 President of its General Partner

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	CA Fund I, a series of 5 Prime Ventures, LP
	By: Fund GP, LLC its General Partner
	By: Belltower Fund Group, Ltd. Manager of the General Partner
		
	By:	 	 /s/ Brett Sagan

	Name:	 	 Brett Sagan

	Title:	 	 Authorized Person

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	LifeSci Venture Partners II, LP
		
	By:	 	 /s/ Paul Yook

	Name:	 	 Paul Yook

	Title:	 	 Managing Member

	
	LifeSci Venture Master SPV, LLC
		
	By:	 	 /s/ Paul Yook

	Name:	 	 Paul Yook

	Title:	 	 Managing Member

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investon’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	James Berger & Marian Feldman
		
	By:	 	 /s/ James Berger

		
	By:	 	 /s/ Marian Feldman

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	E. I. du Pont de Nemours and Company
		
	By:	 	 /s/ George J. Duko

	Name:	 	 George J. Duko

	Title:	 	 Vice President, Mergers & Acquisitions

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	HEALTHCARE INNOVATION INVESTMENT FUND LLC
		
	By:	 	 /s/ Joseph R. Gentile

	Name:	 	 Joseph R. Gentile

	Title:	 	 Manager

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Avego Bioscience Capital, L.P.
	
	By: Avego Bioscience Capital GP, LLC, its general partner
		
	By:	 	 /s/ James Flexner

	Name:	 	 James Flexner

	Title:	 	 Managing Partner

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Pacific Continental Investment Company, LLC
		
	By:	 	 /s/ Marc Stridiron

	Name:	 	 Marc Stridiron

	Title:	 	 Portfolio Manager

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	Pig Improvement Company UK Limited
		
	By:	 	 /s/ Stephen Wilson

	Name:	 	 Stephen Wilson

	Title:	 	 CEO

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	WS Investment Company, LLC (21A)
		
	By:	 	 /s/ James Terranova

	Name:	 	  

	Title:	 	  

	
	WS Investment Company, LLC (2014A)
	By:	 	 /s/ James Terranova

	Name:	 	  

	Title:	 	  

	
	WS Investment Company, LLC (2015A)
	By:	 	 /s/ James Terranova

	Name:	 	  

	Title:	 	  

  

SIGNATURE PAGE TO SECOND AMENDED AND
RESTATED INVESTORS’ RIGHTS AGREEMENT 

 SCHEDULE A 

InvestorsEX-10.1

 Certain identified information has been excluded from this exhibit because it is both not material and
is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

Exhibit 10.1 

Execution Version 

CONFIDENTIAL 

COLLABORATION AND LICENSE AGREEMENT 

Between 
 CARIBOU
BIOSCIENCES, INC. 
 And 

ABBVIE MANUFACTURING MANAGEMENT UNLIMITED COMPANY 

Dated as of February 9, 2021 

 CONFIDENTIAL 

TABLE OF CONTENTS 
  

							
	 ARTICLE 1 DEFINITIONS
	  	 	1	 
		
	 ARTICLE 2 MANAGEMENT OF THE COLLABORATION
	  	 	19	 
			
	 2.1
	 	 Joint Governance Committee.
	  	 	19	 
	 2.2
	 	 Specific Responsibilities.
	  	 	19	 
	 2.3
	 	 Meetings and Minutes.
	  	 	19	 
	 2.4
	 	 Procedural Rules.
	  	 	19	 
	 2.5
	 	 Decision-Making.
	  	 	20	 
	 2.6
	 	 Alliance Managers.
	  	 	20	 
	 2.7
	 	 Discontinuation of Committees.
	  	 	20	 
	 2.8
	 	 Interactions Between a Committee and Internal Teams.
	  	 	20	 
	 2.9
	 	 Working Groups.
	  	 	21	 
	 2.10
	 	 Expenses.
	  	 	21	 
	 2.11
	 	 Authority.
	  	 	21	 
		
	 ARTICLE 3 RESEARCH COLLABORATION
	  	 	21	 
			
	 3.1
	 	 Research Collaboration Overview.
	  	 	21	 
	 3.2
	 	 Program Slots; Research Plans.
	  	 	21	 
	 3.3
	 	 Conduct of Research Plan.
	  	 	24	 
	 3.4
	 	 Caribou Optional and Opt In Technology.
	  	 	24	 
	 3.5
	 	 Research Reports
	  	 	24	 
	 3.6
	 	 Data Packages
	  	 	25	 
	 [***]
	 		  			
	 3.8
	 	 Research Costs.
	  	 	25	 
	 3.9
	 	 Third Party Providers.
	  	 	26	 
	 3.10
	 	 Supply of Technology for Development Purposes
	  	 	26	 
	 3.11
	 	 Provision of Certain Materials.
	  	 	27	 
	 3.12
	 	 Regulatory Matters.
	  	 	27	 
		
	 ARTICLE 4 DEVELOPMENT AND COMMERCIALIZATION BY ABBVIE
	  	 	28	 
			
	 4.1
	 	 AbbVie Development and Commercialization.
	  	 	28	 
	 4.2
	 	 Transition Plan.
	  	 	28	 
	 4.3
	 	 Caribou Transition Obligation.
	  	 	28	 
	 4.4
	 	 Manufacturing.
	  	 	28	 
	 4.5
	 	 Diligence.
	  	 	29	 
	 4.6
	 	 Booking of Sales; Distribution.
	  	 	29	 
	 4.7
	 	 Product Trademarks.
	  	 	29	 
	 4.8
	 	 Markings.
	  	 	30	 
		
	 ARTICLE 5 GRANT OF RIGHTS
	  	 	30	 
			
	 5.1
	 	 Grants to AbbVie.
	  	 	30	 
	 5.2
	 	 Grants to Caribou.
	  	 	31	 
	 5.3
	 	 Sublicenses.
	  	 	31	 
	 5.4
	 	 Distributorships.
	  	 	31	 
	 5.5
	 	 Existing IP Agreements.
	  	 	31	 
	 5.6
	 	 Future In-License Agreements.
	  	 	31	 
	 5.7
	 	 Retention of All Other Rights.
	  	 	34	 
	 [***]
	 		  			
	 5.9
	 	 Exclusivity.
	  	 	35	 
		
	 ARTICLE 6 PAYMENTS AND RECORDS.
	  	 	35	 
			
	 6.1
	 	 Upfront Payment.
	  	 	35	 
	 6.2
	 	 Equity Investment.
	  	 	35	 

  
 - i - 

 CONFIDENTIAL 
  

							
	 6.3
	 	 Additional Program Slot Fees.
	  	 	35	 
	 6.4
	 	 Milestone Payments.
	  	 	35	 
	 6.5
	 	 Royalties.
	  	 	36	 
	 6.6
	 	 Estimated Sales Levels.
	  	 	37	 
	 6.7
	 	 Royalty Payments and Reports.
	  	 	37	 
	 6.8
	 	 Mode of Payment; Offsets.
	  	 	37	 
	 6.9
	 	 Interest on Late Payments.
	  	 	37	 
	 6.10
	 	 Withholding Taxes.
	  	 	37	 
	 6.11
	 	 Indirect Taxes.
	  	 	38	 
	 6.12
	 	 Financial Records.
	  	 	38	 
	 6.13
	 	 Audit.
	  	 	38	 
	 6.14
	 	 Audit Dispute.
	  	 	38	 
	 6.15
	 	 Confidentiality.
	  	 	38	 
	 6.16
	 	 No Other Compensation.
	  	 	39	 
	 6.17
	 	 No Limitation.
	  	 	61	 
		
	 ARTICLE 7 INTELLECTUAL PROPERTY
	  	 	39	 
			
	 7.1
	 	 Ownership of Intellectual Property.
	  	 	39	 
	 7.2
	 	 Maintenance and Prosecution of Patents.
	  	 	40	 
	 7.3
	 	 Enforcement of IP.
	  	 	41	 
	 7.4
	 	 Infringement Claims by Third Parties.
	  	 	42	 
	 7.5
	 	 Invalidity or Unenforceability Defenses or Actions.
	  	 	43	 
	 7.6
	 	 Third Party Patents.
	  	 	44	 
	 7.7
	 	 Product Trademarks.
	  	 	44	 
	 7.8
	 	 Inventor’s Remuneration.
	  	 	44	 
	 7.9
	 	 International Nonproprietary Name.
	  	 	44	 
	 7.10
	 	 Common Interest.
	  	 	45	 
		
	 ARTICLE 8 CONFIDENTIALITY AND
NON-DISCLOSURE
	  	 	45	 
			
	 8.1
	 	 Product Information.
	  	 	45	 
	 8.2
	 	 Confidentiality Obligations.
	  	 	45	 
	 8.3
	 	 Permitted Disclosures.
	  	 	46	 
	 8.4
	 	 Use of Name.
	  	 	47	 
	 8.5
	 	 Public Announcements.
	  	 	47	 
	 8.6
	 	 Publications.
	  	 	48	 
	 8.7
	 	 Return of Confidential Information.
	  	 	48	 
	 8.8
	 	 Survival.
	  	 	49	 
		
	 ARTICLE 9 REPRESENTATIONS AND WARRANTIES
	  	 	49	 
			
	 9.1
	 	 Mutual Representations and Warranties.
	  	 	49	 
	 9.2
	 	 Additional Representations and Warranties of Caribou.
	  	 	49	 
	 9.3
	 	 Additional Representations and Warranties of AbbVie.
	  	 	49	 
	 9.4
	 	 DISCLAIMER OF WARRANTIES.
	  	 	49	 
		
	 ARTICLE 10 INDEMNITY
	  	 	50	 
			
	 10.1
	 	 Indemnification of Caribou.
	  	 	50	 
	 10.2
	 	 Indemnification of AbbVie.
	  	 	50	 
	 10.3
	 	 Notice of Claim.
	  	 	50	 
	 [***]
	 		  			
	 10.5
	 	 Control of Defense.
	  	 	50	 
	 [***]
	 		  			
	 10.7
	 	 Insurance.
	  	 	51	 
		
	 ARTICLE 11 TERM AND TERMINATION
	  	 	52	 
			
	 11.1
	 	 Term.
	  	 	52	 

  
 - ii - 

 CONFIDENTIAL 
  

							
	 11.2
	 	 Termination for Material Breach.
	  	 	52	 
	 11.3
	 	 Additional Termination Rights by AbbVie.
	  	 	53	 
	 11.4
	 	 Termination for Insolvency.
	  	 	53	 
	 11.5
	 	 Rights in Bankruptcy.
	  	 	53	 
	 11.6
	 	 Modification in Lieu of Termination.
	  	 	54	 
	 11.7
	 	 Termination in Entirety.
	  	 	54	 
	 11.8
	 	 Termination of Terminated Territory.
	  	 	54	 
	 11.9
	 	 Remedies.
	  	 	54	 
	 11.10
	 	 Accrued Rights; Surviving Obligations.
	  	 	54	 
		
	 ARTICLE 12 MISCELLANEOUS
	  	 	55	 
			
	 12.1
	 	 Force Majeure.
	  	 	55	 
	 12.2
	 	 Change in Control of Caribou.
	  	 	55	 
	 12.3
	 	 Export Control.
	  	 	55	 
	 12.4
	 	 Assignment.
	  	 	55	 
	 12.5
	 	 Subcontracting.
	  	 	56	 
	 12.6
	 	 Severability.
	  	 	56	 
	 12.7
	 	 Governing Law, Jurisdiction and Service.
	  	 	56	 
	 12.8
	 	 Dispute Resolution.
	  	 	56	 
	 12.9
	 	 Notices.
	  	 	57	 
	 12.10
	 	 Entire Agreement; Amendments.
	  	 	57	 
	 12.11
	 	 English Language.
	  	 	57	 
	 12.12
	 	 Equitable Relief.
	  	 	57	 
	 12.13
	 	 Waiver and Non-Exclusion of Remedies.
	  	 	58	 
	 12.14
	 	 No Benefit to Third Parties.
	  	 	58	 
	 12.15
	 	 Further Assurance.
	  	 	58	 
	 12.16
	 	 Relationship of the Parties.
	  	 	58	 
	 12.17
	 	 Performance by Affiliates.
	  	 	58	 
	 12.18
	 	 Counterparts; Facsimile Execution.
	  	 	58	 
	 12.19
	 	 References.
	  	 	58	 
	 12.20
	 	 Schedules.
	  	 	59	 
	 12.21
	 	 Construction.
	  	 	59	 
		
	 SCHEDULE 1.59
	  	 	62	 
		
	 SCHEDULE 1.64
	  	 	63	 
		
	 SCHEDULE 1.67
	  	 	64	 
		
	 SCHEDULE 1.154
	  	 	67	 
		
	 SCHEDULE 3.2.1(A)
	  	 	68	 
		
	 SCHEDULE 3.2.1(B)
	  	 	69	 
		
	 SCHEDULE 3.2.2
	  	 	70	 
		
	 SCHEDULE 3.2.4
	  	 	71	 
		
	 SCHEDULE 3.9
	  	 	72	 
		
	 SCHEDULE 8.5
	  	 	73	 
		
	 SCHEDULE 9.2.6(C)
	  	 	75	 
		
	 SCHEDULE 12.8.3
	  	 	76	 

  
 - iii - 

 CONFIDENTIAL 

COLLABORATION AND LICENSE AGREEMENT 

This Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of February (the
“Effective Date”) by and between Caribou Biosciences, Inc., a Delaware corporation with its principal place of business at 2929 Seventh St., Suite 105, Berkeley, CA 94710 (“Caribou”), and AbbVie Manufacturing
Management Unlimited Company, a private unlimited company incorporated under the laws of Ireland with its principal place of business at 2.3 Woodford Business Park, Santry, Dublin 9, Ireland (“AbbVie”). Caribou and AbbVie are
sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 
 Recitals

 WHEREAS, Caribou is a biopharmaceutical company focused on CRISPR-Cas genome editing;

 WHEREAS, AbbVie possesses expertise in the research, development, manufacturing, and commercialization of human pharmaceuticals;
and 
 WHEREAS, Caribou and AbbVie desire to engage in a research collaboration in which Caribou will carry out certain pre-clinical research and development activities directed to allogeneic CAR-T products as set forth in the applicable Research Plan (as defined herein), and pursuant to which
AbbVie will assume further development and commercialization of Licensed Products (as defined herein) containing or comprising certain Collaboration CAR-T Products (as defined herein) developed pursuant to a
Research Plan, worldwide, in each case as set forth in, and subject to the terms of, this Agreement. 
 NOW, THEREFORE, in
consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do
hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 Unless
otherwise specifically provided herein, the following terms shall have the following meanings: 
 1.1 “AbbVie” has
the meaning set forth in the preamble hereto. 
 1.2 “AbbVie Background IP” means the AbbVie Background Know-How and the AbbVie Background Patents. 
 1.3 “AbbVie Background Know-How” means all Know-How that is (a) owned or Controlled by AbbVie or any of its Affiliates as of the Effective Date or at any time during the Term and
(b) necessary or reasonably useful for Developing or Manufacturing any Collaboration CAR-T Products or Licensed Products, but excluding any AbbVie Collaboration
Know-How. 
 1.4 “AbbVie Background Patents” means all of the Patents that
are (a) owned or Controlled by AbbVie or any of its Affiliates as of the Effective Date or at any time during the Term and (b) necessary or reasonably useful (or, with respect to Patent applications, would be necessary or reasonably useful
if such Patent applications were to issue as Patents) for Developing or Manufacturing any Collaboration CAR-T Products or Licensed Products in the Field in the Territory, but excluding any AbbVie
Collaboration Patents. 
 1.5 “AbbVie Collaboration Inventions” means any and all Collaboration Inventions other
than Caribou Collaboration Inventions. 
 1.6 “AbbVie Collaboration IP” means the AbbVie Collaboration Inventions,
the AbbVie Collaboration Know-How and the AbbVie Collaboration Patents. 

  
 - 1 - 

 CONFIDENTIAL 
  

 1.7 “AbbVie Collaboration
Know-How” means any and all Collaboration Know-How other than Caribou Collaboration Know-How. [***] 

1.8 “AbbVie Collaboration Patents” means any and all Collaboration Patents other than Caribou Collaboration Patents.
[***] 
 1.9 “AbbVie Indemnitees” has the meaning set forth in Section 10.2. 

1.10 “AbbVie IP” means the AbbVie Background IP and the AbbVie Collaboration IP. 

1.11 “AbbVie Know-How” means the AbbVie Background Know-How and the AbbVie Collaboration Know-How. 
 [***] 

1.13 “AbbVie Patents” means the AbbVie Background Patents and the AbbVie Collaboration Patents. 

1.14 “AbbVie Payment Obligations” has the meaning set forth in Section 3.4.1. 

[***] 
 1.16
“AbbVie-Retained Third Party Provider” has the meaning set forth in Section 3.9.3. 
 1.17
“AbbVie [***]” means a [***] (a) owned or Controlled by AbbVie or its Affiliates, and (b) contributed for use in a Collaboration CAR by AbbVie in its sole discretion. [***] 

1.18 “AbbVie Sublicense Provisions” has the meaning set forth in Section 5.6.4. 

1.19 “Accepted Target” has the meaning set forth in Section 3.2.6. 

1.20 “Accounting Standards” means, with respect to a Party, that such Party shall maintain records and books of
accounts in accordance with United States Generally Accepted Accounting Principles, consistently applied. 
 1.21
“Acquisition” means, with respect to a Party, a merger, acquisition (whether of all of the stock or all or substantially all of the assets of a Person or any operating or business division of a Person) or similar transaction by or
with the Party, other than a Change in Control of the Party. 
 1.22 [***] 

1.23 “Additional Program Slot Fee” has the meaning set forth in Section 6.3. 

1.24 “Additional Program Slot Period” means the period beginning on the Effective Date and ending on the earlier of
(a) the sixtieth (60th) calendar day following completion of Phase I Clinical Studies for the first Licensed Product under the Initial Program Slot; and (b) December 31, 2025. 

[***] 
 1.26
“Adverse Ruling” has the meaning set forth in Section 11.2.1.  
 1.27
“Affiliate” means any corporation or other business entity or Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with a Party for so long as such control
exists. For purposes of this definition, the term “control” (including, the correlative meanings, “controlled 

  
 - 2 - 

 CONFIDENTIAL 
  

 
by” and “under common control with”) means (a) the direct or indirect ownership of at [***] of the stock, voting securities or other ownership interest of a Person (or, with
respect to a limited partnership or other similar entity, its general partner or controlling entity), or (b) the possession, directly or indirectly, of the ability to direct or otherwise control the management or policies of a Person, whether
through the ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise. 
 1.28
“Agreement” has the meaning set forth in the preamble hereto. 
 1.29 “Alliance Manager” has the
meaning set forth in Section 2.6. 
 1.30 “Annual Net
Sales-Based Milestone Payment” has the meaning set forth in Section 6.4.2. 

1.31 “Annual Net Sales-Based Milestone Payment Date” has the meaning
set forth in Section 6.4.2. 
 1.32 “Annual Net
Sales-Based Milestone Table” has the meaning set forth in Section 6.4.2. 

1.33 “Annual Net Sales-Based Milestone Threshold” has the meaning set forth in
Section 6.4.2. 
 1.34 “Applicable Law” means federal, state, local, national and
supra-national laws, statutes, rules, and regulations, including any rules, regulations, regulatory guidelines, or other requirements of the Regulatory Authorities, major national securities exchanges or major securities listing organizations, that
may be in effect from time to time during the Term and applicable to a particular activity or country or other jurisdiction hereunder. 

[***] 
 1.36
“Audit Arbitrator” has the meaning set forth in Section 6.14. 
 1.37 “Bankruptcy
Code” has the meaning set forth in Section 11.5.1. 
 [***] 

1.39 “Biosimilar Application” has the meaning set forth in Section 7.3.3. 

1.40 “Biosimilar Product” means, with respect to a Licensed Product and on a country-by-country basis, a biologic product (a) whose Regulatory Approval, or whose application for such Regulatory Approval, relies in whole or in part on a prior Regulatory Approval granted to the
Licensed Product; (b) whose Regulatory Approval, or whose application for such Regulatory Approval, relies in whole or in part on any data generated in support of a prior Regulatory Approval granted to the Licensed Product; or (c) which is
determined by the FDA or a foreign counterpart thereof to be biosimilar to or interchangeable with such Licensed Product, as set forth at 42 U.S.C. § 262(k) or a foreign equivalent thereof. 

1.41 “BLA” has the meaning set forth in the definition of “Drug Approval Application.” 

[***] 
 [***] 

1.44 “Blocking Platform In-License” has the meaning set forth in
Section 5.6.3. 
 1.45 “Blocking Platform IP” has the meaning set forth in
Section 5.6.3. 
 1.46 “Board of Directors” has the meaning set forth in the definition of
“Change in Control.” 

  
 - 3 - 

 CONFIDENTIAL 
  

 1.47 “Breaching Party” has the meaning set forth in
Section 11.2.1. 
 1.48 “Business Day” means a day other than a Saturday or Sunday on
which banking institutions in Chicago, Illinois are open for business. 
 1.49 “Calendar Quarter” means each
successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately
prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term. 

1.50 “Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and
ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term shall commence on
January 1 of the year in which the Term ends and end on the last day of the Term. 
 1.51 “CAR” means chimeric
antigen receptor. 
 1.52 “Caribou” has the meaning set forth in the preamble hereto. 

1.53 “Caribou Background IP” means the Caribou Background Know-How and the
Caribou Background Patents. 
 1.54 “Caribou Background Know-How” means the
Caribou Cas12a chRDNA Technology Know-How, the Caribou CAR-T Technology Know-How, the Program Materials and the Program
Confidential Information, and all other Know-How that is [***]. 
 1.55 “Caribou
Background Patents” means the Caribou Cas12a chRDNA Technology Patents, the Caribou CAR-T Technology Patents, and all other Patents that are [***]. 

[***] 
 1.62
“Caribou CAR-T Technology” means all technology (a) owned or Controlled by Caribou or any of its Affiliates on the Effective Date or at any time during the Term, and
(b) directed to [***]. 
 1.63 “Caribou CAR-T Technology Know-How” means all Know-How that (a) is owned or Controlled by Caribou or any of its Affiliates as of the Effective Date or during the Term and (b) relates
to the Caribou CAR-T Technology. 
 1.64 “Caribou
CAR-T Technology Patents” means all of the Patents that (a) are owned or Controlled by Caribou or any of its Affiliates as of the Effective Date or during the Term and (b) cover the Caribou
CAR-T Technology or the Exploitation thereof. The Caribou CAR-T Technology Patents existing as of the Effective Date are listed on attached Schedule 1.64. 

1.65 “Caribou Cas12a chRDNA Technology” means all technology (a) owned or Controlled by Caribou or
any of its Affiliates on the Effective Date or at any time during the Term, and (b) [***]. 
 1.66 “Caribou Cas12a chRDNA
Technology Know-How” means all Know-How that (a) is owned or Controlled by Caribou or any of its Affiliates as of the Effective Date or during the Term and
(b) relates to the Caribou Cas12a chRDNA Technology. 
 1.67 “Caribou Cas12a chRDNA Technology
Patents” means all of the Patents that (a) are owned or Controlled by Caribou or any of its Affiliates as of the Effective Date or during the Term and (b) cover the Caribou Cas12a chRDNA Technology or the Exploitation thereof. The
Caribou Cas12a chRDNA Technology Patents existing as of the Effective Date are listed on attached Schedule 1.67. 

  
 - 4 - 

 CONFIDENTIAL 
  

 1.68 “Caribou Collaboration Invention” means any and all
Collaboration Inventions related generally to the Caribou Cas12a chRDNA Technology or Caribou CAR-T Technology, and any and all Collaboration [***] Inventions solely owned by Caribou pursuant to
Section 3.4.1. 
 1.69 “Caribou Collaboration IP” means the Caribou Collaboration
Inventions, the Caribou Collaboration Know-How and the Caribou Collaboration Patents.  

1.70 “Caribou Collaboration Know-How” means any and all Collaboration Know-How related generally to the Caribou Cas12a chRDNA Technology or Caribou CAR-T Technology, and any and all Collaboration [***]
Know-How solely owned by Caribou pursuant to Section 3.4.1. [***]. 

1.71 “Caribou Collaboration Patents” means any and all Collaboration Patents related generally to the Caribou Cas12a
chRDNA Technology or Caribou CAR-T Technology, and any and all Collaboration [***] Patents solely owned by Caribou pursuant to Section 3.4.1. [***]. 

1.72 “Caribou Excluded Know-How” means any
Know-How owned or Controlled by Caribou or any of its Affiliates as of the Effective Date or at any time during the Term: 

[***] 
 1.73
“Caribou Excluded Patents” means any Patents owned or Controlled by Caribou or any of its Affiliates as of the Effective Date or at any time during the Term: 

[***] 
 1.74
“Caribou Indemnitees” has the meaning set forth in Section 10.1. 
 1.75 “Caribou
IP” means the Caribou Background IP, the Caribou Collaboration IP, and Caribou’s right and interest in and to the Collaboration [***] IP. 

1.76 “Caribou Know-How” means the Caribou Background Know-How, the Caribou Collaboration Know-How, and Caribou’s right and interest in and to Collaboration [***] Know-How. 

[***] 
 1.78
“Caribou Owned Pre-Existing Know-How” has the meaning set forth in Section 9.2.1. 

1.79 “Caribou Owned Pre-Existing Patents” has the meaning set forth in
Section 9.2.1. 
 1.80 “Caribou Patents” means the Caribou Background Patents, the
Caribou Collaboration Patents, and Caribou’s right and interest in and to the Collaboration [***] Patents. 
 1.81
“Caribou Platform Technology” means all Caribou Cas12a chRDNA Technology and all Caribou CAR-T Technology owned or Controlled by Caribou or any of its Affiliates on the Effective Date
or at any time during the Term that is necessary or reasonably useful for the Exploitation of the Collaboration CAR-T Products or the Licensed Products. [***] 

[***] 
 1.85
“Caribou Product” means any product that (a) is not a Collaboration CAR-T Product, a Licensed Product, or a product conceived, discovered, developed, or otherwise made under this
Agreement and (b) Caribou (or its Affiliates or (sub)licensees) is Exploiting outside the scope of this Agreement. 

  
 - 5 - 

 CONFIDENTIAL 
  

 [***] 

1.87 [***] 
 [***] 

1.90 “Cas12a chRDNA Compositions” has the meaning set forth in the definition of “Caribou Cas12a chRDNA
Technology.” 
 1.91 “Centralized Approval Procedure” means the procedure through which a MAA filed with the
EMA results in a single marketing authorization valid throughout the European Union. 
 1.92 “Change in Control”
with respect to a Party, shall be deemed to have occurred if any of the following occurs after the Effective Date: 
 1.92.1 any
“person” or “group” (as such terms are defined below) acquires or becomes the “beneficial owner” (as defined below), directly or indirectly, of (a) shares of capital stock or other interests (including partnership
interests) of such Party then outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in the election of the directors, managers or similar supervisory positions (“Voting Stock”) of such Party
representing [***] or more of the total voting power of all outstanding classes of Voting Stock of such Party or (b) the power to elect a majority of the members of the Party’s board of directors, or similar governing body (“Board
of Directors”); or 
 1.92.2 such Party enters into a merger, consolidation or similar transaction with another Person
(whether or not such Party is the surviving entity) and as a result of such merger, consolidation or similar transaction (a) the members of the Board of Directors of such Party immediately prior to such transaction constitute less than a
majority of the members of the Board of Directors of such Party or such surviving Person immediately following such transaction or (b) the Persons that beneficially owned, directly or indirectly, the shares of Voting Stock of such Party
immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of such Party representing at least a majority of the total voting power of all outstanding classes of Voting Stock of the surviving
Person in substantially the same proportions as their ownership of Voting Stock of such Party immediately prior to such transaction; or 

1.92.3 such Party sells or transfers to any Third Party, in one (1) or more related transactions, properties or assets
representing all or substantially all of such Party’s consolidated total assets; or 
 1.92.4 the holders of capital stock of
such Party approve a plan or proposal for the liquidation or dissolution of such Party. 
 1.92.5 For the purpose of this definition
of Change in Control, (a) “person” and “group” have the meanings given such terms under Section 13(d) and 14(d) of the Securities Exchange Act and the term “group” includes any group acting for the purpose of
acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the Securities Exchange Act; (b) a “beneficial owner” shall be determined in accordance with Rule 13d-3 under the Securities Exchange Act; and (c) the terms “beneficially owned” and “beneficially own” shall have meanings correlative to that of “beneficial owner.” 

1.93 “chRDNA” has the meaning set forth in the definition of “Caribou Cas12a chRDNA Technology.” 

[***] 
 1.95
“Clinical Data” means all Information with respect to any Collaboration CAR-T Products or Licensed Products which is made, collected, or otherwise generated under or in connection with
Clinical Studies or Phase IV Studies, including any data (including raw data), reports, and results with respect thereto. 

  
 - 6 - 

 CONFIDENTIAL 
  

 1.96 “Clinical Studies” means Phase 0, Phase I, Phase II, Phase III,
and such other tests and studies in human subjects that are required by Applicable Law, or otherwise recommended by the Regulatory Authorities, to obtain or maintain any Regulatory Approval for a Licensed Product for one (1) or more
indications, including tests or studies that are intended to expand the Product Labeling for such Licensed Product with respect to such indication. 

1.97 “[***] IP” means the [***] Know-How and the [***] Patents. 

1.98 “[***] Know-How” means all
Know-How that (a) is owned or Controlled by Caribou or any of its Affiliates as of the Effective Date and during the Term and (b) relates to a [***]; but excluding any Caribou Excluded Know-How. 
 1.99 “[***] Patents” means all of the Patents that (a) are owned
or Controlled by Caribou or any of its Affiliates as of the Effective Date and during the Term and (b) cover a [***] or the Exploitation thereof; but excluding any Caribou Excluded Patents. 

1.100 “Collaboration [***] Inventions” means any and all Collaboration Inventions that are (i) conceived,
discovered, developed, reduced to practice or otherwise made under this Agreement by or on behalf of either Party (or its Affiliate), either alone or jointly, [***], through practicing the [***], and (ii) not related to (a) a Collaboration
CAR-T Product or a Licensed Product [***] conceived, discovered, developed, reduced to practice or otherwise made under this Agreement, or (d) a molecule, cell, composition, sequence, or vector comprising
or encoding any of the foregoing, or (e) the Exploitation of any of the foregoing. 
 1.101 “Collaboration [***]
IP” means the Collaboration [***] Inventions, the Collaboration [***] Know-How, and the Collaboration [***] Patents. 

1.102 “Collaboration [***] Know-How” means any and all Collaboration Know-How that are (i) conceived, discovered, developed, reduced to practice or otherwise made under this Agreement by or on behalf of either Party (or its Affiliate), either alone or jointly, [***], through
practicing the [***], and (ii) not related to (a) a Collaboration CAR-T Product or a Licensed Product [***] conceived, discovered, developed, reduced to practice or otherwise made under this
Agreement, or (d) a molecule, cell, composition, sequence, or vector comprising or encoding any of the foregoing, or (e) the Exploitation of any of the foregoing. 

1.103 “Collaboration [***] Patents” means any and all Collaboration Patents that claim inventions that are
(i) conceived, discovered, developed, reduced to practice or otherwise made under this Agreement by or on behalf of either Party (or its Affiliate), either alone or jointly, [***], through practicing the [***], and (ii) not related to
(a) a Collaboration CAR-T Product or a Licensed Product [***] conceived, discovered, developed, reduced to practice or otherwise made under this Agreement, or (d) a molecule, cell, composition,
sequence, or vector comprising or encoding any of the foregoing, or (e) the Exploitation of any of the foregoing. 
 1.104
“Collaboration CAR” means a recombinant protein comprising (a) an extracellular domain that includes [***]. 

1.105 “Collaboration CAR-T Product” means (a) any T cell modified with
the Caribou Cas12a chRDNA Technology or, [***], with the [***] that (i) is Developed under this Agreement and (ii) [***] 

1.106 “Collaboration Inventions” has the meaning set forth in Section 7.1.4. 

1.107 “Collaboration IP” means the Collaboration Inventions, the Collaboration
Know-How, and the Collaboration Patents. 
 1.108 “Collaboration Know-How” means any and all Know-How that is conceived, discovered, developed, reduced to practice or otherwise made (a) by or on behalf of either Party (or its
Affiliates); or (b) jointly by or on behalf of AbbVie (or its Affiliates), on the one hand, and Caribou (or its Affiliates), on the other hand, in each case ((a) and (b)), under this Agreement. 

  
 - 7 - 

 CONFIDENTIAL 
  

 1.109 “Collaboration Patents” means any and all Patents that claim an
invention conceived, discovered, developed, reduced to practice or otherwise made (a) by or on behalf of either Party (or its Affiliates); or (b) jointly by or on behalf of AbbVie (or its Affiliates), on the one hand, and Caribou (or its
Affiliates), on the other hand; in each case ((a) and (b)), under this Agreement. 
 1.110 “Combination Product”
means a Licensed Product that is (a) sold in the form of a combination product containing both a Collaboration CAR-T Product as an active pharmaceutical ingredient, and another active pharmaceutical
ingredient; or (b) sold together with another product, process, service or therapy that is administered separately from the Licensed Product, in each case ((a) and (b)) sold as a unit at a single price and excluding any Delivery System.

 1.111 “Commercialization” means any and all activities related to the preparation for sale of, offering for sale
of, or sale of a Collaboration CAR-T Product or Licensed Product, including activities related to marketing, promoting, distributing, importing and exporting such Collaboration
CAR-T Product or Licensed Product, and interacting with Regulatory Authorities or other governmental authorities regarding any of the foregoing. When used as a verb, “to Commercialize” and
“Commercializing” means to engage in Commercialization, and “Commercialized” has a corresponding meaning. 

1.112 “Commercially Reasonable Efforts” means, 

1.112.1 with respect to the efforts and resources to be expended by AbbVie with respect to any objective, activity or decision to be
undertaken with respect to the Development, Commercialization, or Manufacture of a Collaboration CAR-T Product or Licensed Product, the efforts and resources to accomplish such objective, activity or decision
that would be comparable with the efforts and resources that AbbVie would normally use in the exercise of its reasonable business discretion to accomplish a similar objective, activity or decision with respect to a compound or product that is at a
similar stage in its development or product life, is in a similar therapeutic and disease area and is of similar market potential, taking into account all relevant factors (including legal, medical, scientific, technical and commercial factors),
including, expected and actual issues of efficacy, safety and manufacturing, and expected and actual approved labeling, including the discovery of unanticipated toxicity or any material adverse event or condition relating to the safety or efficacy
of such Collaboration CAR-T Product or Licensed Product; the expected and actual competitiveness of alternative products (including Biosimilar Products); adverse changes in the market conditions that affect
the market potential of such Collaboration CAR-T Product or Licensed Product generally or any particular indication of such Collaboration CAR-T Product or Licensed
Product; the expected and actual profile of such Collaboration CAR-T Product or Licensed Product, including the existence of failed or inconclusive Clinical Studies; the nature and extent of expected and
actual market exclusivity (including patent coverage, regulatory and other exclusivity) of such Collaboration CAR-T Product or Licensed Product; the likelihood and expected scope of Regulatory Approval given
the regulatory structure involved, including regulatory or data exclusivity and pricing and reimbursement approval by governmental and private payors, including formulary positioning; changes in clinical or regulatory strategy justified by
compliance with the requirements of regulatory feedback from any Regulatory Authority; and the expected and actual profitability and return on investment of such Collaboration CAR-T Product or Licensed
Product; and 
 1.112.2 with respect to the efforts and resources to be expended by Caribou with respect to an objective, activity
or decision to be undertaken by Caribou hereunder, such reasonable, diligent, and good faith efforts that would be comparable with the efforts and resources that Caribou would normally use in the exercise of its reasonable business discretion (but
in no event less than the efforts and resources that would normally be used by a company in the biotechnology industry of comparable size, resources, and structure to Caribou) to accomplish a similar objective, activity or decision with
respect to research and development of novel biopharmaceutical products. 
 1.112.3 In addition, with regard to AbbVie’s
obligations relating to the Development and Commercialization of Collaboration CAR-T Products(s) and Licensed Products hereunder, “Commercially Reasonable Efforts” shall be determined on a country-by-country or market-by-market basis (as most applicable) and indication-by-indication basis for a particular product, and it is anticipated that the level of effort will change over time, including to reflect changes in the status of
the product and the countries (or markets) involved. 

  
 - 8 - 

 CONFIDENTIAL 
  

 1.112.4 For purposes of clarity, where a Party has an obligation to use Commercially
Reasonable Efforts, the efforts of such Party and its Affiliates, subcontractors and (sub)licensees/Sublicensees shall be considered in determining whether such Party has satisfied such obligation. 

1.113 “Committee” has the meaning set forth in Section 2.2.5. 

1.114 “Companion Diagnostic Field” means all human uses as a companion diagnostic. 

1.115 “Companion Diagnostic Product” means a product used as a companion product to a Collaboration CAR-T Product or a Licensed Product for the purpose of assessing applicability of the Collaboration CAR-T Product or Licensed Product to a specific individual. 

1.116 “Company Participation Right” has the meaning set forth in Section 6.2. 

1.117 “Confidential Information” means any information or data provided orally, visually, in writing or other form by
or on behalf of one (1) Party (or an Affiliate or representative of such Party) to the other Party (or to an Affiliate or representative of such Party) in connection with this Agreement, whether prior to, on, or after the Effective Date,
including information relating to the terms of this Agreement, the Collaboration CAR-T Product or the Licensed Product, any Exploitation of the Collaboration CAR-T
Product the Licensed Product, any know-how with respect thereto developed by or on behalf of the disclosing Party or its Affiliates (including AbbVie Know-How and
Caribou Know-How, as applicable), or the scientific, regulatory or business affairs or other activities of either Party. 

1.118 “Control” means, with respect to any item of Information, Regulatory Documentation, material,
Patent, or other property right, the possession of the right, whether directly or indirectly, and whether by ownership, license, covenant not to sue or otherwise (other than by operation of the Licenses and other grants in Sections 5.1 or
5.2), to grant a license, sublicense or other right (including the right to reference Regulatory Documentation) to or under such Information, Regulatory Documentation, material, Patent, or other property right as provided for herein without
violating the terms of any agreement or other arrangement with any Third Party. 
 1.119 “Convicted Entity” has the
meaning set forth in Section 9.2.19. 
 1.120 “Convicted Individual” has the meaning set
forth in Section 9.2.19. 
 1.121 “Corporate Names” means “Caribou Biosciences,
Inc.” and such other names and logos as Caribou may designate in writing from time to time. 
 1.122 “Data
Package” means a report delivered by Caribou to AbbVie for each Program Slot following [***]. 
 1.123 “Data
Security and Privacy Laws” means all Applicable Law relating to the privacy, Processing, and security of Personal Data. 

1.124 “Debarred Entity” has the meaning set forth in Section 9.2.19. 

1.125 “Debarred Individual” has the meaning set forth in Section 9.2.19. 

1.126 “Default Notice” has the meaning set forth in Section 11.2. 

1.127 “Delivery System” has the meaning set forth in the definition of “Net Sales.” 

1.128 “Development” means all activities related to research, pre-clinical and
other non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing 

  
 - 9 - 

 CONFIDENTIAL 
  

 
scale-up, qualification and validation, quality assurance/quality control, Clinical Studies, including Manufacturing in support thereof, statistical
analysis and report writing, the preparation and submission of Drug Approval Applications, regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory
Authority as a condition or in support of obtaining or maintaining a Regulatory Approval. When used as a verb, “Develop” means to engage in Development. For purposes of clarity, Development shall include any submissions and activities
required in support thereof, required by Applicable Law or a Regulatory Authority as a condition or in support of obtaining a pricing or reimbursement approval for an approved Licensed Product. 

1.129 “Disclosure” has the meaning set forth in Section 8.6.1. 

1.130 “Dispute” has the meaning set forth in Section 12.8. 

1.131 “Distributor” has the meaning set forth in Section 5.4. 

1.132 “Dollars” or “$” means United States Dollars. 

1.133 “Drug Approval Application” means a Biologics License Application (a “BLA”) as
defined in the PHSA, or any corresponding foreign application in the Territory, including, with respect to the European Union, a Marketing Authorization Application (a “MAA”) filed with the EMA pursuant to the Centralized Approval
Procedure or with the applicable Regulatory Authority of a country in Europe with respect to the mutual recognition or any other national approval procedure. 

[***] 
 1.137
“Effective Date” means the effective date of this Agreement as set forth in the preamble hereto. 
 1.138
“EMA” means the European Medicines Agency and any successor agency(ies) or authority having substantially the same function. 

1.139 “European Major Markets” means the following: [***]. 

1.140 “European Union” or “E.U.” means the economic, scientific, and political organization of
member states known as the European Union, as its membership may be altered from time to time, and any successor thereto. 
 1.141
“Excluded Entity” has the meaning set forth in Section 9.2.19. 
 1.142
“Excluded Individual” has the meaning set forth in Section 9.2.19. 
 1.143
“Existing IP Agreements” means the [***], and any other agreement in effect as of the Effective Date pursuant to which Caribou obtains rights to any Caribou Background IP or [***] IP. 

1.144 “Existing Services Agreement” has the meaning set forth in Section 3.9.2. 

1.145 “Existing Third Party Provider” has the meaning set forth in Section 3.9.2. 

1.146 “Exploit” or “Exploitation” means to make, have made, import, use, sell, or offer for sale,
including to research, Develop, Commercialize, register, modify, enhance, improve, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise), formulate, optimize, have used, export, transport, distribute, promote, market, have
sold or otherwise dispose of. 
 1.147 “Fair Market Value” has the meaning set forth in
Section 3.2.9. 

  
 - 10 - 

 CONFIDENTIAL 
  

 1.148 “FDA” means the United States Food and Drug Administration and
any successor agency(ies) or authority having substantially the same function. 
 1.149 “FDCA” means the United
States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq., as amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions, and
modifications thereto). 
 1.150 “Field” means all human diagnostic, prophylactic and therapeutic uses. 

1.151 “First Commercial Sale” means, with respect to a Licensed Product and a country, the first sale for monetary
value for use or consumption by the end user of such Licensed Product in such country after all Regulatory Approvals for such Licensed Product have been obtained in such country. Sales prior to receipt of all Regulatory Approvals for such Licensed
Product, such as so-called “treatment IND sales,” “named patient sales,” and “compassionate use sales,” shall not be construed as a First Commercial Sale. 

1.152 “FTE” means the equivalent of the work of [***] employee full time for [***] Calendar Year (consisting of at
least a total of [***] hours per Calendar Year) of work performing activities for a Collaboration CAR-T Product or Licensed Product. No additional payment shall be made with respect to any person who works
more than [***] hours per Calendar Year and any person who devotes less than [***] hours per Calendar Year (or such other number as may be agreed by the JGC, as applicable) shall be treated as an FTE on a pro rata basis based upon the actual
number of hours worked divided by [***]. 
 1.153 “FTE Costs” means, with respect to a Party for any period,
the applicable FTE Rate multiplied by the applicable number of FTEs of such Party performing the relevant activities during such period in accordance with the applicable Research Plan. 

1.154 “FTE Rate” means the applicable FTE rate set forth on attached Schedule 1.154. 

1.155 “Gatekeeper” has the meaning set forth in Section 3.2.3. 

1.156 “Good Laboratory Practice” or “GLP” means the FDA’s standards for conducting non-clinical laboratory studies contained in 21 C.F.R. Part 58, and any equivalent standards promulgated by the EMA. 

1.157 “Good Manufacturing Practice” or “GMP” means the current good manufacturing practices
applicable from time to time to the Manufacturing of a Collaboration CAR-T Product or Licensed Product or any intermediate thereof pursuant to Applicable Law. 

1.158 “IND” means an application filed with a Regulatory Authority for authorization to commence Clinical Studies,
including (a) an Investigational New Drug Application as defined in the FDCA or any successor application or procedure filed with the FDA (b) any equivalent of a United States IND in other countries or regulatory jurisdictions
(i.e., clinical trial application (CTA)), and (c) all supplements, amendments, variations, extensions and renewals thereof that may be filed with respect to the foregoing. 

1.159 “Indemnification Claim Notice” has the meaning set forth in Section 10.3. 

1.160 “Indemnified Party” has the meaning set forth in Section 10.3. 

1.161 “Indirect Taxes” has the meaning set forth in Section 6.11. 

1.162 “Information” means all knowledge of a technical, scientific, business and other nature, including technology,
means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other
material, regulatory data, and other biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing and quality control data and
information, including study designs and protocols, and biological methodology; in each case (whether or not confidential, proprietary, patented or patentable, of commercial advantage or not) in written, electronic or any other form now known or
hereafter developed. 

  
 - 11 - 

 CONFIDENTIAL 
  

 1.163 “Initial Program Slot” means the first Program
Slot for the Development and Manufacturing activities of Collaboration CAR-T Products and Licensed Products directed towards the Target Combination, as of the Effective Date, as set forth in Section B on
attached Schedule 3.2.1 (the “Initial Program Targets”). 
 1.164 “Initial Research Plan”
has the meaning set forth in the definition of “Research Plan.” 
 1.165 “Initial Unavailable Targets” has
the meaning set forth in Section 3.2.4. 
 1.166 “Initiation” means, with respect to a
Clinical Study, the first dosing of the first human subject in such Clinical Study. 
 1.167 “Intellectual
Property” means Know-How and Patents. 
 1.168 “Intellectual Property
Rights” has the meaning set forth in Section 11.5.1. 
 1.169 “Internal
Reserved Program” means a bona fide internal program of Caribou directed to a Target that has been disclosed to the Gatekeeper and added to the list of Unavailable Targets[***] and [***]. 

1.170 “JGC” has the meaning set forth in Section 2.1. 

1.171 “Know-How” means Information that is not generally known.
Know-How specifically excludes issued Patents and published Patent applications. 

1.172 “Knowledge” means, with respect to Caribou, the actual knowledge of [***], together with the knowledge any such
individuals would reasonably be expected to have after performing a diligent investigation, including consultation with his or her direct reports. [***]. 

1.173 “LIBOR” means the London Interbank Offered Rate for deposits in Dollars having a maturity of one (1) month
published by the British Bankers’ Association, as adjusted from time to time on the first London business day of each month. 

1.174 “Licensed Product” means: any product [***] for use in the Field comprising, containing, encoding, or
expressing a Collaboration CAR-T Product, alone or in combination with one or more other active agents [***] in all forms, in current and future formulations, dosage forms and strengths, and delivery modes.
[***] 
 1.175 “Licenses” has the meaning set forth in Section 5.1.1. 

1.176 “Life Sciences Entity” means any pharmaceutical, biotechnology, medical device, or diagnostic company, including
any Affiliate or any venture capital subsidiary or venture capital organization or division of a pharmaceutical, biotechnology, medical device, or diagnostic company. 

1.177 “Litigation Costs” means all reasonable costs and expenses incurred by or on behalf of [***] in the defense of a
Third Party Infringement Claim, and all damages, royalties, accounting, disgorgement, awards or other monetary payments resulting or arising from an adverse judgement against [***] or any settlement in connection with a Third Party Infringement
Claim. 
 1.178 “Losses” has the meaning set forth in Section 10.1. 

1.179 “MAA” has the meaning set forth in the definition of Drug Approval Application. 

  
 - 12 - 

 CONFIDENTIAL 
  

 1.180 “Major Market” means each of the United States and each
of the countries within the European Major Markets. 
 1.181 “Manufacture” and “Manufacturing”
means all activities related to the synthesis, making, production, processing, filling, finishing, packaging, labeling, shipping, and holding of any Collaboration CAR-T Products or Licensed Products, or any
intermediate thereof, or any reagent used in connection therewith, including process development, process qualification and validation, scale-up, pre-clinical, clinical
and commercial production and analytic development, product characterization, stability testing, quality assurance, and quality control. 

1.182 “Markings” has the meaning set forth in Section 4.8. 

1.183 “Materials” means biological materials [***], chemical compounds, or other tangible materials, including
reagents [***]. 
 1.184 “Mono Product” has the meaning set forth in the definition of “Net Sales.”

 1.185 “Net Sales” means, with respect to a Licensed Product for any period, the total amount billed or
invoiced on sales of such Licensed Product during such period by AbbVie and its Affiliates, or Sublicensees [***] (each, a “Selling Party”) in the Territory to Third Parties (including wholesalers or Distributors), in bona
fide arm’s length transactions, less the following deductions, in each case related specifically to the Licensed Product and actually allowed and taken by such Third Parties and not otherwise recovered by or reimbursed to AbbVie or its
Affiliates: 
 [***] 

Subject to the above, Net Sales shall be calculated in accordance with the standard internal policies and procedures of AbbVie, its
Affiliates, or Sublicensees, which must be in accordance with Accounting Standards. 
 For purposes of calculating Net Sales, all Net Sales
shall be converted into Dollars. 
 In the event a Licensed Product is a Combination Product, the Net Sales for such Combination Product
shall be calculated as follows: 
 (i) [***] 

[***] 
 1.186
“Neutral” has the meaning set forth in attached Schedule 12.8.3. 
 1.187 “Nominated Target”
has the meaning set forth in Section 3.2.6. 
 1.188
“Non-Breaching Party” has the meaning set forth in Section 11.2.1. 

[***] 
 1.190 “Out-of-Pocket Costs” means costs and expenses paid to Third Parties (or payable to Third Parties and accrued in accordance with the Accounting Standards consistently
applied) by Caribou (or its Affiliate) directly incurred in the conduct of any applicable activities under this Agreement; provided that Out-of-Pocket Costs shall
not include costs for general overhead, postage, communications, photocopying, printing or internet expense, professional dues, operating supplies, laboratory supplies (excluding reagents), printers, photocopiers, fax machines or other office
equipment. 
 1.191 “Party” and “Parties” has the meaning set forth in the preamble hereto. 

  
 - 13 - 

 CONFIDENTIAL 
  

 1.192 “Patent Challenge” has the meaning given to such term in [***].

 1.193 “Patent Family” means a group of Patents that share any priority relationship. 

1.194 “Patents” means (a) all national, regional and international patents and patent applications, including
provisional patent applications and rights to claim priority from any of these patents or applications, (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming
priority from either of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals and continued prosecution applications,
(c) any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including utility models, petty patents and design patents and certificates of invention, (d) any and all extensions or
restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any patent term extensions, supplementary protection
certificates, pediatric exclusivities, and the like) of the foregoing patents or patent applications ((a), (b), and (c)), and (e) any similar rights, including so-called pipeline protection or any
importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and patents. 

1.195 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department, or
agency of a government. 
 1.196 “Personal Data” means (a) all information identifying, or in
combination with other information, identifiable to an individual, including pseudonymized (key-coded) Clinical Data containing such information; and (b) any other information that is governed, regulated,
or protected by one or more Data Security and Privacy Laws. 
 1.197 “Phase 0” means an exploratory, first-in-human trial conducted in accordance with the FDA 2006 Guidance on Exploratory Investigational New Drug Studies (or the equivalent in any country or other jurisdiction
outside of the United States) and designed to expedite the development of therapeutic or imaging agents by establishing very early on whether the agent behaves in human subjects as was anticipated from
pre-clinical studies. 
 1.198 “Phase I” means a human clinical trial of a
Collaboration CAR-T Product or Licensed Product, the principal purpose of which is a preliminary determination of safety, tolerability, pharmacological activity or pharmacokinetics in healthy individuals or
patients or similar clinical study prescribed by the Regulatory Authorities, including the trials referred to in 21 C.F.R. § 312.21(a), as amended. 

1.199 “Phase II” means a human clinical trial of a Collaboration CAR-T Product
or Licensed Product, the principal purpose of which is a determination of safety and efficacy in the target patient population, which is prospectively designed to generate sufficient data that may permit commencement of pivotal clinical trials, or a
similar clinical study prescribed by the Regulatory Authorities, from time to time, pursuant to Applicable Law or otherwise, including the trials referred to in 21 C.F.R. § 312.21(b), as amended. 

1.200 “Phase III” means a human clinical trial of a Collaboration CAR-T
Product or Licensed Product on a sufficient number of subjects in an indicated patient population that is designed to establish that a Collaboration CAR-T Product or Licensed Product is safe and efficacious
for its intended use and to determine the benefit/risk relationship, warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is intended to support marketing approval of
such Collaboration CAR-T Product or Licensed Product, including all tests and studies that are required by the FDA from time to time, pursuant to Applicable Law or otherwise, including the trials referred to
in 21 C.F.R. § 312.21(c), as amended. 
 1.201 “Phase IV Study” means a post-marketing human clinical study for
a Licensed Product with respect to any indication as to which all Regulatory Approvals have been received or for a use that is the subject of an investigator-initiated study program. 

1.202 “PHSA” means the United States Public Health Service Act, as amended from time to time. 

  
 - 14 - 

 CONFIDENTIAL 
  

 [***] 

1.204 “Platform Improvement IP” has the meaning set forth in Section 5.6.4. 

1.205 “Platform Improvement IP In-License” has the meaning set forth in
Section 5.6.4. 
 1.206 “Platform Technology IP Agreements” has the meaning set forth in
Section 9.2.5. 
 1.207 “PMDA” means Japan’s Pharmaceuticals and Medical Devices
Agency and any successor agency(ies) or authority having substantially the same function. 
 1.208 “Potential In-License” has the meaning set forth in Section 5.6.1. 
 1.209
“Privacy and Security Obligations” has the meaning set forth in Section 9.2.24. 
 1.210
“Processing” (or its conjugates) means any operation or set of operations that is performed upon Personal Data, whether or not by automatic means, such as collection, recording, organization, storage, adaptation or alternation,
retrieval, consultation, use, disclosure by transmission, dissemination or otherwise making available, alignment or combination, blocking, erasure or destruction. 

1.211 “Product Information” has the meaning set forth in Section 8.1. 

1.212 “Product Infringement” has the meaning set forth in Section 7.3.1. 

1.213 “Product Labeling” means, with respect to a Licensed Product in a country or other jurisdiction in the
Territory, (a) the Regulatory Authority-approved full prescribing information for such Licensed Product for such country or other jurisdiction, including any required patient information, and (b) all
labels and other written, printed, or graphic matter upon a container, wrapper, or any package insert utilized with or for such Licensed Product in such country or other jurisdiction. 

1.214 “Product-Specific In-Licenses” has the meaning set forth in
Section 5.6.2. 
 1.215 “Product-Specific IP” has the meaning set forth in
Section 5.6.2. 
 1.216 “Product Trademarks” means the Trademark(s) to be used by AbbVie
or its Affiliates or its or their respective Sublicensees for the Development or Commercialization of Collaboration CAR-T Products or Licensed Products in the Territory and any registrations thereof or any
pending applications relating thereto in the Territory (excluding, in any event, any trademarks, service marks, names or logos that include any corporate name or logo of the Parties or their Affiliates). 

[***] “Program Confidential Information” has the meaning given to such term [***] 

1.218 “Program Materials” has the meaning given to such term [***]. 

1.219 “Program Slot” means a program under this Agreement for the Development and Manufacturing activities of
Collaboration CAR-T Products and Licensed Products directed to defined Target(s) pursuant to a Research Plan. [***] 

1.220 “Program Slot Exercise Date” has the meaning set forth in Section 3.2.7. 

1.221 “Program Slot Selection Notice” has the meaning set forth in Section 3.2.7. 

  
 - 15 - 

 CONFIDENTIAL 
  

 [***] 

1.223 “Proposed Target” has the meaning set forth in Section 3.2.5. 

1.224 “Provided Materials” means any Materials provided by one Party (or its Affiliates) to the other Party (or its
Affiliates) to conduct activities pursuant to this Agreement.  
 1.225 “Qualified Financing” has the meaning
set forth in Section 6.2. 
 1.226 “Registrational Trial” means, with respect to any
Collaboration CAR-T Product or Licensed Product, (a) a Phase III or (b) any other Clinical Study on a sufficient number of patients, the results of which, together with prior data and information
concerning such product, are intended to be, at the time of initiation, without any additional Clinical Studies, sufficient to meet the evidentiary standard for demonstrating the safety, purity, efficacy, and potency of such Collaboration CAR-T Product or Licensed Product is safe and effective for its intended use in the Territory to support Regulatory Approval of such Collaboration CAR-T Product or Licensed
Product in the Territory for its intended use. 
 1.227 “Regulatory Approval” means, with respect to a country or
other jurisdiction in the Territory, the approvals (including Drug Approval Applications), licenses, registrations, or authorizations of any Regulatory Authority necessary to Commercialize a Collaboration
CAR-T Product or Licensed Product in such country or other jurisdiction, including, where applicable, (a) pricing or reimbursement approval in such country or other jurisdiction, (b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto), and (c) approval of Product Labeling. 

1.228 “Regulatory Authority” means any applicable supra-national, federal, national, regional, state, provincial, or
local governmental or regulatory authority, agency, department, bureau, commission, council, or other entities (e.g., the FDA, EMA and PMDA) regulating or otherwise exercising authority with respect to activities contemplated in this
Agreement, including the Exploitation of the Collaboration CAR-T Products or Licensed Products in the Territory. 

1.229 “Regulatory Documentation” means all (a) applications (including all INDs and Drug Approval Applications
and other major Regulatory Filings), registrations, licenses, authorizations, and approvals (including Regulatory Approvals), (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact
reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all regulatory drug lists, advertising and promotion documents, adverse event files, and complaint files, and
(c) Clinical Data and data contained or relied upon in any of the foregoing, in each case ((a), (b), and (c)) relating to a Collaboration CAR-T Product or Licensed Product. 

1.230 “Regulatory Exclusivity” means, in connection with a Licensed Product, and with respect to any country or other
jurisdiction in the Territory, an additional market protection, other than Patent or Patent-related protection, granted by a Regulatory Authority in such country or other jurisdiction which confers an exclusive Commercialization period during which
AbbVie or its Affiliates have the exclusive right to market and sell, and any other Third Party is prevented from marketing or selling, such Licensed Product in such country or other jurisdiction. 

1.231 “Regulatory Filing” means all (a) applications (including all INDs and Regulatory Approval applications),
registrations, licenses, authorizations, and approvals (including Regulatory Approvals), (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any
communications with any Regulatory Authority) and all supporting documents with respect thereto, including all regulatory drug lists, advertising and promotion documents, adverse event files, and complaint files, and (c) Clinical Data and data
contained or relied upon in any of the foregoing, in each case ((a), (b), and (c)) relating to a Collaboration CAR-T Product or Licensed Product. 

1.232 “Research Collaboration Term” means, on a Program Slot-by-Program Slot basis, the period beginning on the Effective Date and ending [***]. 

  
 - 16 - 

 CONFIDENTIAL 
  

 1.233 “Research Costs” means the FTE Costs and the Out-of-Pocket Costs incurred by or on behalf of Caribou or any of its Affiliates in accordance with the Accounting Standards and this Agreement, that are specifically
attributable to the performance of the Development activities under the applicable Research Plan. 
 1.234 “Research
Plan” means each research and discovery plan and budget to be implemented by the Parties for a Program Slot. The initial Research Plan for the Initial Program Slot is set forth in Section A of attached Schedule 3.2.1 (the
“Initial Research Plan”) with additional Research Plan(s) to be agreed upon by the JGC during the Research Collaboration Term and subsequently included in Schedules to be appended to this Agreement. 

1.235 “Reserved Targets” means the Targets which Caribou has reserved for AbbVie’s exclusive use hereunder and
which are listed on attached Schedule 3.2.2, as such Schedule may be updated from time to time in accordance with Section 3.2.2. 

[***] 
 1.237
“Royalty Term” means, on a Licensed Product-by-Licensed Product and
country-by-country basis, the period of time beginning on the First Commercial Sale of a Licensed Product in a country and ending on the latest of (a) the
expiration, invalidation, revocation, cancellation, or abandonment date of the last Caribou Patent that includes a Valid Claim that claims (i) the Collaboration CAR-T Product in such Licensed
Product, or (ii) the method of making the Collaboration CAR-T Product in such Licensed Product which method is used in the Manufacture of such Licensed Product for commercial sales (in the case of (ii),
only for so long as no Biosimilar Product is commercially available in such country), in such country [***]; (b) ten (10) years from First Commercial Sale of such Licensed Product in such country; and (c) expiration of Regulatory
Exclusivity for such Licensed Product in such country. 
 1.238 “Securities Exchange Act” means United States
Securities Exchange Act of 1934, as amended. 
 1.239 “Sell-Off Period” has
the meaning set forth in Section 11.10.2. 
 1.240 “Selling Party” has the meaning set
forth in the definition of “Net Sales.” 
 1.241 “Senior Officer” means, with respect to Caribou, [***],
and with respect to AbbVie, [***]. 
 [***] 

1.243 “Specified Value” has the meaning set forth in Section 3.2.9 

1.244 “Step-In Activities” has the meaning set forth in
Section 3.7.1. 
 1.245 “Subcommittee” has the meaning set forth in
Section 2.2.5. 
 1.246 “Sublicensee” means a Person, other than an Affiliate or a
Distributor, that is granted a sublicense by AbbVie under the grants in Section 5.1 as provided in Section 5.3. 

1.247 “Substitute Target” has the meaning set forth in Section 3.2.8. 

1.248 “Substitution” has the meaning set forth in Section 3.2.8. 

1.249 “Supplemental Existing Services Agreement Document” has the meaning set forth in
Section 3.9.2. 
 1.250 “Target” means a protein identified by its UniProt# or gene name,
including ones selected and Developed as set forth in a Research Plan, including all splicing and allelic variants thereof. 

  
 - 17 - 

 CONFIDENTIAL 
  

 1.251 “Target Acceptance Date” has the meaning set forth in
Section 3.2.6. 
 1.252 “Target Availability Notice” has the meaning set forth in
Section 3.2.6. 
 [***] 

1.254 “Target Combination” means [***] different Targets selected by AbbVie for a Program Slot. 

1.255 “Target Nomination Notice” has the meaning set forth in Section 3.2.6. 

1.256 “Target-Specific In-Licenses” has the meaning set forth in
Section 5.6.2. 
 1.257 “Target-Specific IP” has the meaning set forth in
Section 5.6.2. 
 1.258 “Target Substitution Period” means, on a Program Slot-by-Program Slot basis, the period beginning on the Effective Date and ending on the [***]. 

1.259 “Term” has the meaning set forth in Section 11.1. 

1.260 “Terminated Territory” means each Major Market with respect to which this Agreement is terminated by
Caribou pursuant to Section 11.2.2, each country or jurisdiction with respect to which this Agreement is terminated by AbbVie pursuant to Section 11.3.2, or, if this Agreement is terminated in its
entirety, the entire Territory. 
 1.261 “Territory” means worldwide. 

1.262 “Third Party” means any Person other than Caribou, AbbVie, and their respective Affiliates. 

1.263 “Third Party Claims” has the meaning set forth in Section 10.1. 

1.264 “Third Party Infringement Claim” has the meaning set forth in Section 7.4.1. 

1.265 “Top-Tier Venture Capital Investor” means a leading reputable venture
capital or crossover investor with such knowledge and experience in financial and business affairs that it is capable of evaluating the merits and risks of purchasing, and other considerations relating to, investments in biotechnology companies, can
afford to bear the economic risk of holding multiple significant investments and routinely makes such investments in the ordinary course. 

1.266 “Trademark” means any word, name, symbol, color, designation or device or any combination thereof that functions
as a source identifier, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo, business symbol or domain names, whether or not registered, and any application therefor. 

1.267 “Transfer Date” means, on a Collaboration CAR-T Product-by-Collaboration CAR-T Product basis[***]. 

1.268 “Transition Plan” has the meaning set forth in Section 4.2. 

1.269 “Unavailable Targets” has the meaning set forth in Section 3.2.3. 

1.270 “United States” means the United States of America and its territories and possessions (including the District
of Columbia and Puerto Rico). 
 1.271 “Upstream Payment Obligations” has the meaning set forth in
Section 5.6.4. 

  
 - 18 - 

 CONFIDENTIAL 
  

 1.272 “Valid Claim” means a claim of any issued and unexpired Patent
whose validity, enforceability, or patentability has not been affected by any of the following: (a) irretrievable lapse, abandonment, revocation, cancellation, dedication to the public, or disclaimer; or (b) a holding, finding, or decision
of invalidity, unenforceability, or non-patentability by a court, governmental agency, national or regional patent office, or other appropriate body that has competent jurisdiction, such holding, finding, or
decision being final and unappealable or unappealed within the time allowed for appeal. [***] 
 1.273 “Voting
Stock” has the meaning set forth in the definition of “Change in Control.” 
 [***] 

1.276 “Withholding Amount” has the meaning set forth in Section 6.10. 

1.277 “Withholding Party” has the meaning set forth in Section 6.10. 

1.278 “Working Group” has the meaning set forth in Section 2.9. 

ARTICLE 2 
 MANAGEMENT OF
THE COLLABORATION 
 2.1 Joint Governance Committee. Within [***] days after the Effective Date, the Parties shall
establish a joint governance committee (the “JGC”) to serve as the oversight and decision making body for the activities to be conducted by the Parties pursuant to the Research Plans, as more fully described in this ARTICLE
2. The JGC shall consist of [***] representatives from each Party, each of whom shall be an employee of such Party and shall have the requisite experience and seniority to enable such person to make decisions on behalf of the Parties with
respect to the issues falling within the jurisdiction of the JGC. From time to time, each Party may substitute [***] or more of its employee representatives to the JGC on prior written notice to the other Party. The JGC chairperson will alternate
between a JGC member of AbbVie and a JGC member of Caribou on an annual basis, with AbbVie having the right to select an AbbVie employee representative as the JGC chairperson until the end of the first full Calendar Year after the Effective Date.
From time to time, the Party appointing the chairperson for the JGC may change the employee representative who will serve as chairperson on prior written notice to the other Party. 

2.2 Specific Responsibilities. The JGC shall perform the following functions, subject to the final decision making
authority of the respective Parties as set forth in Section 2.5: 
 [***] 

2.2.8 [***] 
 2.3
Meetings and Minutes. Each Committee shall meet quarterly, or as otherwise agreed to by the Parties, with the location of such meetings alternating between locations designated by Caribou and locations designated by AbbVie, such
meetings to include the use of virtual meetings, as appropriate. The chairperson of the Committee shall be responsible for calling meetings on no less than [***] Business Days’ notice. Each Party shall make all proposals for agenda items and
shall provide all appropriate information with respect to such proposed items at least [***] Business Days in advance of the applicable meeting; provided that, under exigent circumstances requiring input by a Committee, a Party may provide
its agenda items to the other Party within a shorter period of time in advance of the meeting, or may propose that there not be a specific agenda for a particular meeting, so long as the other Party consents to such later addition of such agenda
items or the absence of a specific agenda for such meeting, such consent not to be unreasonably withheld, conditioned or delayed. Following each meeting, the Alliance Managers shall ensure meeting minutes are prepared and shall circulate an initial
draft thereof to Committee members for review and comment. Alliance Managers shall ensure that the minutes of each meeting of such Committee are reviewed and approved promptly, but in no event later than the next meeting of the relevant Committee.

 2.4 Procedural Rules. The JGC shall have the right to adopt such standing rules as shall be necessary for its work
and the work of each Subcommittee, to the extent that such rules are not inconsistent with this 

  
 - 19 - 

 CONFIDENTIAL 
  

 
Agreement. A quorum of a Committee shall exist whenever there is present at a meeting at least two (2) representatives appointed by each Party. Representatives of the Parties on a Committee
may attend a meeting either in person or by telephone, video conference or similar means in which each participant can hear what is said by, and be heard by, the other participants. Representation by proxy shall be allowed, including by an Alliance
Manager. Each Committee shall take action by consensus of the representatives present at a meeting at which a quorum exists, with each Party having a single vote irrespective of the number of representatives of such Party in attendance, or by a
written resolution signed by at least one (1) representative appointed by each Party. Employees or consultants of either Party who are not representatives of the Parties on a Committee may attend meetings of such Committee; provided that
such attendees (a) shall not vote in the decision-making process of the Committee, and (b) are bound by obligations of confidentiality and non-disclosure
equivalent to those set forth in this Agreement. 
 2.5 Decision-Making. 

2.5.1 Escalation to JGC. Except as otherwise provided herein, all decisions of the JGC and of each Subcommittee and each Working Group
shall be made by consensus, with all of a Party’s voting members collectively having one (1) vote. Decisions of the JGC and each Subcommittee and Working Group shall be made by unanimous vote. If a Subcommittee or Working Group is
incapable of reaching unanimous agreement on a matter before it within [***] Business Days (or such other time period as mutually agreed by the Parties), the matter shall be referred to the JGC for resolution. If the JGC is incapable of reaching
unanimous agreement on a matter before it within [***] Business Days (or such other time period as mutually agreed by the Parties), the matter shall be resolved in accordance with Section 2.5.2. 

2.5.2 Escalation to the Parties; Limitations on Authority. If the JGC cannot agree on a matter within [***] Business Days (or such
other time period as mutually agreed by the Parties) after it has met and attempted to reach such decision, then the matter shall be finally and definitively resolved by AbbVie. Notwithstanding the foregoing, in no event shall the JGC, any
Subcommittee, any Working Group, the Alliance Managers, or any Party alone have the power or authority to: (a) amend this Agreement, (b) amend an existing Research Plan in a manner that would result in (i) a reduction in the budget in
a Research Plan for any Development and/or Manufacturing activities to be performed by Caribou without a commensurate reduction in the nature or scope of such Development and/or Manufacturing activities, or (ii) an increase in the nature or
scope of Development and/or Manufacture activities to be performed by Caribou without a commensurate increase in the budget in the applicable Research Plan(s), (c) determine that a Party has fulfilled its obligations under this Agreement or that the
other Party has breached this Agreement, (d) impose any requirements on either Party to forgo any of its rights under this Agreement, (e) make a decision that is expressly stated to require the mutual agreement of the Parties or approval
of the other Party, or (f) require either Party to perform any act that it reasonably believes to be inconsistent with any Applicable Law. Any decision made by AbbVie in accordance with this Section 2.5.2 shall be
considered a decision made by the JGC. 
 2.6 Alliance Managers. Promptly after the formation of the JGC, each Party
shall appoint an employee (who may not be a then-current member of the JGC) to act as alliance manager for such Party (each, an “Alliance Manager”). Each Alliance Manager shall thereafter be
permitted to attend meetings of the JGC as a nonvoting attendee. The Alliance Managers shall be the primary point of contact for the Parties regarding the activities contemplated by this Agreement. The Alliance Managers shall also be responsible for
assisting the JGC in performing its oversight responsibilities. The name and contact information for each Party’s Alliance Manager, as well as any replacement chosen by such Party, in its sole discretion, from time to time, shall be promptly
provided to the other Party. Any disagreement between the Alliance Managers of AbbVie and Caribou shall be referred to the JGC for resolution. 

2.7 Discontinuation of Committees. On a Program
Slot-by-Program Slot basis, the JGC, each Subcommittee, and each Working Group shall have no further oversight or authority over a Program Slot upon the conclusion of
the applicable Research Collaboration Term for such Program Slot. Unless otherwise agreed by the Parties, the JGC, each Subcommittee, and each Working Group shall be automatically disbanded and the Alliance Manager roles shall be automatically
terminated upon the end of the last-to-expire Research Collaboration Term. Additionally, in the event of a Change in Control of Caribou, AbbVie shall have the right to
disband the JGC pursuant to Section 12.2. 
 2.8 Interactions Between a Committee and Internal
Teams. The Parties recognize that each Party possesses an internal structure (including various committees, teams, and review boards) that will be involved in 

  
 - 20 - 

 CONFIDENTIAL 
  

 
administering such Party’s activities under this Agreement. Nothing contained in this ARTICLE 2 shall prevent a Party from making routine day-to-day decisions relating to the conduct of those activities for which it has a performance or other obligations hereunder, in each case in a manner consistent with the
then-current applicable plan and the terms and conditions of this Agreement. 
 2.9
Working Groups. From time to time, a Committee may establish and delegate duties to sub-committees or directed teams (each, a “Working Group”) on an “as-needed” basis to oversee particular projects or activities (for example, joint project team, joint finance group, and/or joint intellectual property group). Each such Working Group shall be constituted
and shall operate as the relevant Committee determines; provided, that each Working Group shall have equal representation from each Party, unless otherwise mutually agreed. Working Groups may be established on an ad hoc basis for purposes of
a specific project or on such other basis as a Committee may determine. Each Working Group and its activities shall be subject to the oversight, review, and approval of, and shall report to, the Committee that formed such Working Group. In no event
shall the authority of the Working Group exceed that specified for the Committee that formed the Working Group. All decisions of a Working Group shall be by consensus. Any disagreement between the designees of AbbVie and Caribou on a Working Group
shall be referred to the JGC for resolution. 
 2.10 Expenses. Each Party shall be responsible for all travel and related
costs and expenses for its members and other representatives to attend meetings of, and otherwise participate on, a Committee or Working Group. 

2.11 Authority. Each Party will retain the rights, powers and discretion granted to it under this Agreement and no such rights,
powers or discretion will be delegated to or vested in the JGC or any Subcommittee or any Working Group unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. 

ARTICLE 3 
 RESEARCH
COLLABORATION 
 3.1 Research Collaboration Overview. 

3.1.1 Caribou Platform Technology. AbbVie and Caribou will collaborate to use the Caribou Platform Technology to identify, Develop and
Manufacture Collaboration CAR-T Products and Licensed Products. As of the Effective Date, AbbVie has the right to select two (2) Program Slots under this Agreement; thereafter, during the Additional
Program Slot Period, AbbVie may, in its discretion, select up to two (2) additional Program Slots under this Agreement, for a total not to exceed four (4) Program Slots. [***] pursuant to the terms of the applicable Research Plan, as set
forth and subject to the terms of this ARTICLE 3. 
 [***] 

3.2 Program Slots; Research Plans. 

3.2.1 Program Slots. 

(a) Initial Program Slot. Section A of attached Schedule 3.2.1 sets forth the Initial Research Plan. As of the Effective Date,
AbbVie has selected the Target Combination for the Initial Program Slot as set forth in the Initial Research Plan and in Section B of attached Schedule 3.2.1. 

(b) Second Program Slot. At any time during the two (2) year period following the Effective Date, AbbVie shall have the right to
select a Target or Target Combination for the second Program Slot [***]. 
 (c) Two Additional Program Slots. AbbVie shall have the
right at any time during the Additional Program Slot Period to add up to two (2) additional Program Slots in its sole discretion. For each such additional Program Slot beyond the first two (2) Program Slots, AbbVie will pay to Caribou an
Additional Program Slot Fee pursuant to Section 6.3. [***] 

  
 - 21 - 

 CONFIDENTIAL 
  

 3.2.2 Reserved Targets. The Parties agree that: 

(a) Attached Schedule 3.2.2 sets forth a list of six (6) Targets reserved for AbbVie on an exclusive basis to select, at
AbbVie’s sole discretion, as a Target for the second (2nd), third (3rd), or fourth
(4th) Program Slots (or as a Substitute Target) (each a “Reserved Target”). The list of Reserved Targets shall not exceed six (6) Targets at any time; 

(b) The list of Reserved Targets shall be [***] if, prior to expiration of the Additional Program Slot Period, AbbVie elects [***]; 

(c) The list of Reserved Targets shall be reduced to [***] if, prior to expiration of the Additional Program Slot Period, AbbVie elects
[***]; and 
 (d) At any time, AbbVie may replace, at AbbVie’s sole discretion, any Reserved Target provided that,
(i) such replacement shall not occur more than once per Calendar Year and (ii) such replacement shall follow the nomination process in Section 3.2.6, mutatis mutandis, and the Target
Nomination Notice shall identify the to-be-replaced Reserved Target(s). 

3.2.3 Gatekeeper. Within [***] days after the Effective Date, Caribou shall engage an independent Third Party mutually agreeable to
the Parties (the “Gatekeeper”) for the purposes of performing the applicable functions set forth in Sections 3.2.4, 3.2.5, and 3.2.6, including (a) maintaining, in accordance with
Section 3.2.4, a list of Targets that are not available for nomination by AbbVie under this Agreement (“Unavailable Targets”) and (b) confirming whether Proposed Targets and Nominated Targets are on
the list of Unavailable Targets. [***] Such engagement shall be on terms consistent with this Agreement and mutually agreeable to the Parties, including provisions relating to confidentiality. The identity of the Unavailable Targets is deemed to be
the Confidential Information of Caribou and the identity of the Reserved Targets, Proposed Targets, and Nominated Targets is deemed to be the Confidential Information of AbbVie. 

3.2.4 Unavailable Targets. Caribou and the Gatekeeper shall maintain an up-to-date list of Unavailable Targets in accordance with the following: 
 (a) Caribou has
identified an initial list of four (4) Unavailable Targets, which list is attached hereto as Schedule 3.2.4 (the “Initial Unavailable Targets”). [***] 

(b) Notwithstanding anything to the contrary herein, the list of Unavailable Targets shall in no event include any Reserved Target at any
time; 
 (c) The list of Unavailable Targets shall be limited to (i) subject to Section 3.2.4(a), the
Initial Unavailable Targets, (ii) Targets under an effective, executed written agreement (A) with a Third Party with respect to a license or collaboration regarding T cells or other immune cells producing a CAR protein directed against
such Targets and (B) that would preclude Caribou from granting a license to AbbVie under this Agreement, and (iii) Targets that are the subject of an Internal Reserved Program. [***] and 

(d) Caribou shall notify the Gatekeeper within [***] days, (i) after any Target becomes an Unavailable Target in accordance with
Section 3.2.4(c)(ii) and/or Section 3.2.4(c)(iii) and (ii) after any Target on the list of Unavailable Targets no longer meets the criteria set forth in
Section 3.2.4(a), Section 3.2.4(c)(ii) and/or Section 3.2.4(c)(iii) (including termination of an agreement with a Third Party or termination of an Internal Reserved
Program) and is therefore no longer an Unavailable Target. Upon receipt of such notification, the Gatekeeper shall update the list of Unavailable Targets accordingly. 

  
 - 22 - 

 CONFIDENTIAL 
  

 3.2.5 Proposed Targets. Prior to nomination of a Target (whether pursuant to
Section 3.2.6 or Section 3.2.8), AbbVie may, in its discretion, disclose a Target it is considering for potential nomination (a “Proposed Target”) to the Gatekeeper and request in
writing that the Gatekeeper confirm if the Proposed Target is on the list of Unavailable Targets. Within [***] Business Days following the Gatekeeper’s receipt of the identity of a Proposed Target from AbbVie, the Gatekeeper shall verify
whether such Proposed Target is on the list of Unavailable Targets and notify AbbVie in writing whether such Proposed Target is or is not on the list of Unavailable Targets. Notwithstanding anything herein to the contrary (a) AbbVie shall have
no obligation to nominate any Proposed Targets, and (b) in no way shall a request by AbbVie with respect to a Proposed Target under this Section 3.2.5 be deemed to be a nomination of the Target as an Accepted Target
(and such Target shall not be considered nominated unless and until it is formally nominated in accordance with the terms and conditions set forth in Section 3.2.6). 

3.2.6 Nominated Targets. To nominate a Target as an Accepted Target, AbbVie shall provide the Gatekeeper with a confidential written
description of the Target (the “Nominated Target”) including, to the extent available, the NCBI Entrez Gene Symbol, the NCBI RefSeq accession number and the gene sequence for such Target (the “Target Nomination
Notice”). Within [***] Business Days following the Gatekeeper’s receipt of the Target Nomination Notice with respect to a Nominated Target, the Gatekeeper shall verify whether such Nominated Target is on the list of Unavailable Targets
and notify AbbVie in writing (“Target Availability Notice”) whether such Nominated Target is or is not on the list of Unavailable Targets. If the Target Availability Notice indicates that the Nominated Target is not on the list of
Unavailable Targets, then such Nominated Target shall automatically be designated as an “Accepted Target” on the date of AbbVie’s receipt of the Target Availability Notice (the “Target Acceptance Date”), and
the Parties will have all rights and obligations hereunder in connection with such Accepted Target or new Reserved Target (including exclusivity in accordance with Section 5.9) as of the Target Acceptance Date. If the
Target Availability Notice indicates that the Nominated Target is on the list of Unavailable Targets, then (a) if such Nominated Target is subsequently removed from the list of Unavailable Targets, the Gatekeeper shall provide written notice to
AbbVie within [***] Business Days of such Nominated Target’s removal therefrom and (b) AbbVie shall have the right to nominate an alternative Nominated Target (or the same Nominated Target, if it becomes available) in accordance with this
Section 3.2.6. In the event that one or more Third Parties has requested the same Unavailable Target and such Nominated Target is subsequently removed from the list of Unavailable Targets, the Gatekeeper will use reasonable
best efforts to send written notice of the availability of such Nominated Target to AbbVie and any such Third Party(ies) at the same time. In all cases, Caribou acknowledges and agrees that if AbbVie is the first Person to submit a Target Nomination
Notice for a Nominated Target, then unless such Nominated Target is subject to an Internal Reserved Program, such Nominated Target will, subject to the terms of this Agreement, be deemed an Accepted Target. 

3.2.7 Additional Program Slots. 

(a) Target Selection. For each Program Slot other than the Initial Program Slot, AbbVie shall select such Program Slot
by providing written notice to Caribou thereof at any time during the applicable time window as set forth in Sections 3.2.1(b) and 3.2.1(c), which notice shall (i) identify any Reserved Target(s) that will be the subject of such
Program Slot, and/or (ii) notify Caribou of the initiation of the Target nomination process in Section 3.2.6 (each such notice, the “Program Slot Selection Notice”). [***] 

(b) Additional Research Plans. If none of the Targets proposed by AbbVie in a Program Slot Selection Notice corresponds
to Unavailable Target(s), the JGC will promptly agree on a Research Plan for the applicable Program Slot, but in no event less than [***] days following the date of the Program Slot Selection Notice. Upon the JGC’s approval of each such
plan, such plan will be deemed to be a “Research Plan” under this Agreement and AbbVie will be deemed to have selected the applicable Program Slot under this Agreement as of the date on which the JGC approves such Research Plan (the
“Program Slot Exercise Date”). 
 3.2.8 Program Target Substitution. On a Program Slot-by-Program Slot basis during the applicable Target Substitution Period, AbbVie shall have the one-time right, in its sole
discretion, to select a substitute Target or Target Combination (a “Substitute Target” or “Substitute Targets,” as applicable, and a “Substitution”) for each applicable Program Slot, such Target(s)
to be selected from either the Reserved Target list or other available Targets, subject to the selection procedures of Section 3.2.7(a) (Target Selection). Upon a Substitution, the JGC shall promptly agree on a Research
Plan for the Program Slot for such Substitute Targets. Upon the JGC’s approval of such plan, such plan will be deemed a “Research Plan” under this Agreement and AbbVie will be deemed to have selected the applicable Substitute Target
for such Program Slot under this Agreement as of the date on which the JGC approves such Research Plan. [***] 

  
 - 23 - 

 CONFIDENTIAL 
  

 3.2.9 Consideration Reimbursement. In the event that, following the Effective Date,
Caribou acquires or in-licenses from any Third Party a [***] in respect of any Target which is not an Accepted Target, Reserved Target or Substitute Target, and through nomination by AbbVie (whether pursuant
to Section 3.2.6 or Section 3.2.8) such Target becomes an Accepted Target or Substitute Target prior to such Target becoming the subject of an Internal Reserved Program [***]. 

3.3 Conduct of Research Plan. 

3.3.1 Generally. Caribou shall conduct its activities under the applicable Research Plan in accordance with this ARTICLE 3 and
the other terms and conditions of this Agreement. Under the direction and supervision of the JGC, Caribou shall perform all of its Development activities set forth in the applicable Research Plan in good scientific manner and in compliance with all
Applicable Law, including all applicable GMP requirements, GLP requirements and good clinical practice requirements. [***] 
 3.3.2
Diligence. Pursuant to a Research Plan, following [***] Caribou shall complete the tasks set forth in the applicable Research Plan and shall use Commercially Reasonable Efforts to achieve the objectives of the applicable Research Plan as soon
as reasonably practicable and in accordance with the timeline set forth in the applicable Research Plan. Without limiting the foregoing, Caribou shall allocate sufficient time, effort, equipment, and skilled personnel to perform such Development
activities successfully and in accordance with the applicable Research Plan and its obligations under this Agreement. 
 3.3.3
Amendments to Research Plans. Either Party may propose an amendment to a Research Plan by submitting such proposed amendment in writing to the JGC for review and approval. Upon the approval of the JGC, the applicable Research Plan shall be
deemed to be amended by such amendment. Notwithstanding the foregoing or anything to the contrary in this Agreement, the JGC will not have the authority to approve any amendment to a Research Plan that would result in [***], which amendment will
require the mutual written agreement of the Parties. 
 3.3.4 Research Plan Records. Caribou shall, and shall require its Affiliates
and Third Party Providers to, maintain complete, current and accurate hard and/or electronic (as applicable) copies of records of all work conducted pursuant to its Development and Manufacturing activities under a Research Plan, and all results,
data, developments and Collaboration Know-How made in conducting such activities. Such records shall accurately reflect all such work done and results achieved with respect to a Research Plan in sufficient
detail to verify compliance with Caribou’s obligations under this Agreement and shall be in good scientific manner appropriate for applicable patent and regulatory purposes and comply with Applicable Law. Such records shall record only such
activities performed pursuant to this Agreement and shall not include or be commingled with records of activities outside the scope of the Research Plans. Such records shall be retained by Caribou for at least [***] years after the expiration or
termination of this Agreement, or for such longer period as may be required by Applicable Law. AbbVie shall have the right, during normal business hours, and upon reasonable, and no less than [***] calendar days, prior written notice, to inspect and
copy all records maintained pursuant to this Section 3.3.4. 
 3.4 Caribou Optional and
Opt In Technology.  
 [***] 

3.5 Research Reports. During the applicable Research Collaboration Term, [***] in advance of each Calendar Quarter
meeting of the JGC, Caribou shall provide to AbbVie (a) a reasonably detailed, written progress report on the status of its activities under the applicable Program Slot, (b) a reasonably detailed summary of all data with respect to the
applicable Collaboration CAR-T Products resulting from Caribou’s activities under the applicable Program Slot, and (c) access to or copies of written reports of applicable Development activities
under the Program Slot as may be prepared by Caribou. Notwithstanding the foregoing, Caribou shall, within a reasonably prompt period of time following a request by AbbVie, provide to AbbVie such additional Information relating to each applicable
Program Slot as may be 

  
 - 24 - 

 CONFIDENTIAL 
  

 
reasonably requested by AbbVie to enable AbbVie to assess Caribou’s progress under and compliance with the applicable Research Plan. For clarity, research reports submitted by Caribou under
this Section 3.5 may be in PowerPoint format, provided such PowerPoints contain all information specified in the foregoing clauses (a) and (b). 

3.6 Data Packages. On a Program Slot-by-Program Slot
basis, within [***] days after [***] (or such other period of time mutually agreed by the Parties), Caribou shall deliver to AbbVie the complete Data Package with respect to the applicable Program Slot. 

[***] 
 3.8 Research
Costs. Caribou shall use Commercially Reasonable Efforts to ensure that the Research Costs are within the applicable Research Plan budget. Subject to this Section 3.8, AbbVie shall reimburse Caribou for the
Research Costs actually incurred by Caribou after the Effective Date in connection with the performance of Development activities in accordance with the applicable Research Plan and budget set forth therein. Caribou shall calculate and maintain
records of FTE Costs (on an employee percentage allocation basis) and Out-of-Pocket Costs with respect to each Research Plan incurred by it, unless agreed by the Parties
in writing. AbbVie shall have no obligation to reimburse any Research Costs or other costs of Development incurred by Caribou except as expressly set forth in Section 3.4.1(d), Section 3.7, this
Section 3.8, Section 3.9.2, Section 3.9.3, as applicable, and Section 3.10.3. 

3.8.1 Budget Overages. 

(a) In the event Caribou determines that it is likely to incur Research Costs in excess of the applicable Research Plan budget for a Calendar
Year, Caribou shall inform AbbVie of the expected overage within [***] Business Days of making such determination. Prior to incurring any Research Costs in excess of the applicable Research Plan budget, Caribou shall provide to the JGC a reasonably
detailed written explanation of such additional Research Costs. Any overspend of Caribou in excess of [***] of the then-current applicable Research Plan budget shall be borne by Caribou, [***]. 

(b) Any overspend, or potential overspend, by Caribou of the Research Costs set forth in the applicable Research Plan shall not impact
Caribou’s obligations under Section 3.6. Without limiting the foregoing, for so long as Caribou is performing activities under the applicable Research Plan, within [***] days after the end of the [***] of each Calendar
Year, Caribou shall provide to AbbVie (i) an estimate of the FTE Costs and Out-of-Pockets Costs anticipated to be incurred by Caribou during the [***] of such
Calendar Year and (ii) a good faith estimate of the FTE Costs and Out-of-Pockets Costs anticipated to be incurred by Caribou for the following Calendar Year. 

3.8.2 Research Cost Payments. On a Research Plan-by-Research Plan basis, within [***] days after the end of each Calendar Quarter in
which Caribou is performing any Development activities under the applicable Research Plan, Caribou shall provide to AbbVie an invoice setting forth the Research Costs incurred by or on behalf of Caribou during such Calendar Quarter, along with a
summary report of such Research Costs, which report shall (a) specify in reasonable detail all amounts included in the Research Costs during such Calendar Quarter, (b) set forth any payment (or series of payments) to a Third Party that exceeds [***]
and (c) include copies of any invoice(s) or other supporting documentation with respect to payment (or series of payments) to a Third Party that exceeds [***]. Caribou also shall provide, on AbbVie’s request, copies of any other invoices or
other supporting documentation for any payment made to a Third Party. AbbVie shall reimburse Caribou for all undisputed Research Costs set forth in the applicable invoice within [***] calendar days of AbbVie’s receipt thereof, provided,
that if AbbVie disputes in good faith any portion of such invoice, it shall pay the undisputed Research Costs and shall provide Caribou with written notice of the disputed portion and its reasons therefor within [***] calendar days of receipt of
such invoice, and AbbVie shall not be obligated to pay such disputed portion unless and until such dispute is resolved in favor of Caribou. The Parties shall use good faith efforts to resolve any such disputes promptly. If it is determined that
AbbVie disputed any amounts invoiced by Caribou in bad faith, AbbVie shall promptly make payment to Caribou of all such amounts, together with interest thereon, pursuant to Section 6.9. 

  
 - 25 - 

 CONFIDENTIAL 
  

 3.9 Third Party Providers. 

3.9.1 Caribou shall have the right to subcontract any of its Development and Manufacturing activities set forth in the applicable Research
Plan, to a Third Party (a “Third Party Provider”) [***] Except as provided in Section 4.4.2, Caribou further shall use Commercially Reasonable Efforts to assist AbbVie in obtaining from such Third Party
Provider any Manufacturing Process or related technology used in the Manufacture of such Collaboration CAR-T Products or Licensed Products, including all Know-How and
Materials related thereto. 
 3.9.2 In the event that (a) a Third Party Provider is an existing Caribou service provider (each an
“Existing Third Party Provider”) under an existing services agreement (e.g., a master services agreement) (each an “Existing Services Agreement”), and the Existing Third Party Provider will only provide non-GLP, non-GMP activities pursuant to a Research Plan, then, in lieu of a new services agreement, Caribou and the Existing Third Party Provider may enter into a statement of
work or other supplemental document under the Existing Services Agreement with such Existing Third Party Provider to cover the activities subject to this Agreement (each a “Supplemental Existing Services Agreement Document”),
provided that (i) such Supplemental Existing Services Agreement Document complies with each of the requirements set forth in Section 3.9.1, and (ii) Caribou provides AbbVie a copy of the relevant
Supplemental Existing Services Agreement Document and a redacted version of the Existing Services Agreement, such redacted portions being limited to those parts of the Existing Services Agreement that do not relate to the activities of the Existing
Third Party Provider subject to this Agreement. Subject to reimbursement by AbbVie as set forth in Section 3.8, and further subject to Section 3.9.3, Caribou shall directly pay all such Third Party
Providers for all external costs set forth in each Research Plan. Subject to the final decision-making authority of the JGC, Caribou shall direct the activities of such Third Party Providers. 

3.9.3 To the extent Third Party Providers would be required to perform GMP activities (including where, under a single agreement, such Third
Party Providers perform GLP activities in furtherance of GMP activities) pursuant to a Research Plan or this Agreement for the Manufacture of Collaboration CAR-T Products and Licensed Products for use in
AbbVie’s Phase I Clinical Studies, except as otherwise expressly agreed by the Parties, AbbVie shall enter into agreements (including service agreements and quality agreements) with such Third Party Providers (such Third Party Provider, an
“AbbVie-Retained Third Party Provider”) pursuant to which AbbVie shall: (i) directly pay such AbbVie-Retained Third Party Providers’ costs, as set forth in the applicable Research Plan, in lieu of reimbursing Caribou for
such costs; (ii) ensure such AbbVie-Retained Third Party Providers will take instructions from and otherwise reasonably cooperate with Caribou such that Caribou may discharge its obligations under this Agreement; and (iii) list Caribou as
an express third party beneficiary. Caribou agrees that it shall enter into a three-party confidentiality agreement with each relevant AbbVie-Retained Third Party Provider, such that confidentiality obligations run to and among each of Caribou,
AbbVie, and the AbbVie-Retained Third Party Provider, and further agrees that it shall cooperate with AbbVie as reasonably necessary for AbbVie to negotiate and execute such two- and three-party agreements.
Notwithstanding the foregoing, Caribou shall remain responsible for its obligations under the applicable Research Plan and this Agreement and shall provide the necessary instructions to the AbbVie-Retained Third Party Provider for execution of such
applicable obligations. 
 3.10 Supply of Technology for Development Purposes. On a Program Slot-by-Program Slot basis: 
 3.10.1 Promptly after the Effective Date, to the extent not done so
already, Caribou shall, and shall cause its Affiliates to, without additional compensation, disclose and make available to AbbVie, in whatever form AbbVie may reasonably request, Caribou Background Know-How,
[***] Know-How and any other subject matter claimed or covered by any Caribou Background Patent or [***] Patent, all of the foregoing as of the date hereof, to the extent reasonably necessary or useful for
AbbVie’s performance of its obligations under any Research Plan or this Agreement or the exercise of any of AbbVie’s rights under this Agreement; 

3.10.2 During the Term, to the extent not done so already, Caribou shall, and shall cause its Affiliates to, without additional compensation,
reasonably promptly disclose and make available to AbbVie, in such form as maintained by Caribou in the ordinary course of business, such Regulatory Documentation, Caribou Background Know-How, Caribou
Collaboration Know-How, [***] Know-How and any other subject matter claimed or covered by any Caribou Background Patent, Caribou Collaboration Patent or [***] Patent to
the extent reasonably necessary or useful 

  
 - 26 - 

 CONFIDENTIAL 
  

 
for AbbVie’s utilization of the Caribou Platform Technology, AbbVie’s Exploitation of a Collaboration CAR-T Product or a Licensed Product, or
[***] on the terms and conditions set forth in this Agreement, such disclosure to be made reasonably promptly after the making, conception, or reduction to practice of such Regulatory Documentation, Caribou Background
Know-How, Caribou Collaboration Know-How, [***] Know-How and any other Information; and 

[***] During the applicable Research Collaboration Term and subsequent Transition Plan, for no additional consideration Caribou shall provide
AbbVie with all reasonable assistance required in order to provide to AbbVie, in a timely manner, the Regulatory Documentation, Caribou Background Know-How, Caribou Collaboration
Know-How, [***], [***] Know-How and any other subject matter required to be produced pursuant to Section 3.10.2, and shall assist AbbVie with
respect to the Exploitation of any Collaboration CAR-T Products and any Licensed Products, to the extent necessary for AbbVie to reproduce activities performed by Caribou under the applicable Research Plan.
Without prejudice to the generality of the foregoing, if visits of Caribou’s representatives to AbbVie’s facilities are reasonably requested by AbbVie for purposes of providing the Regulatory Documentation, Caribou Background Know-How, Caribou Collaboration Know-How, [***], [***] Know-How and any other subject matter to AbbVie, or for purposes of providing
AbbVie the assistance referenced in the preceding sentence, at AbbVie’s cost, Caribou shall send appropriate representatives to AbbVie’s facilities. [***] 

3.11 Provision of Certain Materials. 

3.11.1 Generally. During the Research Collaboration Term, each Party may provide the other Party with Provided Materials in accordance
with the applicable Research Plan or as otherwise agreed to by the JGC. Neither Party shall administer any Provided Material to any human. 

3.11.2 AbbVie Materials. Caribou shall use any and all Provided Materials received from AbbVie solely in connection with conducting
the activities specified in the applicable Research Plan, as applicable, or for the specific purpose approved by AbbVie. All right, title, and interest in and to Provided Materials of AbbVie shall remain the sole and exclusive property of AbbVie,
notwithstanding the transfer to and use by Caribou of the same. [***] At the end of the Term (or, with respect to Provided Materials provided by AbbVie, such earlier time as AbbVie may request in writing once Caribou no longer needs such Provided
Materials for purposes of the Development activities conducted by Caribou), Caribou shall either destroy or return to AbbVie, at AbbVie’s sole discretion, all unused Provided Materials of AbbVie. 

3.11.3 Caribou Materials. Title in and to any and all Provided Materials of Caribou shall transfer to AbbVie upon AbbVie’s
receipt of such Provided Materials. AbbVie’s use of such Provided Materials shall be subject to and consistent with the Licenses granted to AbbVie under this Agreement. For clarity, the transfer of title to AbbVie for Provided Materials of
Caribou shall not preclude or restrict Caribou’s use of any materials retained in Caribou’s possession. 
 3.12
Regulatory Matters. AbbVie shall, as between the Parties, have the sole right to prepare, obtain and maintain (including the setting of the overall regulatory strategy therefor) all INDs, Drug Approval Applications, other Regulatory
Approvals and other submissions and to conduct communications with the Regulatory Authorities and governmental authorities in the Territory for the applicable Collaboration CAR-T Product and corresponding
Licensed Products. Caribou shall perform the regulatory activities allocated to Caribou in the applicable Research Plan, including drafting certain portions of any IND, and shall otherwise support AbbVie (at Caribou’s cost), as may be
reasonably necessary, in obtaining Regulatory Approvals for such Collaboration CAR-T Product and Licensed Products and in the activities in support thereof, including providing all documents or other materials
in the possession or control of Caribou or any of its Affiliates, upon reasonable request, as may be necessary or reasonably useful for AbbVie or any of its Affiliates or its or their Sublicensees to obtain Regulatory Approvals for the Licensed
Products. All Regulatory Documentation (including all Regulatory Approvals) in the Territory relating to the applicable Collaboration CAR-T Product and corresponding Licensed Products shall be owned by, and
shall be the sole property and held in the name of, AbbVie or its designated Affiliate, Sublicensee or designee. 

  
 - 27 - 

 CONFIDENTIAL 
  

 ARTICLE 4 

DEVELOPMENT AND COMMERCIALIZATION BY ABBVIE 

4.1 AbbVie Development and Commercialization. On a Collaboration CAR-T Product-by-Collaboration CAR-T Product basis, following the occurrence of the Transfer Date, AbbVie shall have the sole right to
Develop, Manufacture, Commercialize and otherwise Exploit such Collaboration CAR-T Product and applicable Licensed Products in the Field in the Territory in accordance with the terms and conditions of this
Agreement; provided that (a) Caribou shall continue to be responsible for Manufacturing activities and the supply of Licensed Product for the Phase I Clinical Studies in accordance with the applicable Research Plan, and (b) as set
out more fully in the applicable Research Plan, Caribou shall assist AbbVie with the preparation and filing of the applicable IND and in responding to any communications from FDA in respect of the IND. 

4.2 Transition Plan. Within [***] days prior to the Transfer Date with respect to a Collaboration
CAR-T Product, without additional consideration to Caribou, the Parties shall agree in good faith to a plan (“Transition Plan”) to transfer to AbbVie (or its designee) as
efficiently as possible all Development activities relating to such Collaboration CAR-T Product and any Licensed Products corresponding to such Collaboration CAR-T
Product then being undertaken by Caribou. Caribou shall use Commercially Reasonable Efforts to transition all such activities to AbbVie in accordance with the Transition Plan. 

4.3 Caribou Transition Obligation. Upon AbbVie’s request with respect to a Collaboration
CAR-T Product after the applicable Transfer Date, without limiting Section 4.2 and without additional consideration to Caribou: 

4.3.1 Caribou shall transfer to AbbVie all of its right, title, and interest in and to, and shall deliver to AbbVie, all Materials used,
acquired by, or generated by or on behalf of Caribou or any of its Affiliates or Third Party Providers under the applicable Research Plan; 

4.3.2 Caribou shall provide to AbbVie copies of all Know-How Controlled by Caribou arising out of the
applicable Program Slot or any Manufacturing activities with respect thereto, including all pre-clinical data and all safety data resulting from a Program Slot or any Manufacturing activities in connection
with either of the foregoing; and 
 4.3.3 Caribou shall assist AbbVie in responding to any communications from the FDA in respect of the
IND in accordance with Section 3.12. 
 4.4 Manufacturing. 

4.4.1 General. Unless the Parties otherwise agree, Caribou shall perform the Manufacturing activities designated to it as set
forth in the applicable Research Plan, including the designated activities for Manufacture and supply of all pre-clinical requirements of Collaboration CAR-T Products
and Licensed Products and managing Third Parties engaged for supply of Phase I clinical requirements of Collaboration CAR-T Products and Licensed Products under each Research Plan in accordance with the terms
hereof. 
 4.4.2 Manufacturing Technology Transfer. Upon AbbVie’s written request with respect to a given Collaboration CAR-T Product and Licensed Product, Caribou shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party Provider) of all Materials and
Know-How Controlled by Caribou relating to the then-current process for the Manufacture of such Collaboration CAR-T Product and
any corresponding Licensed Products (each, a “Manufacturing Process”). Caribou shall provide, shall cause its Affiliates to provide, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all Third Party Providers
to provide, all reasonable assistance requested by AbbVie to enable AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to implement each Manufacturing Process at the facilities designated by AbbVie. If requested by AbbVie,
such assistance shall include facilitating the entering into of agreements with applicable Third Party suppliers relating to such Collaboration CAR-T Product and any corresponding Licensed Products. Without
limitation of the foregoing, in connection with the Manufacturing Process and related transfer: 
 (a) Caribou shall, and shall cause its
Affiliates to, make available to AbbVie (or its Affiliate or designated Third Party Provider, as applicable), and shall use Commercially Reasonable Efforts to assist AbbVie in causing all Third Party Providers to make available to AbbVie, from time
to time as AbbVie may request, all Materials and Manufacturing-related Know-How Controlled by Caribou relating to each Manufacturing Process, including methods, reagents
and processes and testing/characterization Know-How, and all documentation constituting material support, performance advice, shop practice, standard operating procedures, specifications as to Materials to be
used, and control methods, that are necessary or reasonably useful to enable AbbVie (or its Affiliate or designated Third Party manufacturer, as applicable) to use and practice such Manufacturing Process; 

  
 - 28 - 

 CONFIDENTIAL 
  

 (b) Caribou shall cause all appropriate employees and representatives of Caribou and its
Affiliates, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all appropriate employees and representatives of Third Party Providers, to meet with employees or representatives of AbbVie (or its Affiliate or designated Third
Party Provider, as applicable) at the applicable manufacturing facility at mutually convenient times to assist with the working up and use of each Manufacturing Process and with the training of the personnel of AbbVie (or its Affiliate or designated
Third Party Provider, as applicable) to the extent necessary or reasonably useful to enable AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to use and practice such Manufacturing Process; 

(c) Without limiting the generality of this Section 4.4.2, Caribou shall cause all appropriate analytical and
quality control laboratory employees and representatives of Caribou and its Affiliates, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all appropriate analytical and quality control laboratory employees and representatives
of Third Party Providers, to meet with employees or representatives of AbbVie (or its Affiliate or designated Third Party Provider, as applicable) at the applicable manufacturing facility and make available all necessary equipment, at mutually
convenient times, to support and execute the provision of all applicable analytical methods and the validation thereof (including all applicable Know-How, Information and Materials Controlled by Caribou, and
sufficient supplies of all primary and other reference standards); 
 (d) Caribou shall, and shall cause its Affiliates to, take such
steps, and shall use Commercially Reasonable Efforts to assist AbbVie in causing Third Party Providers take such steps, as are necessary or reasonably useful to assist AbbVie (or its Affiliate or designated Third Party Provider, as applicable) in
obtaining any necessary licenses, permits or approvals from Regulatory Authorities with respect to the Manufacture of the applicable Collaboration CAR-T Products and corresponding Licensed Products at the
applicable facilities; and 
 (e) Caribou shall, and shall cause its Affiliates to, provide, and shall use Commercially Reasonable Efforts
to assist AbbVie in causing Third Party Providers to provide, such other assistance as AbbVie (or its Affiliate or designated Third Party Provider, as applicable) may reasonably request to enable AbbVie (or its Affiliate or designated Third Party
Provider, as applicable) to use and practice each Manufacturing Process and otherwise to Manufacture the applicable Collaboration CAR-T Products and corresponding Licensed Products. 

4.5 Diligence. Following the first occurrence of a Transfer Date, AbbVie shall use Commercially Reasonable Efforts to Develop
and Commercialize [***] during the Royalty Term under this Agreement. Caribou acknowledges and agrees that nothing in this Section 4.5 is intended, or shall be construed, to require AbbVie to Develop or Commercialize a
specific Licensed Product. Except as set forth in this Section 4.5, AbbVie shall have no other diligence obligations, express or implied, with respect to the Development, Commercialization or other Exploitation of the
Licensed Products in the Territory. 
 4.6 Booking of Sales; Distribution. AbbVie will have the sole right to invoice and book
sales, establish all terms of sale (including pricing and discounts) and warehousing, and distribute the Licensed Products in the Territory and to perform or cause to be performed all related services. AbbVie will handle all returns, recalls or
withdrawals, order processing, invoicing, collection, distribution, and inventory management with respect to the Licensed Products in the Territory. 

4.7 Product Trademarks. Subject to Section 4.8, AbbVie will have the sole right to determine and own
the Product Trademarks to be used with respect to the Exploitation of the Licensed Products on a worldwide basis. Caribou will not, and will not permit its Affiliates to, (a) use in their respective businesses, any Trademark that is

  
 - 29 - 

 CONFIDENTIAL 
  

 
confusingly similar to, misleading or deceptive with respect to or that dilutes any (or any part) of the Product Trademarks or (b) do any act which endangers, destroys, or similarly affects,
in any material respect, the value of the goodwill pertaining to the Product Trademarks. Caribou agrees to, and will cause its Affiliates to, conform (i) to the customary industry standards for the protection of Product Trademarks for products
and such guidelines of AbbVie with respect to manner of use (as provided in writing by AbbVie) of the Product Trademarks, and (ii) to maintain the quality standards of AbbVie with respect to the goods sold and services provided in connection
with such Product Trademarks. Caribou will not, and will not permit its Affiliates to, attack, dispute or contest the validity of or ownership of such Product Trademarks anywhere in the Territory or any registrations issued or pending with respect
thereto. 
 4.8 Markings. To the extent required by Applicable Law in a country in the Territory, the promotional materials,
packaging and Product Labeling used by AbbVie, its Affiliates and its and their Sublicensees in connection with the Licensed Products in such country will contain (a) the Corporate Name of Caribou and (b) the logo and corporate name of the
manufacturer (if other than AbbVie or an Affiliate) (collectively, the “Markings”). 
 ARTICLE 5 

GRANT OF RIGHTS 
 5.1
Grants to AbbVie. 
 5.1.1 Caribou Platform Technology and Other Licenses. Subject to Sections 5.3 and
5.7.1, upon the Effective Date, Caribou (on behalf of itself and its Affiliates) hereby grants to AbbVie and its Affiliates the following licenses (collectively, the “Licenses”): 

(a) an exclusive (including with regard to Caribou and its Affiliates), royalty-bearing license (or sublicense), with the right to grant
sublicenses in accordance with Section 5.3, under all Caribou IP other than: (i) [***] and (ii) [***] IP (which, for clarity, is licensed solely pursuant to Section 5.1.3), in all cases solely to
Develop, Commercialize, Manufacture and otherwise Exploit the Collaboration CAR-T Products and Licensed Products in the Field in the Territory; 

(b) an exclusive (including with regard to Caribou and its Affiliates) license and right of reference, with the right to grant sublicenses
and further rights of reference in accordance with Section 5.3, under all Regulatory Approval and any other Regulatory Documentation that Caribou or its Affiliates may Control with respect to the Collaboration CAR-T Products or Licensed Products as necessary solely for purposes of Exploiting the Collaboration CAR-T Products and Licensed Products in the Field in the Territory;

 (c) a non-exclusive, royalty-free license (or sublicense), with the right to grant sublicenses
in accordance with Section 5.3, under the Caribou IP other than: (i) [***] and (ii) [***] IP (which, for clarity, is licensed solely pursuant to Section 5.1.3), solely to Develop, Commercialize,
Manufacture and otherwise Exploit Companion Diagnostic Products in the Companion Diagnostic Field in the Territory; and 
 (d) subject to
Section 7.1.7, a non-exclusive license, with the right to grant sublicenses in accordance with Section 5.3, to use Caribou’s Corporate Names solely as
required by Applicable Law to Exploit the Collaboration CAR-T Products or Licensed Products in the Field in the Territory and for no other purpose. 

5.1.2 [***] Subject to Sections 5.3, 5.7.1, and 5.9.3, upon: 

(a) AbbVie’s selection of [***] as a Target for a Program Slot and during the corresponding Research Collaboration Term, Caribou (on
behalf of itself and its Affiliates) hereby grants to AbbVie and its Affiliates an exclusive (including with regard to Caribou and its Affiliates), royalty-bearing license (or sublicense), with the right to grant sublicenses in accordance with
Section 5.3, under the [***], solely to Develop Collaboration CAR-T Products and Licensed Products in the Field in the Territory. [***]; and 

(b)[***], Caribou (on behalf of itself and its Affiliates) hereby grants to AbbVie and its Affiliates an exclusive (including with regard to
Caribou and its Affiliates), royalty-bearing license (or sublicense), with the right to grant sublicenses in accordance with Section 5.3, under [***], solely to Develop, Commercialize, Manufacture and otherwise Exploit the
Collaboration CAR-T Products and Licensed Products in the Field in the Territory. [***] 

  
 - 30 - 

 CONFIDENTIAL 
  

 5.1.3 [***] IP. Subject to Sections 3.4.1 and 5.7.1, [***] Caribou (on
behalf of itself and its Affiliates) hereby grants to AbbVie and its Affiliates an exclusive (including with regard to Caribou and its Affiliates), royalty-bearing license (or sublicense), with the right to grant sublicenses in accordance with
Section 5.3, under the [***] solely to Develop, Commercialize, Manufacture and otherwise Exploit the Collaboration CAR-T Products and Licensed Products in the Field in the Territory.
 
 5.2 Grants to Caribou. Upon the Effective Date, AbbVie hereby grants to Caribou and its Affiliates a non-exclusive, royalty-free license, without the right to grant sublicenses (except to Third Party Providers pursuant to Section 3.9), under the AbbVie IP to Develop or Manufacture the
Collaboration CAR-T Products and Licensed Products in the Territory solely for purposes of performing its obligations as set forth in, and subject to, each applicable Research Plan. 

5.3 Sublicenses. AbbVie and its Affiliates shall have the right to grant sublicenses (or further rights of reference), through
multiple tiers of sublicensees, under and within the scope of the Licenses and rights of reference granted in Section 5.1, to its Affiliates and other Persons; provided that any such sublicenses shall be consistent
with and subject to the terms and conditions of this Agreement. 
 5.4 Distributorships. AbbVie shall have the right, in its
sole discretion, to appoint its Affiliates, and AbbVie and its Affiliates shall have the right, in their sole discretion, to appoint any other Persons, in the Territory or in any country or other jurisdiction of the Territory, to distribute, market,
and sell the Licensed Products (with or without packaging rights). Where AbbVie or its Affiliates appoints such a Person and such Person is not an Affiliate of AbbVie, that Person shall be a “Distributor” for purposes of this
Agreement. The term “packaging rights” in this Section 5.4 means the right for the Distributor to package Licensed Products supplied in unpackaged bulk form into individual ready-for-sale packs. 
 5.5 Existing IP Agreements. 

5.5.1 Generally. Except as otherwise expressly set forth in this Agreement, including Sections 3.4 and 5.5.2, all
financial obligations, including royalties, due from Caribou to Third Parties under the Existing IP Agreements in consideration of Caribou’s or AbbVie’s Exploitation of the Caribou IP, the Collaboration
CAR-T Products or the Licensed Products as contemplated hereunder are the sole responsibility of Caribou. 

5.5.2 [***] Notwithstanding the provisions of Section 5.5.1, if AbbVie selects the [***] in accordance with
Section 3.4.2, until the earlier of (a) expiration of the Term (as defined in the [***]), and (b) expiration of the Royalty Term, the royalty rate applicable to Net Sales of such Licensed Product containing such
[***] hereunder shall be increased by (i) [***], for annual Net Sales of such Licensed Product less than or equal to [***], and (ii) [***] for annual Net Sales in excess of [***], subject in each case ((i) and (ii)) to the provisions of
Section 6.5.4. 
 5.6 Future In-License Agreements. 

5.6.1 Notification. If, during the Term, either Party becomes aware of any Intellectual Property Controlled by a Third Party
that (a) relates to the Caribou Platform Technology (or any use thereof or improvement thereto), or (b) otherwise would be necessary or reasonably useful (or, with respect to Patent applications, would be necessary or reasonably useful if
such Patent applications were to issue as Patents) for the Development, Manufacture, Commercialization or other Exploitation of a Collaboration CAR-T Product or a Licensed Product in the Field in the
Territory, then such Party will notify the JGC that the Development, Manufacture or Commercialization of Collaboration CAR-T Products or Licensed Products may require or benefit from a grant of rights under
additional Intellectual Property of Third Parties, whether by license or acquisition (each, a “Potential In-License”). 

  
 - 31 - 

 CONFIDENTIAL 
  

 5.6.2 Target- or Product-Specific
In-Licenses. 
 (a) Except as set forth in Section 5.6.2(b), AbbVie
will have the sole right to enter into Potential In-Licenses in respect of Intellectual Property directed primarily to (i) the then-current Targets or Target Combinations selected and used for the
Collaboration CAR-T Products or Licensed Products (such Intellectual Property, “Target-Specific IP” and such Potential In-License,
“Target-Specific In-Licenses”) or (ii) the Collaboration CAR-T Products or Licensed Products, (such Intellectual Property,
“Product-Specific IP” and such Potential In-License, “Product-Specific In-Licenses”), in each case ((i) and (ii)), directly without
consultation of Caribou, the JGC or any other Committee hereunder. 
 (b) AbbVie will have the sole right to enter into
(i) Target-Specific In-Licenses for Target-Specific IP directed primarily to [***] for use with Collaboration CAR-T Products and Licensed Products that are directed
to [***], and (ii) Product-Specific In-Licenses for Product-Specific IP for use with Collaboration CAR-T Products or Licensed Products that are directed to [***];
and, subject to Caribou’s compliance with Section 5.9.3, Caribou will have the sole right to enter into (x) Target-Specific In-Licenses for Target-Specific IP directed to
[***] for use with Caribou Products, and (y) other in-licenses for IP directed primarily to Caribou Products for use with such Caribou Products that are directed to [***]. 

(c) Subject to the reduction limit as set forth in Section 6.5.4, AbbVie shall be entitled to offset [***] of the
costs of any Target-Specific In-License or Product-Specific In-License [***]. 

5.6.3 Blocking Platform In-Licenses. 

(a) Generally. 
 (i)
Caribou shall have the sole right to enter into Potential In-Licenses in respect of Intellectual Property that, assuming that such Intellectual Property is valid and enforceable, would be necessary for
utilizing the Caribou Platform Technology (such Intellectual Property, “Blocking Platform IP” and such Potential In-License, a “Blocking Platform
In-License”) in connection with Exploitation of, to the extent permitted in Section 5.9, (x) cell therapy products Developed using the Caribou Platform Technology and
directed towards Targets other than the then-current Initial Program Targets, Reserved Targets, or Accepted Targets, or (y) cell therapy products Developed using the Caribou Platform Technology and containing the [***] that are not a
Collaboration CAR-T Product or a Licensed Product. If Caribou enters into a Blocking Platform In-License, it shall be solely responsible for [***] of the costs of such
Blocking Platform In-License[***]. 
 (ii) AbbVie and its Affiliates shall have the sole right to
enter into Potential In-Licenses in respect of Blocking Platform IP in connection with Exploitation of a Collaboration CAR-T Product in a Licensed Product but not for
the Exploitation of any Caribou Product(s). If AbbVie or its Affiliates enters into such a Blocking Platform In-License it shall have the right to offset the costs of such Blocking Platform In-License[***]. 
 (iii) The Parties hereby acknowledge and agree that their mutual intent with respect
to Blocking Platform In-Licenses, including [***] as defined in Section 5.6.3(b), is for each Party (and its Affiliates) to act completely independent of, and without regard to, the
interest, benefit, or protection of, the other Party (and its Affiliate) in the identification, negotiation and execution of any Blocking Platform In-License. Without limiting the foregoing, 

(A) the Parties acknowledge that each Party has its own assessment about the validity, patentability, enforceability, infringement,
liability, or uncertainties associated with potential patent litigation, in connection with any Blocking Platform IP, and that one Party’s effort to negotiate or enter into a Blocking Platform In-License
for such Blocking Platform IP, including a [***], shall not in any way suggest or indicate that the other Party agrees with the former Party’s assessment of the validity, patentability, enforceability, infringement, liability, or any
uncertainties associated with potential patent litigation, in connection with such Blocking Platform IP; 

  
 - 32 - 

 CONFIDENTIAL 
  

 (B) Each Party that negotiates or enters into a Blocking Platform In-License hereby agrees that (1) the other Party is not, nor is intended to be, a third party beneficiary of such Blocking Platform In-License and (2) absent prior
written consent of the other Party, such Party shall not suggest in any way to the counterparty of the Blocking Platform In-License, or otherwise indicate in the Blocking Platform In-License, that the other Party is or may be a third party beneficiary of such Blocking Platform In-License; 

(C) Caribou shall not, and shall ensure that its Affiliates shall not, identify, negotiate or enter into, or assist any Third Party to
negotiate or enter into, a Blocking Platform In-License, intended for the benefit or interest of any Collaboration CAR-T Product, Licensed Product or the Exploitation
thereof; and 
 (D) AbbVie shall not, and shall ensure that its Affiliates shall not, identify, negotiate or enter into, or assist any
Third Party to negotiate or enter into, a Blocking Platform In-License, intended for the benefit or interest of any Caribou Product(s) or the Exploitation thereof. 

(E) [***] 
 (b) [***] 

(i) Generally. Notwithstanding Sections 5.6.3(a)(i) and (ii), but subject in all cases to
Section 5.6.3(a)(iii), either Party shall have the right to enter into Potential In-Licenses in respect of Intellectual Property that, assuming such Intellectual Property is valid and
enforceable, would be necessary for utilizing [***]. 
 (ii) Caribou Obtains License. Notwithstanding Sections 5.6.3(a)(i) and
(ii), but subject in all cases to Section 5.6.3(a)(iii): 
 (A) Caribou shall have the sole discretion to
enter into a [***], as long as the [***] in-licensed pursuant to such In-License claims or covers a Caribou Product(s) and does not claim or cover the then-current
Initial Program Targets, Reserved Targets, or Accepted Targets, or any Collaboration CAR-T Product or Licensed Product or the Exploitation thereof; 

(B) Caribou may also enter into a [***] for [***] that claims or covers a Caribou Product(s), and also claims or covers any of the
then-current Initial Program Targets, Reserved Targets, or Accepted Targets, or any Collaboration CAR-T Product or Licensed Product or the Exploitation thereof, provided that such [***] is not intended
for the benefit or interest of any Collaboration CAR-T Product, Licensed Product or the Exploitation thereof. Caribou may, in its sole discretion, include in such [***] the following provisions: Caribou has
the right to grant a sublicense (further sublicensable through multiple tiers) under all Intellectual Property in-licensed pursuant to such In-License, which, upon the
election of a Third Party (the scope of which includes AbbVie and its Affiliates) to receive a sublicense, such sublicense grants to such Third Party and its Affiliates exclusive or non-exclusive rights under
such Intellectual Property to Exploit a product (the scope of which includes Collaboration CAR-T Products and Licensed Products) in a field and territory (the scope of which includes the Field and the
Territory). 
 (C) Caribou shall provide written notice to AbbVie promptly after entering into a [***], and shall disclose in such
notice whether such license includes within its scope the right to practice any in-licensed [***] with any then-current Initial Program Targets, Reserved Targets, or Accepted Targets. Any such in-licensed [***] will be excluded from Caribou Background IP unless and until AbbVie elects to receive a sublicense pursuant to Section 5.6.3(b)(ii)(D). 

(D) AbbVie may, in its discretion and on written notice to Caribou at any time during the Term, elect to receive a sublicense under any [***]
executed by Caribou hereunder to use in the practice of the Licenses and AbbVie’s exercise of rights under this Agreement. If AbbVie exercises this right to receive a sublicense, then (1) the Parties shall document the exercise of such
right by executing an addendum to this Agreement memorializing AbbVie’s receipt of sublicense under the [***] (for clarity, such addendum shall not contain any additional terms or conditions); and (2) all [***] in-licensed thereunder shall be deemed Caribou Background IP. 

  
 - 33 - 

 CONFIDENTIAL 
  

 (E) If Caribou enters into a [***], it shall be solely responsible for [***] of the costs of
such [***]. 
 (iii) AbbVie Obtains License. If AbbVie or its Affiliates enters into a [***], it shall have the right to offset the
costs of such [***] in connection with Exploitation of any Collaboration CAR-T Product or Licensed Product, as provided in Section 6.5.4(c). 

5.6.4 Platform Improvement IP In-Licenses. 

(a) Caribou will have the first right, in its sole discretion, to enter into Potential In-Licenses in
respect of Intellectual Property other than Target-Specific IP, Product-Specific IP, Blocking Platform IP or [***] that would be necessary or reasonably useful for the Exploitation of a Collaboration CAR-T
Product or a Licensed Product (such Intellectual Property, “Platform Improvement IP” and such Potential In-License, a “Platform Improvement IP
In-License”). 
 [***] 

5.6.5 Reserved Rights. Except as otherwise expressly set forth in Sections 3.9.1 or 5.6 (including
Section 5.6.2, with respect to products directed to [***]), during the Term, (a) Caribou and its Affiliates shall be free, without AbbVie’s prior written consent, to enter into any agreement with a Third Party in
respect of any Information, regulatory documentation, Materials, Patents, or other Intellectual Property not directed primarily to the then-current Targets or Target Combinations selected and used for the Collaboration
CAR-T Products or Licensed Products, and (b) neither Caribou nor any of its Affiliates shall, without AbbVie’s prior written consent, enter into any agreement with a Third Party in respect of any
Information, Regulatory Documentation, Materials, Patents, or other Intellectual Property directed primarily to the then-current Targets or Target Combinations selected and used for the Collaboration CAR-T
Products or Licensed Products. 
 5.7 Retention of All Other Rights. 

5.7.1 Notwithstanding the exclusive licenses granted to AbbVie pursuant to Section 5.1, Caribou retains the right
to practice under the Caribou IP, all Regulatory Approvals and any other Regulatory Documentation to perform (and to sublicense Third Parties to perform as permitted hereunder) its obligations under this Agreement (including Development, Manufacture
and supply of Collaboration CAR-T Products and Licensed Products to AbbVie, as applicable). 

5.7.2 Except as expressly provided herein, Caribou grants no other right license or interest of any kind or nature, including any rights,
licenses or interests in or to the Caribou Background IP, [***] IP, [***], Regulatory Documentation, Caribou Corporate Names, or any other Patent, technology, or intellectual property or other proprietary rights, including, without limitation, with
respect to any Targets not subject to this Agreement or upon Targets ceasing to be the subject of the collaboration under this Agreement pursuant to Section 5.9.2. 

5.7.3 Except as expressly provided herein, AbbVie grants no other right or license of any kind or nature, including any rights, licenses or
interests in or to the AbbVie IP, the Regulatory Documentation, or any other Patent, technology or intellectual property rights or other proprietary rights not otherwise expressly granted herein. 

5.7.4 Notwithstanding the inclusion or incorporation of any [***] in a Collaboration CAR-T Product or
Licensed Product, Caribou retains the right to use such [***] independent of this Agreement if, at the time of such inclusion, (a) such [***] constituted Caribou Background IP, or (b) such [***] is generally known in the industry and not
claimed or covered by a Patent owned or Controlled by AbbVie or any of its Affiliates at the time of such use by Caribou; provided that in no event shall Caribou incorporate or benefit from any AbbVie Background
Know-How or AbbVie Collaboration Know-How in such use. 

[***] 

  
 - 34 - 

 CONFIDENTIAL 
  

 5.9 Exclusivity. 

5.9.1 On a Target-by-Target and Target Combination-by-Target Combination basis, commencing as of the date that such Target or Target Combination first becomes (as outlined below) a subject of the collaboration
under this Agreement and ending on [***] Caribou shall not, itself or with or through any Affiliate, license, authorize, appoint, or otherwise enable any Third Party to, directly or indirectly, Develop, Commercialize, or otherwise Exploit any
molecule, compound, or other therapeutic that binds to, inhibits or otherwise modulates such Target or Target Combination [***], or any derivative of the foregoing that also binds to, inhibits, or otherwise modulates such Target or Target
Combination [***], in each case anywhere in the Territory. 
 5.9.2 For the purposes of this Section 5.9, (a) a
Target or Target Combination (including any single Target within the set of Targets comprising such Target Combination) becomes a subject of the collaboration under this Agreement as of (i) the Effective Date for the Target Combination in the
Initial Program Slot or (ii) the date that a Target becomes an Accepted Target, a Substitute Target, or a Reserved Target; and (b) a Target or Target Combination will cease to be subject of the collaboration under this Agreement if
(i) either (A) such Target is substituted out of a Program Slot pursuant to Section 3.2.8 (upon Substitution), (B) a Program Slot directed to such Target or Target Combination is terminated, in accordance with
ARTICLE 11 (upon the effective date of such termination), or (C) such Target ceases to be a Reserved Target pursuant to Section 3.2.2; and (ii) such Target is not otherwise selected as a Target (or part of
a Target Combination) of an active Program Slot under this Agreement.
 5.9.3 Notwithstanding the provisions of
Section 5.9.1, Caribou shall have the rights to Develop, Commercialize, or otherwise Exploit, or enable a Third Party to Develop, Commercialize, or otherwise Exploit, the [***]. 

ARTICLE 6 
 PAYMENTS AND
RECORDS. 
 6.1 Upfront Payment. No later than [***] calendar days following the Effective Date, AbbVie shall pay Caribou
a one-time upfront payment equal to Thirty Million Dollars (US$30,000,000). Such payment shall be non-refundable and
non-creditable against any other payments due hereunder. 
 6.2 Equity Investment.
[***] 
 6.3 Additional Program Slot Fees. For each additional Program Slot beyond the first two (2) Program Slots,
AbbVie shall pay to Caribou a one-time, non-refundable payment equal to [***] (each, an “Additional Program Slot Fee”) for each such additional Program
Slot within [***] calendar days after the applicable Program Slot Exercise Date. 
 6.4 Milestone Payments. 

6.4.1 Development and Regulatory Milestones. In partial consideration of the rights and licenses granted by Caribou to AbbVie
hereunder, subject to Section 6.5.4, AbbVie shall pay to Caribou a one-time milestone payment within [***] days after the achievement of each of the following milestones, in respect
of the first Licensed Product in a Program Slot to attain such milestone, regardless of whether such milestones were achieved by AbbVie or its Affiliates or Sublicensees, calculated as follows: 

[***] 
 Each such milestone
payment shall be non-refundable and payable on a Program Slot-by-Program Slot basis only upon the first achievement of such
milestone with respect to such Program Slot, and no amounts shall be due for subsequent or repeated achievements of such milestone, whether by the same or a different Licensed Product, with respect to such Program Slot. 

  
 - 35 - 

 CONFIDENTIAL 
  

 6.4.2 Sales-Based Milestones. In partial consideration of the rights and licenses
granted by Caribou to AbbVie hereunder, and subject to Section 6.5.4, in the event that the annual Net Sales of a particular Licensed Product by AbbVie or any of its Affiliates or Sublicensees in a given Calendar Year
exceeds a threshold (each, an “Annual Net Sales-Based Milestone Threshold”) set forth in the left-hand column of the table in this Section 6.4.2 (the “Annual
Net Sales-Based Milestone Table”), AbbVie shall pay to Caribou a milestone payment (each, an “Annual Net Sales-Based Milestone
Payment”) in the corresponding amount set forth in the right-hand column, as applicable, of the Annual Net Sales-Based Milestone Table. In the event that in a given Calendar Year more than one
(1) Annual Net Sales-Based Milestone Threshold is exceeded, AbbVie shall pay to Caribou a separate Annual Net Sales-Based Milestone Payment with respect to each Annual Net Sales-Based Milestone Threshold
that is exceeded in such Calendar Year. Each such milestone payment shall be due within [***] days of the end of the Calendar Year in which such milestone was achieved (each, an “Annual Net
Sales-Based Milestone Payment Date”). Each Annual Net Sales-Based Milestone Payment shall be payable on a Program Slot-by-Program Slot basis only upon the first achievement of such milestone with respect to such Program Slot, and no amounts shall be due for subsequent or repeated achievements of such milestone, whether
by the same or a different Licensed Product, with respect to such Program Slot. 
  

					
	 Annual Net Sales-Based Milestone Threshold
	  	Annual Net Sales-Based Milestone
Payment	 
		
	 Annual Net Sales greater than [***]
	  	 	[***	] 
		
	 Annual Net Sales greater than [***]
	  	 	[***	] 
		
	 Annual Net Sales greater than [***]
	  	 	[***	] 

 6.4.3 For clarity, for each Program Slot the aggregate maximum Development and Regulatory Milestones payable
is [***] and the aggregate maximum Sales-Based Milestones payable is [***]. 
 6.5 Royalties. 

6.5.1 Royalty Rates. As further consideration for the rights and licenses granted to AbbVie hereunder, subject to
Section 6.5.4, commencing upon the First Commercial Sale of a Licensed Product and on a Licensed Product-by-Licensed Product basis and country-by-country basis, AbbVie shall pay to Caribou a tiered royalty on incremental annual Net Sales of such Licensed Product sold by AbbVie and its Affiliates and
Sublicensees thereof in the Territory (including all countries in which the Royalty Term has not expired) for each Calendar Year based on the following (and subject to the rate adjustments set forth in Section 5.5.2 and the
adjustments set forth below): 
  

					
	 Annual Net Sales of a Licensed Product
	  	Royalty Rate	 
		
	 Annual Net Sales less than or equal to [***]
	  	 	[***	] 
		
	 Annual Net Sales greater than [***] and less than or equal to [***]
	  	 	[***	] 
		
	 Annual Net Sales greater than [***]
	  	 	[***	] 

  
 - 36 - 

 CONFIDENTIAL 
  

 [***] 

6.5.2 Calculation of Royalties. With respect to each Licensed Product, royalties on annual Net Sales shall be paid at the rate
applicable to the portion of Net Sales of such Licensed Product within each of the Net Sales tiers during such Calendar Year. [***] 

6.5.3 Royalty Term. AbbVie shall have no obligation to pay any royalty with respect to Net Sales of any Licensed Product in any
country or other jurisdiction after the Royalty Term for such Licensed Product in such country or other jurisdiction has expired. 
 6.5.4
Reductions. [***] 
 [***] 

6.6 Estimated Sales Levels. Caribou acknowledges and agrees that the sales levels set forth in
Section 6.4 shall not be construed as representing an estimate or projection of anticipated sales of the Licensed Products, or implying any level of diligence or Commercially Reasonable Efforts, in the Territory and that
the sales levels set forth in such Section are merely intended to define AbbVie’s royalty obligations in the event such sales levels are achieved. 

6.7 Royalty Payments and Reports. AbbVie shall calculate all amounts payable to Caribou pursuant to
Section 6.5 at the end of each Calendar Quarter, which amounts shall be converted to Dollars. AbbVie shall pay to Caribou the royalty amounts due with respect to a given Calendar Quarter within [***] days after the end of
such Calendar Quarter. Following First Commercial Sale of a Licensed Product in any country, and regardless of whether a payment is due for a particular Calendar Quarter, each Calendar Quarter of the Term AbbVie shall provide to Caribou a statement
of the Net Sales of each Licensed Product in each country or other jurisdiction in the Territory during the applicable Calendar Quarter and a calculation of the amount of royalty payment due (if any) on such Net Sales for such Calendar Quarter. 

6.8 Mode of Payment; Offsets. All payments to either Party under this Agreement shall be made by deposit of United States
Dollars in the requisite amount to such bank account as the receiving Party may from time to time designate by notice to the paying Party. For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this Agreement
(including the calculation of Net Sales expressed in currencies other than Dollars), a Party shall convert any amount expressed in a foreign currency into Dollar equivalents using its, its Affiliate’s or Sublicensee’s standard conversion
methodology consistent with Accounting Standards. AbbVie shall have the right to offset any payment that is owed by Caribou but not paid against any payments owed by AbbVie, if any, under this Agreement. 

6.9 Interest on Late Payments. If any payment due to either Party under this Agreement is not paid when due, then such paying
Party shall pay interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) of [***] basis points above [***], such interest to run from the date on which payment of such became due until payment
thereof in full together with such interest; provided, however, that if the [***] rate is unavailable, then such interest shall be at an annual rate of [***] above the effective federal funds rate published by the Federal Reserve Bank
of New York, as adjusted from time to time on the first New York business day of each month. 
 6.10 Withholding
Taxes. Where any sum due to be paid to either Party hereunder is subject to any withholding or similar tax, the Parties shall use their Commercially Reasonable Efforts to do all such acts and things and to sign all such documents
as will enable them to take advantage of any applicable double taxation agreement or treaty. In the event there is no applicable double taxation agreement or treaty, or if an applicable double taxation agreement or treaty reduces but does not
eliminate such withholding or similar tax, the payor shall remit such withholding or similar tax to the appropriate government authority, deduct the amount paid from the amount due to payee and secure and send to payee the best available evidence of
the payment of such withholding or similar tax. Any such amounts deducted by the payor in respect of such withholding or similar tax shall be treated as having been paid by the payor for purposes of this Agreement. In the event that a government
authority retroactively determines that a payment made by a Party to the other pursuant to this Agreement should have been subject to withholding or similar (or to additional withholding or 

  
 - 37 - 

 CONFIDENTIAL 
  

 
similar) taxes, and such Party (the “Withholding Party”) remits such withholding or similar taxes to the government authority, including any interest and penalties that may be
imposed thereon (together with the tax paid, the “Withholding Amount”), the Withholding Party will have the right (a) to offset the Withholding Amount, against future payment obligations of the Withholding Party under this
Agreement, (b) to invoice the other Party for the Withholding Amount (which shall be payable by the other Party within [***] days of its receipt of such invoice), or (c) to pursue reimbursement by any other available remedy. 

6.11 Indirect Taxes. All payments are exclusive of value added taxes, sales taxes, consumption taxes and other similar taxes
(the “Indirect Taxes”). If any Indirect Taxes are chargeable in respect of any payments, the paying Party shall pay such Indirect Taxes at the applicable rate in respect of such payments following receipt, where applicable, of an
Indirect Taxes invoice in the appropriate form issued by the receiving Party in respect of those payments. The Parties shall issue invoices for all amounts payable under this Agreement consistent with Indirect Tax requirements and irrespective of
whether the sums may be netted for settlement purposes. If the Indirect Taxes originally paid or otherwise borne by the paying Party are in whole or in part subsequently determined not to have been chargeable, all commercially reasonable steps will
be taken by the receiving Party to receive a refund of these undue Indirect Taxes from the applicable governmental authority or other fiscal authority and any amount of undue Indirect Taxes repaid by such authority to the receiving Party will be
transferred to the paying Party within [***] days of receipt. 
 6.12 Financial Records. AbbVie shall, and shall cause
its Affiliates to, keep complete and accurate books and records pertaining to sales of Licensed Products, and the amount and calculation of Net Sales of Licensed Products, in each case in sufficient detail to calculate all amounts payable hereunder
and to verify compliance with its obligations under this Agreement. Caribou shall, and shall cause its Affiliates to, keep complete and accurate books and records pertaining to (a) Research Costs under each Research Plan, including books and
records of actual expenditures with respect to the budgets set forth in each Research Plan and budget, and (b) amounts paid under (i) the [***] in the event AbbVie selects the [***] in accordance with
Section 3.4.2, and (ii) any Platform Improvement IP In-License for which AbbVie elects to receive a sublicense pursuant to Section 5.6.4(e), in each
case ((a) and (b)), in sufficient detail to calculate all amounts payable hereunder and to verify compliance with its obligations under this Agreement. Each Party and its Affiliates shall retain such books and records until the later of (x) [***]
years after the end of the period to which such books and records pertain, and (y) [***]. 
 6.13 Audit. Each
Party shall, and shall cause its Affiliates to, permit the other Party or an independent public accounting firm of nationally recognized standing designated by such Party and reasonably acceptable to the other Party, at reasonable times during
normal business hours and upon [***] days’ prior written notice, to audit the books and records maintained pursuant to this Agreement to ensure the accuracy of all reports and payments made under this Agreement. Such examinations may not
(a) be conducted for any Calendar Quarter more than [***] years after the end of such quarter, (b) be conducted more than once in any [***] month period (unless discrepancies are found in a previous audit) or (c) be repeated for any
Calendar Quarter. In the course of any audits conducted by an accounting firm, the accounting firm shall disclose only whether the reports are correct or not, and the specific details concerning any discrepancies. No other information shall be
shared. Except as provided below, the cost of such audit shall be borne by the requesting Party, unless the audit reveals a variance of [***] or greater from the reported amounts, in which case the audited Party shall pay the variance and reimburse
the cost of the audit within [***] days. 
 6.14 Audit Dispute. In the event of a dispute with respect to any audit,
Caribou and AbbVie shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***] days, the dispute shall be submitted for resolution to a certified public
accounting firm jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Audit Arbitrator”). The decision of the Audit Arbitrator shall be final and the
costs of such arbitration as well as the initial audit shall be borne between the Parties in such manner as the Audit Arbitrator shall determine. Not later than [***] days after such decision and in accordance with such decision, the audited
Party shall pay the additional amounts, with interest from the date originally due, or the auditing Party shall reimburse the excess payments, as applicable. 

6.15 Confidentiality. The receiving Party shall treat all information subject to review under this ARTICLE 6 in
accordance with the confidentiality provisions of ARTICLE 8 and the Parties shall cause the Audit Arbitrator to enter into a reasonably acceptable confidentiality agreement with the audited Party obligating such firm to retain all such
financial information in confidence pursuant to such confidentiality agreement. 

  
 - 38 - 

 CONFIDENTIAL 
  

 6.16 No Other Compensation. Each Party hereby agrees that the terms of this
Agreement fully define all consideration, compensation, and benefits, monetary or otherwise, to be paid, granted, or delivered by one (1) Party to the other Party in connection with the transactions contemplated herein. Neither Party previously
has paid or entered into any other commitment to pay, whether orally or in writing, any of the other Party’s employees, directly or indirectly, any consideration, compensation, or benefits, monetary or otherwise, in connection with the
transaction contemplated herein. 
 [***] 

ARTICLE 7 
 INTELLECTUAL
PROPERTY 
 7.1 Ownership of Intellectual Property. 

7.1.1 Ownership of Caribou Background IP. Subject to the rights and licenses granted in Section 5.1 and the
other terms and conditions of this Agreement, Caribou (as used in this ARTICLE 7, including its designated Affiliate) shall retain its right, title and interest in and to Caribou Background IP. [***] 

7.1.2 Ownership of AbbVie Background IP. Subject to the rights and licenses granted in Section 5.2 and the
other terms and conditions of this Agreement, AbbVie (as used in this ARTICLE 7, including its designated Affiliate) shall retain its right, title and interest in and to AbbVie Background IP. [***] 

7.1.3 Ownership of Collaboration IP. Subject to the rights and licenses granted in Sections 5.1 and 5.2, as between the
Parties: 
 (a) AbbVie shall solely and exclusively own all right, title, and interest in and to any and all AbbVie Collaboration IP and
Caribou shall assign and hereby assigns, and shall cause its Affiliates to assign, to AbbVie all of its right, title, and interest in and to all any and all AbbVie Collaboration IP [***]; 

(b) Subject to Caribou’s compliance with Section 5.6.4(b), (i) Caribou shall solely and exclusively own all
right, title and interest in and to any and all Caribou Collaboration IP and (ii) AbbVie shall assign and hereby assigns, and shall cause its Affiliates to assign, to Caribou all of its right, title, and interest in and to all any and all
Caribou Collaboration IP; and 
 (c) no Collaboration IP shall be jointly owned by the Parties. 

7.1.4 Invention Disclosure. Each Party shall promptly disclose to the other Party in writing, and shall cause any of its Affiliates
and use Commercially Reasonable Efforts to cause any other Person performing activities for such Party or Affiliate under this Agreement to disclose in writing, any invention conceived, reduced to practice, discovered, developed, or made by or on
behalf of such Party or Affiliate pursuant to a Research Plan (each a “Collaboration Invention”). Caribou hereby covenants and agrees that, without AbbVie’s prior written consent, following the Effective Date Caribou shall not,
and shall ensure that its Affiliates do not, claim, exemplify or provide sufficient written description for any Collaboration CAR-T Products, Licensed Products, or the Exploitation thereof in any of its patent
filings or include or rely on in any of such patent filings any Information generated under this Agreement or permit or authorize any Third Party to do any of the foregoing. [***]

7.1.5 United States Law. The determination of inventorship and whether Collaboration Inventions are conceived, reduced to practice,
discovered, developed, or made by or on behalf of a Party, shall, for purposes of this Agreement, be made in accordance with United States patent law and other Applicable Law in the United States irrespective of where such conception, reduction to
practice, discovery, development or making occurs. 
 7.1.6 Assignment Obligations. Each Party shall cause all Persons who perform
any activities for such Party under this Agreement to assign (or, if such Party is unable to cause such Person to assign despite such Party’s exercise of Commercially Reasonable Efforts, then to contractually obligate such Person to assign; or
if such Party is unable to contractually obligate such Person to assign despite such Party’s exercise of Commercially Reasonable Efforts, then provide a license under) their rights in any Collaboration Inventions resulting therefrom to such
Party. 

  
 - 39 - 

 CONFIDENTIAL 
  

 7.1.7 Ownership of Corporate Names. As between the Parties, Caribou shall retain all
right, title, and interest in and to its Corporate Names. 
 7.2 Maintenance and Prosecution of Patents. 

7.2.1 Patent Prosecution and Maintenance of Caribou Collaboration Patents and [***]. Caribou shall have the right, but not the
obligation, through the use of internal or outside counsel reasonably acceptable to AbbVie, to prepare, file, prosecute, defend in any oppositions or post-grant proceedings, and maintain the Caribou Collaboration Patents and [***] worldwide, at
Caribou’s sole cost and expense. Caribou shall keep AbbVie fully informed of all material steps with regard to the preparation, filing, prosecution, defense, and maintenance of Caribou Collaboration Patents and, solely during the [***]
including by providing AbbVie with a copy of material communications to and from any patent authority in the Territory regarding such Caribou Collaboration Patents and, as applicable, such [***], and by providing AbbVie drafts of any material
filings or responses to be made to such patent authorities in the Territory sufficiently in advance of submitting such filings or responses so as to allow for a reasonable opportunity for AbbVie to review and comment thereon. Caribou shall consider
in good faith the requests and suggestions of AbbVie with respect to such Caribou drafts and with respect to strategies for filing and prosecuting the Caribou Collaboration Patents and, solely during the [***], in the Territory[***]. Notwithstanding
the foregoing, Caribou shall promptly notify AbbVie of any request for, or filing or declaration of, any interference, opposition, or reexamination relating to a Caribou Collaboration Patent or, solely during the [***], in the Territory. The Parties
shall thereafter consult and cooperate to determine a course of action with respect to any such proceeding in the Territory and Caribou shall consider in good faith all comments, requests and suggestions provided by AbbVie[***]. Caribou shall not
initiate any such adversarial patent office proceeding relating to a Caribou Collaboration Patent or, solely during the [***], in the Territory without first consulting AbbVie. In the event that Caribou decides not to prepare, file, prosecute,
defend, or maintain a Caribou Collaboration Patent or, solely during the [***], in a country or other jurisdiction in the Territory, Caribou shall provide reasonable prior written notice to AbbVie of such intention, and AbbVie shall thereupon have
the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution, defense, and maintenance of such Caribou Collaboration Patent and, as applicable, such [***] at its expense in such country or other
jurisdiction. Caribou shall reasonably cooperate with AbbVie in such country or other jurisdiction as provided under Section 7.2.3. 

7.2.2 Patent Prosecution and Maintenance of AbbVie Collaboration Patents. AbbVie shall have the right, but not
the obligation, to prepare, file, prosecute, defend in any oppositions or post-grant proceedings, and maintain the AbbVie Collaboration Patents worldwide, at AbbVie’s sole cost and expense. AbbVie shall keep Caribou fully informed of all
material steps with regard to the preparation, filing, prosecution, defense, and maintenance of AbbVie Collaboration Patents, including by providing Caribou with a copy of material communications to and from any patent authority in the Territory
regarding such AbbVie Collaboration Patents, and by providing Caribou drafts of any material filings or responses to be made to such patent authorities in the Territory sufficiently in advance of submitting such filings or responses so as to allow
for a reasonable opportunity for Caribou to review and comment thereon. AbbVie shall consider in good faith the requests and suggestions of Caribou with respect to such AbbVie drafts and with respect to strategies for filing and prosecuting the
AbbVie Collaboration Patents in the Territory. 
 7.2.3 Cooperation. The Parties agree to cooperate fully in the preparation,
filing, prosecution, defense in oppositions or post-grant proceedings, and maintenance of the Caribou Collaboration Patents, the AbbVie Collaboration Patents and, solely during the [***], in the Territory under this Agreement. Cooperation shall
include: 
 (a) without limiting any other rights and obligations of the Parties under this Agreement, cooperating with respect to the
timing, scope and filing of such Patents to preserve and enhance the patent protection for Collaboration CAR-T Products and Licensed Products, including the manufacture and use thereof; 

(b) executing all papers and instruments, or requiring its employees or contractors to execute such papers and instruments, so as to
(i) effectuate the ownership of Intellectual Property set forth in Section 7.1.3, (ii) enable the other Party to apply for and to prosecute Patent applications in the Territory, and (iii) obtain and maintain
any patent term extensions, supplementary protection certificates, and the like with respect to such Patents in the Territory; in each case ((i), (ii), and (iii)), to the extent provided for in this Agreement; 

  
 - 40 - 

 CONFIDENTIAL 
  

 (c) consistent with this Agreement, assisting in any license, transfer or assignment
registration processes with applicable governmental authorities that may be available in the Territory for the protection of a Party’s interests in this Agreement; and 

(d) promptly informing the other Party of any matters coming to such Party’s attention that may materially affect the preparation,
filing, prosecution, defense, or maintenance of any such Patents in the Territory. 
 7.2.4 Patent Term Extension and Supplementary
Protection Certificate. Notwithstanding anything to the contrary in this Section 7.2, with respect to each Collaboration CAR-T Product or Licensed Product, [***] shall have the
sole right at its sole expense to make decisions regarding, and [***] shall have the sole right at its sole expense to apply for, any extension (including patent term extensions, supplementary protection certificate, and pediatric exclusivity) with
respect to any Collaboration Patents or any Patent Controlled by [***]. [***] shall keep [***] reasonably informed of its efforts to obtain such extension. [***] shall provide timely and reasonable assistance, as requested by [***], including by
taking such action as patent holder as is required under any Applicable Law to obtain any such extension in the Territory. [***] shall have no right to apply for any extension (including patent term extensions, supplementary protection certificate,
and pediatric exclusivity) for any Patents in connection with any Collaboration CAR-T Product or Licensed Product. [***] 

7.2.5 Patent Listings. As between the Parties, solely with respect to each Collaboration CAR-T
Product or Licensed Product, [***] shall have the sole right to determine and make all filings with Regulatory Authorities or other governmental authorities in the Territory with respect to any Patents, including as required or allowed Applicable
Law, provided that [***] shall obtain [***]’s written consent which shall not be unreasonably withheld, conditioned or delayed, prior to including any [***] [***]in such filings. [***] shall (i) provide to [***] all Information,
including a correct and complete list of [***] covering the Collaboration CAR-T Product or Licensed Product or otherwise necessary or reasonably useful to enable [***]to make such filings with Regulatory
Authorities or other governmental authorities in the Territory with respect to such Patents, and (ii) cooperate with [***]’s reasonable requests in connection therewith, including provision or submission of relevant documents as a patent
owner; in each case ((i) and (ii)), to the extent required or permitted by Applicable Law. [***] shall keep [***] reasonably informed of such listings. [***] 

7.3 Enforcement of IP. 

7.3.1 Enforcement of Caribou IP. Each Party shall promptly notify the other Party in writing of any alleged or threatened infringement
or misappropriation of the Caribou IP by a Third Party in the Territory, of which such Party becomes aware, based on the Exploitation of or an application to register or market, a product containing a Collaboration
CAR-T Product or any Licensed Product in the Territory (the “Product Infringement”). [***] shall have the first right, but not the obligation, to prosecute any Product Infringement in the
Territory [***] at its sole expense and [***] shall retain control of the prosecution of such claim, suit or proceeding[***] In the event [***] prosecutes any [***] [***] shall have the right to join as a party to such claim, suit, or proceeding in
the Territory and participate with its own counsel at its own expense; provided that [***] shall retain control of the prosecution of such claim, suit, or proceeding. [***] shall keep [***] reasonably informed of any material development in
such claim, suit, or proceeding. If [***] decides not to prosecute an [***] [***], then [***] shall timely inform [***] and [***] may prosecute [***] at its own expense. 

7.3.2 Enforcement of AbbVie Collaboration IP. Each Party shall promptly notify the other Party in writing of any alleged or threatened
infringement or misappropriation of the AbbVie Collaboration IP by a Third Party in the Territory, of which such Party becomes aware, based on the Exploitation of, or an application to register or market, a product containing a Collaboration CAR-T Product or any Licensed Product in the Territory. [***] 

  
 - 41 - 

 CONFIDENTIAL 
  

 7.3.3 Biosimilar Applicants. 

(a) Notwithstanding anything to the contrary in this Agreement, [***] shall have the sole right, but not the obligation, to prosecute, manage
and settle any litigation with respect to Biosimilar Products and any proceedings associated therewith, including any invalidity, unpatentability or unenforceability challenges, oppositions, and post-grant proceedings in connection therewith. If
[***] receives notice or a copy of an application submitted to the FDA or its foreign counterpart for a Biosimilar Product (a “Biosimilar Application”) for which a Licensed Product is a “reference product,” as such term is
used in Section 351(i)(4) of the PHSA or the same or like term used in the foreign counterpart, whether or not such notice or copy is provided under any Applicable Law, or otherwise becomes aware that such a Biosimilar Application has been
submitted to a Regulatory Authority for a Drug Approval Application, [***] shall, within [***] Business Days, notify and provide [***] copies of such notice or communication to the extent permitted by Applicable Law. [***] shall carry out any such
rights and responsibilities of the “reference product sponsor,” as defined in Section 351(l)(1)(A) of the PHSA, for purposes of such Biosimilar Application, including bringing an action for patent infringement under
Section 351(1)(6) of the PHSA based on any Patents. If requested by [***], [***] shall seek to obtain access to the Biosimilar Application and related confidential information, including in accordance with Section 351(l)(1)(B)(iii) of the
PHSA, if applicable. 
 (b) If permitted pursuant to Applicable Law, upon [***]’s request, [***] shall assist [***] in identifying and
listing any Patents pursuant to Section 351(l)(1)(3)(A) or Section 351(l)(7) of the PHSA, in preparing, pursuant to section 351(l)(3)(C) of the PHSA, a detailed statement regarding the reference product sponsor’s opinion that the
Patent will be infringed and a response to the statement by the filer of the Biosimilar Application concerning validity and enforceability, in negotiating with the filer of the Biosimilar Application pursuant to Section 351(l)(4) of the PHSA,
and in selecting Patents for and conducting litigation pursuant to Section 351(l)(5), Section 351(l)(6), and Section 351(l)(9) of the PHSA, to the extent applicable, and shall cooperate with [***] in responding to relevant
communications with respect to such lists and statements from the filer of the Biosimilar Application. Upon [***]’s request, [***] shall assist in seeking an injunction against any commercial marketing by the filer of a Biosimilar Application
as permitted pursuant to Section 351(l)(8)(B) of the PHSA or in filing an action for infringement against the filer of such Biosimilar Application. 

7.3.4 Cooperation. The Parties agree to cooperate fully in any infringement action pursuant to this
Section 7.3. Where a Party brings such an action, the other Party shall, where necessary, join in or be named as a necessary party to such action, or furnish a power of attorney solely for such purpose. Unless otherwise set
forth herein, the Party that manages any patent infringement litigation in accordance with this Section 7.3 shall have the right to settle such claim; provided that neither Party shall have the right to settle any
patent infringement litigation under this Section 7.3 in a manner that imposes any out-of-pocket costs or liability on, or involves any
admission by, the other Party, without the express written consent of such other Party. The Party commencing the litigation shall keep the other Party reasonably informed of all material developments during the course of the proceedings if doing so
would not waive any privilege or violate any court order or Applicable Law. 
 7.3.5 Recovery. Except as otherwise agreed by the
Parties in connection with a cost sharing arrangement, any recovery realized as a result of such litigation described in Section 7.3 (whether by way of settlement or otherwise) shall be first, allocated to reimburse the
Parties for their costs and expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover the totality of such expenses). Any remainder after such reimbursement is made shall be retained by the Party that has
exercised its right to bring the enforcement action[***].
 7.3.6 Costs and Expenses. Subject at all times to
Section 6.5.4(f), [***] shall be entitled to offset [***] of the reasonable out-of-pocket costs of such litigation described in
Section 7.3 that are borne by [***]. 
 7.4 Infringement Claims by Third Parties. 

7.4.1 Control. If the Exploitation of a Collaboration CAR-T Product or Licensed Product
in the Territory pursuant to this Agreement results in, or may result in, any claim, suit, or proceeding by a Third Party alleging patent infringement by one Party (or its Affiliates), such Party shall promptly notify the other Party thereof in
writing (a “Third Party Infringement Claim”). The alleged infringing Party (or its Affiliates) shall have the first right, but not the obligation, to defend and control the defense of any such Third Party Infringement Claim at its
own expense 

  
 - 42 - 

 CONFIDENTIAL 
  

 
(but subject to deduction as provided below), using counsel of its own choice. Without limitation of the foregoing, if the alleged infringing Party finds it necessary or desirable to join the
other Party as a party to any such action, the other Party shall execute all papers and perform such acts as shall be reasonably required. Each Party shall keep the other Party reasonably informed of all material developments in connection with any
such Third Party Infringement Claim. 
 7.4.2 Costs. 

(a) [***] shall be entitled to offset [***] of all Litigation Costs resulting or arising from a Third Party Infringement Claim arising from
use of the Caribou Platform Technology that are borne by [***]. 
 (b) Subject at all times to
Section 6.5.4(f), [***] shall be entitled to offset [***] of all Litigation Costs resulting or arising from all other Third Party Infringement Claims that are borne by [***] 

7.5 Invalidity or Unenforceability Defenses or Actions. 

7.5.1 Notice. Each Party shall promptly notify the other Party in writing of any alleged or threatened assertion of invalidity,
unpatentability, or unenforceability of any of the Caribou Patents or AbbVie Patents, by a Third Party, in each case in the Territory and of which such Party becomes aware. 

7.5.1 Caribou Background Patents. Caribou shall have the sole right, but not the obligation, to defend and control the defense of the
validity, patentability, and enforceability of the Caribou Background Patents at its own expense in the Territory. 
 7.5.2 Caribou
Collaboration Patents and [***]. Caribou shall have the first right, but not the obligation, to defend and control the defense of the validity, patentability, and enforceability of the Caribou Collaboration Patents and the [***] at its own
expense in the Territory. AbbVie may participate in any such claim, suit, or proceeding in the Territory with counsel of its choice at its own expense; provided that AbbVie shall have this right in respect of the [***] solely during the
[***]; and further provided that, in all cases, Caribou shall retain control of the defense in such claim, suit, or proceeding. If Caribou elects not to defend or control the defense of such Caribou Collaboration Patents or, during the
[***], in a suit brought in the Territory, or otherwise fails to initiate and maintain the defense of any such claim, suit, or proceeding, then AbbVie may conduct and control the defense of any such claim, suit, or proceeding at its own expense.

 7.5.3 AbbVie Collaboration Patents. AbbVie shall have the sole right, but not the obligation, to defend and control the defense
of the validity, patentability, and enforceability of the AbbVie Collaboration Patents at its own expense in the Territory. 
 7.5.4
Cooperation. Each Party shall assist and cooperate with the other Party as such other Party may reasonably request from time to time in connection with its activities set forth in this Section 7.5, including by being
joined as a necessary party in such claim, suit or proceeding, providing access to relevant documents and other evidence, and making its employees available at reasonable business hours. In connection with any such defense or claim or counterclaim,
the controlling Party shall consider in good faith any comments from the other Party and shall keep the other Party reasonably informed of any material steps taken if doing so would not waive any privilege or violate any court order or Applicable
Law. Subject to the other terms and conditions of this Agreement, the controlling Party shall have the right to settle such claim, suit or proceeding under this Section 7.5, provided that the controlling Party shall
not settle any such claim, suit or proceeding in a manner that imposes any out-of-pocket costs or liability on, or involves any admission by, the other Party, without
the express written consent of such other Party. 
 7.5.5 Costs and Expenses. Subject at all times to Section 6.5.4(f), [***]
shall be entitled to offset [***] of the reasonable out-of-pocket costs of defending such claim, suit, or proceeding under this Section 7.5 that are borne by [***]. 

  
 - 43 - 

 CONFIDENTIAL 
  

 7.6 Third Party Patents. 

7.6.1 Without limiting the provisions of Section 5.6, if a Third Party’s Patent primarily relates to the
Development, Manufacture, Commercialization or other Exploitation of a Collaboration CAR-T Product or corresponding Licensed Product [***] by [***], [***] shall have the sole right, but not the obligation, to
challenge the patentability, validity or enforceability of such Patent in any court of competent jurisdiction or before any supra-national, federal, national, regional, state, provincial and local governmental body of competent jurisdiction,
including the United States Patent and Trademark Office and the European Patent Office. [***]. [***] shall assist and cooperate with [***] as [***] may reasonably request from time to time in connection with the activities set forth in this
Section 7.6. 
 7.6.2 Notwithstanding anything to the contrary in this Agreement, during the Term either Party
(including its Affiliates) shall have the right, but not the obligation to challenge the patentability, validity or enforceability of any Blocking Platform IP in any court or before any federal, national, regional, state, provincial, local or
supra-national governmental body, including before the United States Patent and Trademark Office, throughout the Territory, [***] [***] Neither Party (nor its Affiliates) will support or control in any way a challenge initiated by the other Party
(or its Affiliates) against the patentability, validity or enforceability of any Blocking Platform IP. 
 7.7 Product Trademarks.

 7.7.1 Ownership and Prosecution of Product Trademarks. [***] shall own all right, title, and interest to the Product
Trademarks in the Territory, and shall be responsible for the registration, prosecution, and maintenance thereof. All costs and expenses of registering, prosecuting, and maintaining the Product Trademarks shall be borne solely by [***]. 

7.7.2 Enforcement of Product Trademarks. [***] shall have the sole right and responsibility for taking such action as [***], after
consultation with [***], deems necessary against a Third Party based on any alleged, threatened, or actual infringement, dilution, misappropriation, or other violation of, or unfair trade practices or any other like offense relating to, the Product
Trademarks by a Third Party in the Territory. [***] shall bear the costs and expenses relating to any enforcement action commenced pursuant to this Section 7.7.2 and any settlements and judgments with respect thereto, and
shall retain any damages or other amounts collected in connection therewith. 
 7.7.3 Third Party Claims. [***] shall have the sole
right and responsibility for defending against any alleged, threatened, or actual claim by a Third Party that the use or registration of the Product Trademarks in the Territory infringes, dilutes, misappropriates, or otherwise violates any Trademark
or other right of that Third Party or constitutes unfair trade practices or any other like offense, or any other claims as may be brought by a Third Party against a Party in connection with the use of the Product Trademarks with respect to a
Licensed Product in the Territory. [***] shall bear the costs and expenses relating to any defense commenced pursuant to this Section 7.7.3 and any settlements and judgments with respect thereto, and shall retain any
damages or other amounts collected in connection therewith. 
 7.7.4 Notice and Cooperation. In the event [***] becomes aware of any
actual or threatened infringement of the Product Trademarks in the Territory and/or of any actual or threatened claim that the use of the Product Trademarks in the Territory violates the rights of any Third Party, [***] shall provide [***] with
written notice of same. Each Party agrees to cooperate fully with the other Party with respect to any enforcement action or defense commenced pursuant to this Section 7.7. 

7.8 Inventor’s Remuneration. Each Party shall be solely responsible for any remuneration that may be due to such
Party’s inventors under any applicable inventor remuneration laws. 
 7.9 International Nonproprietary Name. As between
the Parties, [***] shall have the sole right and responsibility to select the International Nonproprietary Name or other name or identifier for any Collaboration CAR-T Products or Licensed Products. [***]
shall have the sole right and responsibility to apply for submission to the World Health Organization for the International Nonproprietary Name, and submission to the United States Adopted Names Council for the United States Adopted Name. 

  
 - 44 - 

 CONFIDENTIAL 
  

 7.10 Common Interest. All information exchanged between the Parties regarding
the prosecution, maintenance, enforcement and defense of Patents under this ARTICLE 7 will be deemed to be Confidential Information of the disclosing Party. In addition, the Parties acknowledge and agree that, with regard to such prosecution,
maintenance, enforcement and defense, the interests of the Parties as collaborators, licensors and/or licensees are, for their mutual benefit, to obtain patent protection and plan patent defense against potential patentability/invalidity challenges
or infringement activities by Third Parties, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning Patents
under this ARTICLE 7, including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding anything to the contrary in this Agreement, to the extent a Party has a good faith belief that any information
required to be disclosed by such Party to the other Party under this ARTICLE 7 is protected by attorney-client privilege or any other applicable legal privilege or immunity, such Party shall not be required to disclose such information and
the Parties shall in good faith cooperate to agree upon a procedure (which may include entering into a specific common interest agreement, disclosing such information on a “for counsel eyes only” basis or similar procedure) under which
such information may be disclosed without waiving or breaching such privilege or immunity. 
 ARTICLE 8 

CONFIDENTIALITY AND NON-DISCLOSURE 

8.1 Product Information. Caribou recognizes that by reason of, inter alia, AbbVie’s status as an exclusive licensee
pursuant to the grants under Section 5.1, AbbVie has an interest in Caribou maintaining the confidentiality of certain information of Caribou. [***] 

8.2 Confidentiality Obligations. At all times during the Term and for a period of [***] years following termination or
expiration of this Agreement in its entirety, each Party shall, and shall cause its officers, directors, employees and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for any
purpose, any Confidential Information furnished or otherwise made known to it, directly or indirectly, by the other Party, except to the extent such disclosure or use is expressly permitted by the terms of this Agreement or is reasonably necessary
for the performance of, or the exercise of such Party’s rights under, this Agreement. Notwithstanding the foregoing, to the extent the receiving Party can be demonstrated by documentation or other competent proof, the confidentiality and non-use obligations under this Section 8.2 with respect to any Confidential Information shall not include any information that: 

8.2.1 has been published by a Third Party or otherwise is or hereafter becomes publicly available by public use, publication, general
knowledge or the like through no wrongful act, fault, or negligence on the part of the receiving Party; 
 8.2.2 has been in the receiving
Party’s possession prior to disclosure by the disclosing Party without any obligation of confidentiality with respect to such information; 

8.2.3 is subsequently received by the receiving Party from a Third Party without restriction and without breach of any agreement between such
Third Party and the disclosing Party; 
 8.2.4 is generally made available to Third Parties by the disclosing Party without restriction on
disclosure; or 
 8.2.5 has been independently developed by or for the receiving Party without reference to, or use or disclosure of, the
disclosing Party’s Confidential Information; 
 Specific aspects or details of Confidential Information shall not be deemed to be publicly available or
in the possession of the receiving Party merely because the Confidential Information is embraced by more general information publicly available or in the possession of the receiving Party. Further, any combination of Confidential Information shall
not be considered publicly available or in the possession of the receiving Party merely because individual elements of such Confidential Information are publicly available or in the possession of the receiving Party unless the combination and its
principles are publicly available or in the possession of the receiving Party. 

  
 - 45 - 

 CONFIDENTIAL 
  

 8.3 Permitted Disclosures. Each Party may disclose Confidential Information of
the other Party to the extent that such disclosure is: 
 8.3.1 in the reasonable opinion of the receiving Party’s legal counsel,
required to be disclosed pursuant to law, regulation or a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial and local governmental body of competent jurisdiction, (including by
reason of filing with securities regulators, but subject to Section 8.5); provided that the receiving Party shall first have given prompt written notice (and to the extent possible, at least [***] Business Days’
notice) to the disclosing Party and given the disclosing Party a reasonable opportunity to take whatever action it deems necessary to protect its Confidential Information (such as, for example, to quash such order or to obtain a protective order or
confidential treatment requiring that the Confidential Information and documents that are the subject of such order be held in confidence by such court or governmental body or, if disclosed, be used only for the purposes for which the order was
issued). In the event that no protective order or other remedy is obtained, or the disclosing Party waives compliance with the terms of this Agreement, the receiving Party shall furnish only that portion of Confidential Information which the
receiving Party is advised by counsel is legally required to be disclosed; 
 8.3.2 made by or on behalf of the receiving Party to the
Regulatory Authorities as required in connection with any filing, application or request for any Regulatory Approval in accordance with the terms of this Agreement; provided that reasonable measures shall be taken to assure confidential
treatment of such Confidential Information to the extent practicable and consistent with Applicable Law; 
 8.3.3 made by or on behalf of
the receiving Party to a patent authority as may be reasonably necessary or useful for purposes of preparing, obtaining, defending or enforcing a Patent in accordance with the terms of this Agreement; provided that reasonable measures shall
be taken to assure confidential treatment of such Confidential Information, to the extent such protection is available; 
 8.3.4 made to
its or its Affiliates’ financial and legal advisors who have a need to know such disclosing Party’s Confidential Information and are either under professional codes of conduct giving rise to expectations of confidentiality and non-use or under written agreements of confidentiality and non-use, in each case, at least as restrictive as those set forth in this Agreement; provided that the
receiving Party shall remain responsible for any failure by such financial and legal advisors, to treat such Confidential Information as required under this ARTICLE 8; 

8.3.5 made by AbbVie or its Affiliates or Sublicensees to its or their advisors, consultants, clinicians, vendors, service providers,
contractors, existing or prospective collaboration partners, licensees, sublicensees, or other Third Parties as may be necessary or useful in connection with the Exploitation of a Collaboration CAR-T Product
or Licensed Product, [***] employed in a Collaboration CAR-T Product or Licensed Product, or to a molecule, cell, composition, sequence, or vector comprising or encoding such [***], or such specific [***] or
otherwise in connection with the performance of its obligations or exercise of its rights as contemplated by this Agreement; provided that such Persons shall be subject to obligations of confidentiality and
non-use with respect to such Confidential Information substantially similar to the obligations of confidentiality and non-use of the receiving Party pursuant to this
ARTICLE 8, with a duration of confidentiality and non-use obligations as appropriate that is no less than [***] years from the effective date of such obligations or, if the disclosure includes [***],
with a duration of confidentiality and non-use obligations that is no less than [***] years from the effective date of such obligations); or 

8.3.6 made by Caribou or its Affiliates, to its or their advisors, consultants, clinicians, vendors, service providers, contractors, or
existing or prospective investors and acquirers, as may be necessary in assisting with Caribou’s activities contemplated by this Agreement and/or in evaluating such potential or actual investment or acquisition, as applicable; provided
that:  
 (a) all such Persons to which disclosures are made pursuant to this
Section 8.3.6 shall be subject to obligations of confidentiality and non-use with respect to such Confidential Information of AbbVie substantially similar to the obligations of
confidentiality and non-use of Caribou set forth in this ARTICLE 8, with a duration of confidentiality and non-use obligations as appropriate that is no less than
[***] years from the effective date of such obligations for Life Sciences Entities and [***] years from the effective date of such obligations for any other Person; 

  
 - 46 - 

 CONFIDENTIAL 
  

 (b) to the extent such disclosures are made to existing or prospective investors and
acquirors, such disclosures shall require AbbVie’s prior written consent, not to be unreasonably withheld, conditioned, or delayed; provided that Caribou may make a disclosure to existing or prospective investors and acquirors that are not Life
Sciences Entities without AbbVie’s prior written consent if (i)(1) the disclosure is limited solely to disclosure of this Agreement (excluding all Research Plans and with the then-current Initial Program Targets, Reserved Targets, and Accepted
Targets redacted) and (2) the receiving party has agreed in writing to be bound to the confidentiality requirements set out in clause (a) above, or (ii) (1) the disclosure is limited solely to disclosure of this Agreement (excluding
all Research Plans) and a list consisting solely of the UniProt# or gene name of the then-current Initial Program Targets, Reserved Targets, or Accepted Targets, and (2) the receiving party has agreed in writing to be bound to the
confidentiality requirements with a duration of confidentiality and non-use obligations no less than [***] years from the effective date of such obligations; and 

(c) any disclosure made to existing or prospective investors and acquirors must comply with the following requirements: (a) such
investor or acquirer, as applicable, shall be obligated to (1) use the Confidential Information of AbbVie solely for the purposes of evaluating the applicable transaction and shall be prohibited for using any Confidential Information of AbbVie
for any other purposes, (2) limit disclosure to persons within such investor or acquirer with a need to know such Confidential Information of AbbVie in order for such acquirer or investor to evaluate the applicable transaction, and (3) use
reasonable and customary measures to protect the secrecy of, and avoid any unauthorized use or disclosure of, any Confidential Information of AbbVie; and (b) Caribou shall contractually require each such investor or acquirer with whom Caribou
does not enter into a definitive agreement regarding a transaction to return or destroy all Confidential Information of AbbVie upon the termination of negotiations with respect to the applicable transaction, provided that such investor or
acquirer may (i) keep one (1) copy of the Confidential Information for the sole purpose of compliance or archival purposes, and (ii) retain such additional copies of or any computer records or files containing such Confidential
Information that have been created solely by such investor’s or acquirer’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such
investor’s or acquirer’s standard archiving and back-up procedures, but not for any other use or purpose. 

8.4 Use of Name. Except as expressly provided herein, neither Party shall mention or otherwise use the name, logo, or
Trademark of the other Party or any of its Affiliates (or any abbreviation or adaptation thereof) in any publication, press release, marketing and promotional material, or other form of publicity without the prior written approval of such other
Party in each instance. The restrictions imposed by this Section 8.4 shall not prohibit either Party from: (a) making any disclosure identifying the other Party that, in the opinion of the disclosing Party’s
counsel, is required by Applicable Law; provided that such Party shall submit the proposed disclosure identifying the other Party in writing to the other Party as far in advance as reasonably practicable (and in no event less than [***]
Business Days prior to the anticipated date of disclosure) so as to provide a reasonable opportunity to comment thereon; and (b) using a brief description of the subject of this Agreement (including, the other Party’s name and logo, title
and date of the Agreement, and general scope of the Licenses, but no other terms or conditions thereof) on its website and in corporate presentations; provided that a Party proposing such description shall provide a written copy of the
proposed language to the other Party for review prior to making such use, and, once approved, that description may be used (without substantive changes) thereafter without the need to seek pre-approval.  
 8.5 Public Announcements. The Parties have agreed upon the content
of a joint press release which shall be issued substantially in the form attached hereto as Schedule 8.5, the release of which the Parties shall coordinate in order to accomplish such release promptly (and in no event longer than [***]
Business Days, or as otherwise mutually agreed by the Parties) after execution of this Agreement. Except for such press release or to the extent required by Applicable Law, neither Party shall issue any other public announcement, press release, or
other public disclosure or make or direct their representatives to make, directly or indirectly, any public comment, statement or communication with respect to, or otherwise disclose or permit the disclosure of the terms, conditions or other aspects
of this Agreement or its subject matter without the other Party’s prior written consent. If any such disclosure is, in the opinion of the disclosing Party’s counsel, required by Applicable Law or the rules of a stock exchange on which the
securities of the disclosing Party are listed, such Party shall submit the proposed disclosure in writing to the other Party as far in advance as reasonably practicable (and in no event less than [***] Business Days prior to the anticipated date of
disclosure) along with the 

  
 - 47 - 

 CONFIDENTIAL 
  

 
reasons such disclosure is required by Applicable Law, and the time and place the disclosure will be made so as to provide a reasonable opportunity to comment thereon. The Party proposing to make
the disclosure will consider in good faith any comments of the other Party related to such disclosure. 
 8.6
Publications. The Parties acknowledge that scientific publications must be monitored to prevent any adverse effect from premature publication of results of the activities contemplated hereunder and hereby agree that: 

8.6.1 Caribou may publish, present, or otherwise disclose (each a “Disclosure”) Caribou
Know-How specifically related to the Caribou Platform Technology; provided that Caribou shall not Disclose, and shall cause its Affiliates and shall cause its Third Party Providers and its and their
employees and agents not to Disclose any AbbVie Confidential Information or any other Know-How related to the Exploitation of Collaboration CAR-T Products or Licensed
Products. 
 8.6.2 AbbVie, its Sublicensees and its and their respective Affiliates shall have the sole right to Disclose information
(including with respect to regulatory matters) regarding the Exploitation of any Collaboration CAR-T Products and Licensed Products; provided that (a) such Disclosure is subject to the
provisions of ARTICLE 8 with respect to Caribou’s Confidential Information, (b) AbbVie may not use the name of Caribou (or insignia, or any contraction, abbreviation or adaptation thereof) without Caribou’s prior written
permission and (c) AbbVie has provided Caribou with the opportunity for prior review pursuant to Section 8.6.3 solely with respect to any Disclosure related to a Collaboration
CAR-T Product or Licensed Product prior to the Initiation of a first Registrational Trial for such Collaboration CAR-T Product or Licensed Product. Following Initiation
of a first Registrational Trial for such Collaboration CAR-T Product or Licensed Product, AbbVie shall provide Caribou a courtesy copy of any scientific or technical proposed Disclosure at least a [***]
Business Days prior to such Disclosure. [***] 
 8.6.3 Except as set forth in Section 8.6.2, each Party shall
have the right to prior review of any proposed Disclosure relating to the Collaboration CAR-T Products or Licensed Products or that includes Confidential Information of the other Party. Before any such
proposed Disclosure is made, the proposing Party shall deliver a then-current copy of such Disclosure to the other Party at least [***] days prior to submitting the paper to a publisher or making the proposed Disclosure. The other Party shall review
any such proposed Disclosure and give its comments to the publishing Party within [***] days of the delivery of such proposed Disclosure to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make
reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the proposing Party with appropriate comments, if any, but in no event later than [***] days from the date of delivery to
the other Party. Notwithstanding the foregoing, the proposing Party shall comply with any request by the other Party to delete references to such other Party’s Confidential Information in any such proposed Disclosure and will withhold
publication of any such proposed Disclosure for an additional [***] days in order to permit the Parties to obtain Patent protection if either Party deems it necessary. Any Disclosure shall include recognition of the contributions of the other Party
according to standard practice for assigning scientific credit, either through authorship or acknowledgement, as may be appropriate. 

8.7 Return of Confidential Information. Upon the effective date of expiration or termination of this Agreement for any
reason, either Party may request in writing, and the other Party shall either, with respect to Confidential Information (in the event of termination of this Agreement with respect to one (1) or more Terminated Territories but not in its
entirety, solely to the extent relating to such Terminated Territories) to which such other Party does not retain relevant rights under the surviving provisions of this Agreement: (a) as soon as reasonably practicable, destroy all copies of
such Confidential Information in the possession of the other Party and confirm such destruction in writing to the requesting Party, or (b) as soon as reasonably practicable, deliver to the requesting Party, at the other Party’s expense,
all copies of such Confidential Information in the possession of the other Party; provided that the other Party shall be permitted to retain one (1) copy of such Confidential Information for the sole purpose of performing any continuing
obligations hereunder, as required by Applicable Law, or for archival purposes. Notwithstanding the foregoing, such other Party also shall be permitted to retain such additional copies of or any computer records or files containing such Confidential
Information that have been created solely by such Party’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such other Party’s standard
archiving and back-up procedures, but not for any other use or purpose. 

  
 - 48 - 

 CONFIDENTIAL 
  

 8.8 Survival. (a) Except as set forth in the following sentence, this
ARTICLE 8 shall survive termination or expiration of this Agreement, and (b) all Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in Section 8.2.
Sections 8.4(b) and 8.6.3 shall not survive termination or expiration of this Agreement; provided, however, that after the effective date of termination neither Party shall have the right to publish the Confidential
Information of the other Party without the other Party’s prior written consent. 
 ARTICLE 9 

REPRESENTATIONS AND WARRANTIES 

9.1 Mutual Representations and Warranties. Caribou and AbbVie each represents and warrants to the other, as of the Effective
Date, and covenants, as follows: 
 9.1.1 Organization. It is a corporation duly organized, validly existing, and in good standing
under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement. 

9.1.2 Authorization. The execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby
have been duly authorized by all necessary corporate action, and do not violate (a) such Party’s charter documents, bylaws, or other organizational documents, (b) in any material respect, any agreement, instrument, or contractual
obligation to which such Party is bound, (c) any requirement of any Applicable Law, or (d) any order, writ, judgment, injunction, decree, determination, or award of any court or governmental agency presently in effect applicable to such
Party. 
 9.1.3 Binding Agreement. This Agreement is a legal, valid, and binding obligation of such Party enforceable against it in
accordance with its terms and conditions, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance,
and general principles of equity (whether enforceability is considered a proceeding at law or equity). 
 9.1.4 No Inconsistent
Obligation. It is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement, or that would impede the diligent and complete fulfillment of
its obligations hereunder. 
 9.1.5 Provided Materials. It has all rights, permissions and consents in and to the Provided Materials
it provides under this Agreement necessary to enable the receiving Party to receive, access and use such Provided Materials as contemplated and authorized by this Agreement, including, to Develop and/or Manufacture Collaboration CAR-T Products and Licensed Products, and, if applicable, to provide any Personal Data Processed by it in connection with its obligations and activities under this Agreement. 

9.2 Additional Representations and Warranties of Caribou. [***] 

[***] 
 9.3 Additional
Representations and Warranties of AbbVie. [***] 
 [***] 

9.4 DISCLAIMER OF WARRANTIES. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR
GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY,
MERCHANTABILITY, OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

  
 - 49 - 

 CONFIDENTIAL 
  

 ARTICLE 10 

INDEMNITY 
 10.1
Indemnification of Caribou. AbbVie shall indemnify Caribou, its Affiliates and its and their respective directors, officers, employees, and agents (the “Caribou Indemnitees”) and defend and save each of them harmless, from
and against any and all losses, damages, liabilities, penalties, costs, and expenses (including reasonable attorneys’ fees and expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims, or
demands of Third Parties (collectively, “Third Party Claims”) incurred by or rendered against the Caribou Indemnitees arising from or occurring as a result of: [***]. 

10.2 Indemnification of AbbVie. Caribou shall indemnify AbbVie, its Affiliates and its and their respective directors, officers,
employees, and agents (the “AbbVie Indemnitees”), and defend and save each of them harmless, from and against any and all Losses in connection with any and all Third Party Claims incurred by or rendered against the AbbVie
Indemnitees arising from or occurring as a result of: [***]. 
 10.3 Notice of Claim. All indemnification claims in respect of
a Party, its Affiliates, or their respective directors, officers, and employees shall be made solely by such Party to this Agreement (the “Indemnified Party”). The Indemnified Party shall give the indemnifying Party prompt
written notice (an “Indemnification Claim Notice”) of any Losses, Third Party Claim, or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under this ARTICLE 10,
but in no event shall the indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the Third Party Claim and the nature and amount of such Loss
(to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party
Claims. 
 [***] 

10.5 Control of Defense. 

10.5.1 In General. Subject to the provisions of Section 10.4, at its option, the indemnifying Party
may assume the defense of any Third Party Claim by giving written notice to the Indemnified Party within [***] days after the indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim
by the indemnifying Party shall not be construed as an acknowledgment that the indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the indemnifying Party of any
defenses it may assert against the Indemnified Party’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel
selected by the indemnifying Party which shall be reasonably acceptable to the Indemnified Party. In the event the indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall immediately deliver to the indemnifying
Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party Claim. Should the indemnifying Party assume the defense of a Third Party Claim, except as provided in
Section 10.5.2, the indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third
Party Claim unless specifically requested in writing by the indemnifying Party. In the event that it is ultimately determined that the indemnifying Party is not obligated to indemnify, defend, or hold harmless the Indemnified Party from and against
the Third Party Claim, the Indemnified Party shall reimburse the indemnifying Party for any Losses incurred by the indemnifying Party in its defense of the Third Party Claim. 

10.5.2 Right to Participate in Defense. Without limiting Section 10.5.1, any Indemnified Party shall be
entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided that such employment shall be at the Indemnified Party’s own expense unless (a) the
employment thereof, and the assumption by the indemnifying Party of such expense, has been specifically authorized by the indemnifying Party in writing, (b) the indemnifying Party has failed to assume the defense and employ counsel in
accordance with Section 10.5.1 (in which case the Indemnified Party shall control the defense), or (c) the interests of the Indemnified Party and the indemnifying Party with respect to such Third Party Claim are
sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Law, ethical rules or equitable principles. 

  
 - 50 - 

 CONFIDENTIAL 
  

 10.5.3 Settlement. Subject to the provisions of
Section 10.4, with respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and that shall not result in the Indemnified Party’s becoming subject to injunctive or
other relief, and as to which the indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into
any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with Third Party Claims, where the indemnifying Party has
assumed the defense of the Third Party Claim in accordance with Section 10.5.1, the indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such
Loss; provided that it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). If the indemnifying Party does not assume and conduct the defense of a Third Party
Claim as provided above, the Indemnified Party may defend against such Third Party Claim. Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnified Party shall admit any liability with respect
to, or settle, compromise or dispose of any Third Party Claim without the prior written consent of the indemnifying Party, which consent shall not to be unreasonably withheld, conditioned or delayed. The indemnifying Party shall not be liable for
any settlement, compromise or other disposition of a Loss by an Indemnified Party that is reached without the written consent of the indemnifying Party, which consent shall not be unreasonably withheld, conditioned, or delayed. 

10.5.4 Cooperation. Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified
Party shall, and shall cause each indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials
and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the indemnifying Party to, and reasonable retention by the Indemnified Party of, records and
information that are reasonably relevant to such Third Party Claim, and making Indemnified Parties and other employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and
the indemnifying Party shall reimburse the Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith. 

10.5.5 Expenses. Except as provided above, the reasonable and verifiable costs and expenses, including fees and disbursements of
counsel, incurred by the Indemnified Party in connection with any Third Party Claim shall be reimbursed [***] by the indemnifying Party, without prejudice to the indemnifying Party’s right to contest the Indemnified Party’s right to
indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

[***] 
 10.7
Insurance. Each Party shall obtain and carry in full force and effect the minimum insurance requirements set forth herein from an insurance company properly licensed to provide the required insurance. Such insurance (a) shall be
primary insurance with respect to each Party’s own participation under this Agreement, (b) shall be issued by a recognized insurer rated by A.M. Best “A-IX” (or its equivalent) or better,
or an insurer pre-approved in writing by the other Party, and (c) shall list the other Party as an additional insured under the General Liability insurance. Each Party shall bear its own costs for
obtaining and maintaining insurance with respect to each Party’s own participation under this Agreement. 
 10.7.1 Types and
Minimum Limits. The types of insurance, and minimum limits shall include at least the following: 
 (a) Worker’s Compensation with
statutory limits in compliance with the Worker’s Compensation laws of the state or states in which the Party has employees in the United States (excluding Puerto Rico); 

(b) Employer’s Liability coverage with a minimum limit of [***] per occurrence; provided that a Party has employees in the United
States (excluding Puerto Rico); and 
 (c) General Liability Insurance with a minimum limit of [***] per occurrence and [***] in the
aggregate. 

  
 - 51 - 

 CONFIDENTIAL 
  

 Each Party shall at all times maintain in force any insurance policy that is required by any
federal, state, national or other such Applicable Law that may govern or have jurisdiction over any provision of this Agreement and at all times remain fully compliant with any such Applicable Law. 

10.7.2 Certificates of Insurance. Upon request by a Party, the other Party shall provide Certificates of Insurance evidencing
compliance with the above requirements of this Section 10.7. The insurance policies shall be under an occurrence form, but if only a claims-made form is available to a Party, then such Party shall continue to maintain such
insurance after the expiration or termination of this Agreement for the longer of (a) a period of [***] years following termination or (b) expiration of this Agreement in its entirety. 

10.7.3 Self-Insurance. Notwithstanding the foregoing, [***] may self-insure, in whole or in part, the insurance requirements described
above. 
 ARTICLE 11 

TERM AND TERMINATION 

11.1 Term. 
 11.1.1
Term. This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance herewith, shall continue in force and effect until the date of expiration of the last Royalty Term of the last country in which a Licensed
Product is Exploited (such period, the “Term”). 
 11.1.2 Effect of Expiration of the Term. [***] 

11.2 Termination for Material Breach. 

11.2.1 Material Breach. If either Party (the “Non-Breaching Party”) believes
that the other Party (the “Breaching Party”) has materially breached one (1) or more of its material obligations under this Agreement, then the Non-Breaching Party may deliver written
notice of such material breach to the Breaching Party (a “Default Notice”). If the Breaching Party does not dispute that it has committed a material breach of one (1) or more of its material obligations under this Agreement,
and the Breaching Party fails to cure such breach, or fails to take steps as would be considered reasonable to effectively cure such breach, within [***] after receipt of the Default Notice, or if such compliance cannot be fully achieved within such
[***] period and the Breaching Party has failed to commence compliance or has failed to use diligent efforts to achieve full compliance as soon thereafter as is reasonably possible, the Non-Breaching Party may
terminate this Agreement. If the Breaching Party disputes that it has materially breached one (1) of its material obligations under this Agreement, the dispute shall be resolved pursuant to Section 12.8 and the Non-Breaching Party may not terminate for such alleged material breach pursuant to this Section 11.2.1 (a) during the pendency of such dispute resolution proceedings or (b) if, as a
result of the application of such dispute resolution proceedings, the Breaching Party is determined not to be in any of the material breach(es) alleged by the Non-Breaching Party. If, as a result of the
application of such dispute resolution procedures, the Breaching Party is determined to be in material breach of one (1) or more of its material obligations under this Agreement (an “Adverse Ruling”), then if the Breaching
Party fails to complete the actions specified by the Adverse Ruling to cure such material breach within [***] after such ruling, or if such compliance cannot be fully achieved within such [***] period and the Breaching Party has failed to commence
compliance or has failed to use diligent efforts to achieve full compliance as soon thereafter as is reasonably possible, then the Non-Breaching Party may terminate this Agreement upon written notice to the
Breaching Party. 
 11.2.2 Material Breach Related to Diligence. Notwithstanding Section 11.2.1, if at any time
Caribou has a reasonable basis to believe that AbbVie is in material breach of its material obligations under Section 4.5, then Caribou shall so notify AbbVie, specifying the basis for its belief, and the Parties shall meet within [***] after
such notice to discuss in good faith Caribou’s concerns and AbbVie’s plans with respect to the applicable Licensed Product, and prior to such meeting Caribou shall not deliver to AbbVie any Default Notice with respect to such alleged
material breach. Further, if the material breach and failure to cure contemplated by Section 11.2.1 with respect to AbbVie’s obligations under Section 4.5 is solely with respect to a Major Market, to the extent Caribou has the
right to terminate following the meeting between the Parties to discuss, Caribou shall not have the right to terminate this Agreement in its entirety, but shall have the right to terminate this Agreement solely with respect to such Major Market.

  
 - 52 - 

 CONFIDENTIAL 
  

 11.2.3 Material Breach Related to a Licensed Product. Notwithstanding
Section 11.2.1, if the material breach and failure to cure contemplated by Section 11.2.1 is with respect to AbbVie’s obligations under this Agreement with respect to any particular Licensed
Product, Caribou shall not have the right to terminate this Agreement in its entirety, but shall have the right to terminate this Agreement solely with respect to such Licensed Product. 

11.2.4 Invocation of Termination for Material Breach. Notwithstanding the foregoing, the Parties agree that termination pursuant to
this Section 11.2 is a remedy to be invoked only if the breach cannot be adequately remedied through a combination of specific performance and the payment of money damages. 

11.3 Additional Termination Rights by AbbVie. 

11.3.1 For Safety. AbbVie may terminate this Agreement, in its entirety or on a Licensed Product-by-Licensed Product basis, effective immediately upon written notice to Caribou if AbbVie in good faith believes that it is not advisable for AbbVie to continue to Exploit the Collaboration CAR-T Product(s) or Licensed Product(s) as a result of a perceived serious safety issue regarding the use of any Collaboration CAR-T Product or Licensed Product. 

11.3.2 For Convenience. AbbVie may terminate this Agreement in its entirety, or on a Licensed Product-by-Licensed Product, country-by-country or other
jurisdiction-by-other jurisdiction basis, for any or no reason, upon ninety (90) days’ prior written notice to Caribou. 

11.4 Termination for Insolvency. In the event that either Party (a) files for protection under bankruptcy or insolvency
laws, (b) makes an assignment for the benefit of creditors, (c) appoints or suffers appointment of a receiver or trustee over substantially all of its property that is not discharged within [***] after such filing, (d) proposes a
written agreement of composition or extension of its debts, (e) proposes or is a party to any dissolution or liquidation, (f) files a petition under any bankruptcy or insolvency act or has any such petition filed against that is not
discharged within [***] of the filing thereof, or (g) admits in writing its inability generally to meet its obligations as they fall due in the general course, then the other Party may terminate this Agreement in its entirety effective
immediately upon written notice to such Party. 
 11.5 Rights in Bankruptcy. 

11.5.1 Applicability of 11 U.S.C. § 365(n). All rights and licenses (collectively, the “Intellectual
Property Rights”) granted under or pursuant to this Agreement, including all rights and licenses to use improvements or enhancements developed during the Term, are intended to be, and shall otherwise be deemed to be, for purposes of
Section 365(n) of the United States Bankruptcy Code (the “Bankruptcy Code”) or any analogous provisions in any other country or jurisdiction, licenses of rights to “intellectual property” as defined under
Section 101(35A) of the Bankruptcy Code. The Parties agree that the licensee of such Intellectual Property Rights under this Agreement shall retain and may fully exercise all of its rights and elections under the Bankruptcy Code, including
Section 365(n) of the Bankruptcy Code, or any analogous provisions in any other country or jurisdiction. All of the rights granted to either Party under this Agreement shall be deemed to exist immediately before the occurrence of any bankruptcy
case in which the other Party is the debtor. 
 11.5.2 Rights of non-Debtor Party in Bankruptcy. If a bankruptcy
proceeding is commenced by or against either Party under the Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the non-debtor Party shall be entitled to a complete duplicate of (or complete access to, as appropriate)
any Intellectual Property Rights and all embodiments of such Intellectual Property Rights, which, if not already in the non-debtor Party’s possession, shall be delivered to the non-debtor Party within [***] of such request; provided,
that the debtor Party is excused from its obligation to deliver the Intellectual Property Rights to the extent the debtor Party continues to perform all of its obligations under this Agreement and the Agreement has not been rejected pursuant to
the Bankruptcy Code or any analogous provision in any other country or jurisdiction. 

  
 - 53 - 

 CONFIDENTIAL 
  

 11.6 Modification in Lieu of Termination. If, at any time during the
Term, AbbVie has the right to terminate this Agreement pursuant to Sections 11.2.1 or 11.4, in which case, effective as of the date AbbVie delivers such notice of such election to Caribou: 

11.6.1 the royalties payable by AbbVie to Caribou hereunder with respect to any Net Sales thereafter shall be equal to [***] of the
applicable royalty rate; 
 11.6.2 the amount of any milestone payment payable by AbbVie to Caribou under
Section 6.4 for any milestone event achieved thereafter shall be reduced by [***] of the applicable amount set forth in Section 6.4, as applicable; 

11.6.3 AbbVie’s diligence obligations pursuant to Section 4.5 shall terminate and be of no further force or
effect; 
 11.6.4 AbbVie shall have the right, in its sole and absolute discretion, to, at its election, disband the JGC and assume all
decision making authority previously designated to the JGC; and 
 11.6.5 all other provisions of this Agreement shall remain in full force
and effect without change. 
 11.7 Termination in Entirety. In the event of a termination of this Agreement in its entirety by
either Party: 
 11.7.1 all rights and licenses granted by Caribou hereunder shall immediately terminate; and 

11.7.2 all rights and licenses granted by AbbVie hereunder shall immediately terminate. 

11.8 Termination of Terminated Territory. In the event of a termination of this Agreement with respect to a country or other
jurisdiction by AbbVie pursuant to Section 11.3.2 or with respect to a Terminated Territory by Caribou pursuant to Section 11.2.2 (but not in the case of any termination of this Agreement in its
entirety) all rights and licenses granted by Caribou hereunder (a) shall automatically be deemed to be amended to exclude, if applicable, the right to market, promote, detail, distribute, import, sell, offer for sale, file any Drug Approval
Application for, or seek any Regulatory Approval for Collaboration CAR-T Products or Licensed Products in such Terminated Territory, and (b) shall otherwise survive and continue in effect in such
Terminated Territory solely for the purpose of furthering any Commercialization of the Collaboration CAR-T Products or Licensed Products in the Territory or any Development or Manufacturing in support thereof.

 11.9 Remedies. Except as otherwise expressly provided herein, termination of this Agreement (either in its entirety
or with respect to one (1) or more country(ies) or other jurisdiction(s)) in accordance with the provisions hereof shall not limit remedies that may otherwise be available in law or equity. 

11.10 Accrued Rights; Surviving Obligations. 

11.10.1 Termination or expiration of this Agreement (either in its entirety or with respect to one (1) or more country(ies) or other
jurisdiction(s)) for any reason shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are
expressly indicated to survive the termination or expiration of this Agreement. Without limiting the foregoing, [***] shall survive the termination or expiration of this Agreement for any reason. If this Agreement is terminated with respect to the
Terminated Territory but not in its entirety, then following such termination the foregoing provisions of this Agreement shall remain in effect with respect to the Terminated Territory (to the extent they would survive and apply in the event the
Agreement expires or is terminated in its entirety), and all provisions not surviving in accordance with the foregoing shall terminate upon termination of this Agreement with respect to the Terminated Territory and be of no further force and effect
(and, for purposes of clarity, all provisions of this Agreement shall remain in effect with respect to all countries in the Territory other than the Terminated Territory). 

  
 - 54 - 

 CONFIDENTIAL 
  

 11.10.2 Notwithstanding the termination of AbbVie’s licenses and other rights under
this Agreement, AbbVie shall have the right for [***] after the effective date of such termination (“Sell-Off Period”) during which to sell or otherwise dispose of all Collaboration CAR-T Products or Licensed Products then in its inventory as of the date of notice of termination, as though this Agreement had not terminated, and such sale or disposition shall not constitute infringement of
Caribou’s or its Affiliates’ Patent or other intellectual property or other proprietary rights. [***] 
 ARTICLE 12 

MISCELLANEOUS 
 12.1
Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such
failure or delay is caused by or results from events beyond the reasonable control of the non-performing Party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics, pandemics,
quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots, civil commotion, strikes, lockouts, or other labor disturbances (whether involving the workforce of the
non-performing Party or of any other Person), acts of God or acts, omissions or delays in acting by any governmental authority (except to the extent such delay results from the breach by the non-performing Party or any of its Affiliates of any term or condition of this Agreement). The non-performing Party shall notify the other Party of such force majeure within
[***] days after such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater
scope and no longer duration than is necessary and the non-performing Party shall use Commercially Reasonable Efforts to remedy its inability to perform. 

12.2 Change in Control of Caribou. 

12.2.1 Caribou (or its successor) shall provide AbbVie with written notice of any Change in Control of Caribou or Acquisition by Caribou
within [***] following the signing date of such transaction. 
 12.2.2 In the event of a Change in Control of Caribou or Acquisition by
Caribou, then AbbVie shall have the right, in its sole and absolute discretion, by written notice delivered to Caribou (or its successor) at any time during the [***] following the written notice contemplated by
Section 12.2.1, to, at its election (a) disband the JGC and assume all decision making authority previously designated to the JGC, (b) terminate any or all provisions of this Agreement relating to the delivery of
information from AbbVie to Caribou, other than any requirements under ARTICLE 6, (c) assume any remaining activities assigned to Caribou hereunder as Step-In Activities following the procedures set
forth in Section 3.7 (mutatis mutandis) and/or (d) require Caribou and the Change in Control party to adopt reasonable procedures to be agreed upon in writing to prevent disclosure of Confidential Information of
AbbVie. 
 12.3 Export Control. This Agreement is made subject to any restrictions concerning the export of products or
technical information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under
this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the
appropriate agency or other governmental entity in accordance with Applicable Law. 
 12.4 Assignment. Without
the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned, or delayed, neither Party shall sell, transfer, assign, delegate, pledge, or otherwise dispose of, whether voluntarily, involuntarily, by
operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided that AbbVie may make such an assignment without the other Party’s consent to its Affiliate or to a successor, whether in a merger, sale of
stock, sale of assets or any other transaction, of the business to which this Agreement relates, to one or more Licensed Products or to its business generally. Any attempted assignment or delegation in violation of this
Section 12.4 shall be void and of no effect. All validly assigned and delegated rights and obligations of the Parties hereunder shall be binding upon and inure to the benefit of and be enforceable by and against the
successors and permitted assigns of Caribou or AbbVie, as the case may be. The permitted assignee or transferee shall assume all obligations of its assignor or transferor under this Agreement. Without limiting the foregoing, the grant of rights set
forth 

  
 - 55 - 

 CONFIDENTIAL 
  

 
in this Agreement shall be binding upon any successor or permitted assignee of Caribou, and the obligations of AbbVie, including the payment obligations, shall run in favor of any such successor
or permitted assignee of Caribou’s benefits under this Agreement. 
 12.5 Subcontracting. 

12.5.1 AbbVie shall have the right to engage Affiliates or Third Party subcontractors (including by appointing one or more contract sales
forces, or Distributors) to perform any of its activities under this Agreement. 
 12.5.2 Caribou shall have the right to subcontract its
Development and Manufacturing activities to Third Party Providers subject to Section 3.9. 
 12.5.3 Any Affiliate
or Third Party subcontractor/Third Party Providers to be engaged by a Party to perform a Party’s obligations set forth in this Agreement shall meet the qualifications typically required by such Party for the performance of work similar in scope
and complexity to the subcontracted activity. Any Party engaging an Affiliate or Third Party subcontractor/Third Party Provider hereunder shall remain principally responsible and obligated for such activities. In addition, each Party engaging a
Third Party subcontractor/Third Party Provider with respect to its obligations under a Research Plan shall in all cases retain or obtain exclusive Control of any and all Know-How, Patents or other Intellectual
Property created by such subcontractor as a result of such subcontracted activity. 
 12.6 Severability. If any
provision of this Agreement is held to be illegal, invalid, or unenforceable under any present or future law, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such
provision shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid, or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain
in full force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal, invalid, or unenforceable provision, there shall be added automatically as a
part of this Agreement a legal, valid, and enforceable provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law,
each Party hereby waives any provision of law that would render any provision hereof illegal, invalid, or unenforceable in any respect. 

12.7 Governing Law, Jurisdiction and Service. 

12.7.1 Governing Law. This Agreement or the performance, enforcement, breach or termination hereof shall be interpreted, governed by
and construed in accordance with the laws of the State of Delaware, United States, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law
of another jurisdiction; provided, that all questions concerning (a) inventorship of Patents under this Agreement shall be determined in accordance with Section 7.1.5 and (b) the construction or effect of
Patents shall be determined in accordance with the laws of the country or other jurisdiction in which the particular Patent has been filed or granted, as the case may be. The Parties agree to exclude the application to this Agreement of the United
Nations Convention on Contracts for the International Sale of Goods. 
 12.7.2 Service. Each Party further agrees that service of
any process, summons, notice or document by registered mail to its address set forth in Section 12.9 shall be effective service of process for any action, suit, or proceeding brought against it under this Agreement in any
such court. 
 12.8 Dispute Resolution. Except for disputes resolved by the procedures set forth in
Sections 6.14 or 12.12, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith (a “Dispute”), it shall
be resolved pursuant to this Section 12.8. 
 12.8.1 General. Any Dispute shall first be referred to the
Senior Officers of the Parties, who shall confer in good faith on the resolution of the issue. Any final decision mutually agreed to by the Senior Officers shall be conclusive and binding on the Parties. If the Senior Officers are not able to agree
on the resolution of any such issue within [***] (or such other period of time as mutually agreed by the Senior Officers) after such issue was first referred to them, then, [***] 

  
 - 56 - 

 CONFIDENTIAL 
  

 12.8.2 Intellectual Property Disputes. [***] 

[***] 
 12.8.4 Adverse Ruling.
Any determination pursuant to this Section 12.8 that a Party is in material breach of its material obligations hereunder shall specify a (nonexclusive) set of actions to be taken to cure such material breach, if feasible.

 12.8.5 Interim Relief and Tolling. [***]. 

12.9 Notices. 
 12.9.1
Notice Requirements. Any notice, request, demand, waiver, consent, approval, or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if
(a) delivered by hand, (b) sent by facsimile transmission (with transmission confirmed), or (c) by internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective
addresses specified below or to such other address as the Party to whom notice is to be given may have provided to the other Party in accordance with this Section 12.9.1. Such notice shall be deemed to have been given as of
the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on the second Business Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by
facsimile shall be confirmed by a hard copy delivered as soon as practicable thereafter. This Section 12.9.1 is not intended to govern the
day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 

12.9.2 Address for Notices. 

If to AbbVie, to: 
 [***] 

with a copy (which shall not constitute notice) to: 

[***] 
 If to Caribou, to: 

[***] 
 [***] 

12.10 Entire Agreement; Amendments. This Agreement, together with the Schedules attached hereto, sets forth and
constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises, and representations, whether written or oral, with respect thereto are superseded
hereby [***]. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement. No amendment, modification, release, or discharge shall be binding upon the Parties
unless in writing and duly executed by authorized representatives of both Parties. 
 12.11 English Language. This
Agreement shall be written and executed in, and all other communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event
of any conflict in interpretation between the English version and such translation, the English version shall control. 
 12.12
Equitable Relief. Each Party acknowledges and agrees that the restrictions set forth in Section 5.9, ARTICLE 7 and ARTICLE 8 are reasonable and necessary to protect the legitimate interests of the other
Party and that such other Party would not have entered into this Agreement in the absence of such restrictions, and that any breach 

  
 - 57 - 

 CONFIDENTIAL 
  

 
or threatened breach of any provision of such Section or Articles will result in irreparable injury to such other Party for which there will be no adequate remedy at law. In the event of a breach
or threatened breach of any provision of such Section or Articles, the non-breaching Party shall be authorized and entitled to seek from any court of competent jurisdiction injunctive relief, whether
preliminary or permanent, specific performance, and an equitable accounting of all earnings, profits, and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which such non-breaching Party may be entitled in law or equity. Both Parties agree to waive any requirement that the other (a) post a bond or other security as a condition for obtaining any such relief, and (b) show
irreparable harm, balancing of harms, consideration of the public interest, or inadequacy of monetary damages as a remedy. Nothing in this Section 12.12 is intended, or should be construed, to limit either Party’s
right to equitable relief or any other remedy for a breach of any other provision of this Agreement. 
 12.13 Waiver and Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in
a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of
any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law
or otherwise available except as expressly set forth herein. 
 12.14 No Benefit to Third Parties. Except as provided
in ARTICLE 10, covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other Persons. 

12.15 Further Assurance. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such
further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary or as the other Party may reasonably request in connection with this
Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

12.16 Relationship of the Parties. It is expressly agreed that Caribou, on the one hand, and AbbVie, on the other hand,
shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture, or agency, including for all tax purposes. Neither Caribou, on the one hand, nor AbbVie, on the other hand, shall have
the authority to make any statements, representations, or commitments of any kind, or to take any action, which shall be binding on the other, without the prior written consent of the other Party to do so. All persons employed by a Party shall be
employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such Party. 

12.17 Performance by Affiliates. Each Party may use one (1) or more of its Affiliates to perform its obligations and duties
hereunder and such Party Affiliates are expressly granted certain rights herein; provided that each such Affiliate shall be bound by the corresponding obligations of such Party and, subject to an assignment to such Affiliate pursuant to
Section 12.4, such Party shall remain liable hereunder for the prompt payment and performance of all its respective obligations hereunder. 

12.18 Counterparts; Facsimile Execution. This Agreement may be executed in two (2) or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument. This Agreement may be executed by facsimile or electronically transmitted signatures and such signatures shall be deemed to bind each
Party hereto as if they were original signatures. 
 12.19 References. Unless otherwise specified, (a) references
in this Agreement to any Article, Section or Schedule shall mean references to such Article, Section or Schedule of this Agreement, (b) references in any Section to any clause are references to such clause of such Section, and
(c) references to any agreement, instrument, or other document in this Agreement refer to such agreement, instrument, or other document as originally executed or, if subsequently amended, replaced, or supplemented from time to time, as so
amended, replaced, or supplemented and in effect at the relevant time of reference thereto. 

  
 - 58 - 

 CONFIDENTIAL 
  

 12.20 Schedules. In the event of any inconsistencies between this Agreement and
any schedules or other attachments hereto, the terms of this Agreement shall control. 
 12.21 Construction. Except
where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or).
Whenever this Agreement refers to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend, or limit the scope or
intent of this Agreement or the intent of any provision contained in this Agreement. The term “including,” “include,” or “includes” as used herein shall mean “including, but not limited to,” and shall not
limit the generality of any description preceding such term. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto. Each Party
represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree
that no presumption will apply against the Party which drafted such terms and provisions. 
 [SIGNATURE PAGES FOLLOW.] 

  
 - 59 - 

 THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the
Effective Date. 
  

			
	CARIBOU BIOSCIENCES, INC.
		
	By:	 	 /s/ Rachel E. Haurwitz

		
	Name:	 	 Rachel E. Haurwitz

		
	Title:	 	 President and CEO

  
 [Signature Page to
Collaboration and License Agreement] 

 THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the
Effective Date. 
  

			
	ABBVIE MANUFACTURING MANAGEMENT UNLIMITED COMPANY
		
	By:	 	 /s/ James Egan

		
	Name:	 	 James Egan

		
	Title:	 	 Director

  
 [Signature Page to
Collaboration and License Agreement] 

 CONFIDENTIAL 
  

 Schedule 1.59 

[***] 

 CONFIDENTIAL 
  

 Schedule 1.64 

Caribou CAR-T Technology Patents 

 

							
	[***]

 CONFIDENTIAL 
  

 Schedule 1.67 

Caribou Cas12a chRDNA Technology Patents 
  

							
	[***]

 CONFIDENTIAL 
  

 Schedule 1.154 

FTE Rates 
 [***] 

 CONFIDENTIAL 
  

 Schedule 3.2.1(A) 

Initial Research Plan 

(with accompanying budget and auxiliary sheets) 

[***] 

 CONFIDENTIAL 
  

 Schedule 3.2.1(B) 

Initial Program Slot 

[***] 

 CONFIDENTIAL 
  

 Schedule 3.2.2 

Reserved Targets 
 [***]

 CONFIDENTIAL 
  

 Schedule 3.2.4 

Unavailable Targets 
 [***]

 CONFIDENTIAL 
  

 Schedule 3.9 

Third Party Providers 

[***] 

 CONFIDENTIAL 
  

 Schedule 8.5 

Joint Press Release 
 PRESS RELEASE

 AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products

  

	–	 Collaboration leverages Caribou’s next-generation CRISPR genome editing technology platform and
AbbVie’s antigen-specific binders 

 NORTH CHICAGO, Ill., and BERKELEY, Calif., Feb. XX, 2021 – AbbVie (NYSE: ABBV)
and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Although allogeneic, “off-the-shelf” CAR-T cell therapies
have shown early promise in some cancer patients, the need for overcoming the rejection of allogeneic CAR-T cells by the host immune system remains a key challenge to their broader development. Employing
Caribou’s CRISPR genome editing platform to engineer CAR-T cells to withstand host immune attack would enable the development of the next-generation of “off-the-shelf” cellular therapies to benefit a broader patient population. 
 Under the multi-year
agreement, AbbVie will utilize Caribou’s next-generation Cas12a CRISPR hybrid RNA-DNA (chRDNA) genome editing and cell therapy technologies to research and develop two new
CAR-T cell therapies directed to targets specified by AbbVie. AbbVie will have exclusive rights to Caribou’s next-generation Cas12a chRDNA genome editing and cell therapy technologies for the selected
targets. Caribou will conduct certain pre-clinical research, development, and manufacturing activities for the collaboration programs, and AbbVie will reimburse Caribou for all such activities pursuant to the
collaboration. AbbVie is responsible for all clinical development, commercialization, and manufacturing efforts. AbbVie has the option to pay a fee to expand the collaboration to include up to an additional two
CAR-T cell therapies. Caribou will receive $40 million in an upfront cash payment and equity investment, along with up to $300 million in future development, regulatory, and launch milestones.
Caribou may also receive additional payments for commercial milestones as well as global tiered royalties. 
 “We are excited to partner with AbbVie on
the development of new CAR-T cell therapies. This collaboration validates Caribou’s differentiated next-generation CRISPR genome editing technologies that provide best-in-class efficiency and specificity,” said Rachel Haurwitz, Ph.D., President and Chief Executive Officer of Caribou. “We believe AbbVie is an ideal partner for Caribou as we expand upon the
number of targets and diseases addressable by our technologies. Genome-edited CAR-T cell therapies hold tremendous potential for patients, and this partnership accelerates our ability to address significant
unmet medical need.” 
 “CAR-T therapies have shown to be a promising breakthrough in cancer
treatment,” said Steve Davidsen, Ph.D., Vice President, Oncology Discovery, AbbVie. “Collaborating with Caribou and their cutting-edge CRISPR platform will help AbbVie advance our efforts to deliver new hope for patients.” 

About AbbVie 
 AbbVie’s mission is to discover and
deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology,
neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on
Twitter, Facebook, Instagram, YouTube and LinkedIn. 
 About Caribou Biosciences, Inc. 

Caribou is a leading clinical-stage CRISPR genome editing biotechnology company founded by pioneers of CRISPR biology. Outside of this collaboration, Caribou
is advancing an internal pipeline of allogeneic cell therapies for oncology. CB-010, Caribou’s lead allogeneic CAR-T cell program, targets CD19 and is being
evaluated in a Phase 1 clinical trial for patients with relapsed/refractory B cell non-Hodgkin lymphoma. CB-011, Caribou’s second

 CONFIDENTIAL 
  

 
allogeneic CAR-T cell therapy, targets BCMA for multiple myeloma, and CB-012, Caribou’s third allogeneic CAR-T cell therapy, targets CD371 for acute myeloid leukemia. CB-011 and CB-012 are in preclinical development. Additionally, Caribou
is developing iPSC-derived allogeneic natural killer (NK) cell therapies for solid tumors. Through its next-generation CRISPR genome editing technologies, Caribou is implementing multiple strategies to boost
CAR-T and NK cell persistence to overcome cell exhaustion and to prevent rapid immune-mediated clearance. These sophisticated edits drive the durability of clinical benefit of these off-the-shelf medicines. 
 For more information about Caribou, visit
www.cariboubio.com and follow the Company @CaribouBio. 
 “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou
Biosciences, Inc. 
 AbbVie Forward-Looking Statements 

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of
1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are
subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from
AbbVie’s acquisition of Allergan plc (“Allergan”), failure to promptly and effectively integrate Allergan’s businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research
and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19.
Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release
publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

### 
  

			
	 AbbVie Media:

 Gentry Lassiter

+1 (224) 219-6670

Gentry.lassiter@abbvie.com
	  	 Caribou Biosciences Media:
 Greg
Kelley
 +1 (617) 461-4023

Gregory.kelley@ogilvy.com

 CONFIDENTIAL 
  

 Schedule 9.2.6(c) 

Other Program IP - [***] 

[***] 

 CONFIDENTIAL 
  

 Schedule 12.8.3 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]